KR101792032B1 - Tfpi inhibitors and methods of use - Google Patents

Abstract

The present invention provides peptides that bind to a tissue factor pathway inhibitor (TFPI), such as TFPI-inhibiting peptides, and compositions thereof. Peptides may be used to inhibit TFPI and / or to enhance thrombin formation in a coagulation factor-deficient subject, to increase blood clot formation in a subject, and / or to treat blood clotting disorders in a subject have.

Description

TFPI INHIBITORS AND METHODS OF USE [0002]

The present invention relates generally to peptides that bind to a tissue factor pathway inhibitor (TFPI) and uses thereof.

Cross-references to related applications and inclusion by reference

This application claims priority to U.S. Provisional Patent Application No. 61 / 139,272 filed on December 19, 2008, the disclosure of which is incorporated by reference in its entirety.

Hemostasis depends on complex coagulation cascades, where a series of events mediated by blood coagulation factors causes the conversion of prothrombin to thrombin. Factor X (FX) activation is the central event of both the coagulation cascade of native and extrinsic pathways. The exogenous pathway has been proposed as the primary activator of the coagulation cascade (Mackman et al., Arterioscler. Thromb. Casc Biol, 27, 1687-1693 (2007)). Circulating Tissue Factor (TF) and Activated Factor VII (FVIIa) interact to form an "extrinsic complex ", which mediates the activation of FX. The coagulation cascade is amplified by the intrinsic pathway, while the subsequent activation of factors XII, XI, IX, and VIII also results in the formation of a "native" FIXa-FVIIIa complex that mediates FX activation. Activated FX promotes thrombin formation, which is required by the body to produce fibrin and to effectively limit bleeding.

Severe bleeding disorders such as hemophilia are caused by the destruction of the blood coagulation cascade. The most common type of hemophilia, hemophilia A, is due to a deficiency of factor VIII, whereas hemophilia B is associated with a deficiency of factor IX (FIX). Hemophilia C is caused by a deficiency of factor XI (FXI) (Cawthern et al., Blood, 91 (12), 4581-4592 (1998)). Currently there is no cure for hemophilia and other coagulation diseases. Factor replacement therapy is the most common treatment for blood clotting disorders. However, blood coagulation factors are usually cleared from the blood stream immediately after administration. To be effective, the patient must undergo frequent intravenous infusion of plasma-derived or recombinant factor concentrates, which is inconvenient, requires a clinical environment, is expensive, and time consuming. In addition, the therapeutic efficacy of factor replacement therapy can be greatly reduced in the formation of inhibitory antibodies. Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies that neutralize Factor VIII (FVIII) (Peerlinck and Hermans, Haemophilia, 12, 579-590 (2006)). Patients with anti-factor antibodies have few options.

Thus, there is a need in the art for compositions and methods for treating blood coagulation disorders. The present invention provides such compositions and methods.

Summary of the Invention

The present invention provides peptides that bind to a tissue factor pathway inhibitor (TFPI), such as TFPI antagonistic peptides that have the ability to modulate a blood coagulation cascade. For example, the invention provides peptides comprising the following amino acid sequences:

X ₇ X ₈ X ₉ X ₁₀ X ₁₁ X ₁₂ X ₁₃ X ₁₄ X ₁₅ X ₁₆ X ₁₇ X ₁₈ X ₁₉ X ₂₀ X ₂₁ (SEQ ID NO: 3109)

here,

X ₇ is selected from the group consisting of L, P, K, S, W, V, N, and Q;

X ₈ is selected from the group consisting of L, R, N, F, and I;

X ₉ is selected from the group consisting of Y, V, P, and C;

X ₁₀ is selected from the group consisting of F, L, and G;

X ₁₁ is selected from the group consisting of L, W, V, A, M, T and S;

X ₁₂ is selected from the group consisting of T, F, V, R, A, D, L, E, S, and Y;

X ₁₃ is selected from the group consisting of I, M, G, Q, D, and R;

X ₁₄ is selected from the group consisting of G, W, Y, L, M, and H;

X ₁₅ is selected from the group consisting of N, P, F, H, K and Y;

X ₁₆ is selected from the group consisting of M, D, E, V, G, and K;

X ₁₇ is selected from the group consisting of G, I, R, S, T, and L;

X ₁₈ is selected from the group consisting of M, K, L, and I;

X ₁₉ is selected from the group consisting of Y, G, R, and S;

X ₂₀ is selected from the group consisting of A, E, S, C, and Y;

X ₂₁ is selected from the group consisting of A, V, K, and E.

In one aspect, the peptide comprises one or more N-terminal amino acid (s) directly linked to X ₇ , wherein the N-terminal amino acid (s)

X ₆ ,

X ₅ X ₆ ,

X ₄ X ₅ X ₆ ,

X ₃ X ₄ X ₅ X ₆ (SEQ ID NO: 3110),

X ₂ X ₃ X ₄ X ₅ X ₆ (SEQ ID NO: 3111), and

X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ (SEQ ID NO: 3112), wherein

X < ₁ > is selected from the group consisting of T and G; X ₂ is selected from the group consisting of F and V; X ₃ is selected from the group consisting of V, W, Y, and F; X ₄ is selected from the group consisting of D, Q, and S; X ₅ is selected from the group consisting of E, T, N, and S; X ₆ is selected from the group consisting of R, H, K, and A.

Alternatively or additionally, the peptide comprises one or more C-terminal amino acids directly linked to X ₂₁ , wherein the C-terminal amino acid (s)

X ₂₂ ,

X ₂₂ X ₂₃ ,

X ₂₂ X ₂₃ X ₂₄ ,

X ₂₂ X ₂₃ X ₂₄ X ₂₅ (SEQ ID NO: 3113),

X ₂₂ X ₂₃ X ₂₄ X ₂₅ X ₂₆ (SEQ ID NO: 3114), and

X ₂₂ X ₂₃ X ₂₄ X ₂₅ X ₂₆ X ₂₇ (SEQ ID NO: 3115), wherein the amino acid sequence is selected from the group consisting of

X ₂₂ is selected from the group consisting of Q, I, E, W, R, L, and N; X ₂₃ is selected from the group consisting of L, V, M, and R; X ₂₄ is selected from the group consisting of K, L, A, and Y; X ₂₅ is F; X ₂₆ is G; X ₂₇ is T.

In one aspect, the invention provides peptides comprising the amino acid sequence set forth in any one of the peptides comprising the amino acid sequences set forth in SEQ ID NOs: 1-7, for example, JBT0132, JBT0303, JBT0193, JBT0178, JBT0120, and JBT0224 , Which inhibits TFPI activity in the blood coagulation cascade. The present invention relates to a method for producing a Phe-Gln-Ser-Lys-Gly-Asn-Val-Phe-Val-Asp-Gly-Tyr-Phe-Glu-Arg- Leu-Arg-Ala-Lys- Leu (FQSKGNVFVDGYFERLRAKL) Also provided is a peptide that binds to TFPI, comprising an amino acid sequence of at least 60% identity to the sequence.

The invention also provides a peptide that binds to TFPI, wherein the peptide comprises the structure of formula (I): X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013 -X1014-X1015-X1016-X1017-X1018-X1019-X1020 (I) (SEQ ID NO: 3116).

In formula (I)

X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y;

X1002 is an amino acid selected from the group consisting of G, K and Q;

X1003 is selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Amino acids;

X1004 can be expressed as A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y Amino acids selected from the group consisting of;

X1005 is selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, An amino acid selected from the group consisting of Y;

X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, ego;

X1007 is an amino acid selected from the group consisting of A, F, G, I, K, L, Nmv, P, Q, S, V, W and Y;

X1008 is an amino acid selected from the group consisting of F, H, K, W and Y;

X1009 is an amino acid selected from the group consisting of A, Aib, f, I, K, S, T and V;

X1010 is selected from the group consisting of A, Aib, C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, Amino acids;

X1011 is an amino acid selected from the group consisting of Aib, C, K, G and Nmg;

X1012 is Y;

X1013 is an amino acid selected from the group consisting of A, Aib, C, E, F, G, H, K, L, M, Q, R, W and Y;

X1014 is selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Amino acids;

X1015 is an amino acid selected from the group consisting of (omega-methyl) -R, D, E, K and R;

X1016 is L;

X1017 is (omega-methyl) -R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hle, Amino acids selected from the group consisting of L, M, N, Nle, Nva, Opa, Orn, Q, R, S, T, V, W and Y;

X1018 is an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

X1019 is an amino acid selected from the group consisting of Bhk, K, R and V;

X1020 is present or absent and X1020 is selected from the group consisting of Aib, Bhl, C, F, G, H, I, K, L, Nml, Q, R, S, T, V, Amino acids.

In one aspect, the peptide that binds to TFPI comprises a structure of Formula III: X1001-Q-X1003-X1004-X1005-X1006-I / V-X1008-V-X1010-GYC / F- X1017-X1018-KK / L (III) (SEQ ID NO: 3117). In formula (III), X1001, X1003, X1004, X1005, X1006, X1008, X1010, X1014, X1017 and X1018 are each independently selected from any amino acid.

The invention further provides a TFPI-binding peptide comprising a structure of formula V: X2001-X2002-X2003-X2004-X2005-X2006- [X2007-X2008-X2009-X2010-X2011-X2012-X2013- X2015-X2016-X2017-X2018] -X2019-X2020-X2021-X2022-X2023 (V) (SEQ ID NO: 3118). In Formula V, X2001, X2002, and X2023 are independently present or absent. When present, X2001 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W; X2002 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, Add to,

X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;

X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;

X2005 is W;

X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W;

X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K, preferably an amino acid selected from the group consisting of C and Hcy;

X2008 is an amino acid selected from the group consisting of A, G, R, S and T;

X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R and V;

X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;

X2011 is an amino acid selected from the group consisting of D, E, G, S and T;

X2012 is a group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, T, t, V, v, W and w;

X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;

X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, R, S, T, V and W;

X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W;

X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, T, V, W and Y;

X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;

X2018 is an amino acid selected from the group consisting of C and D (preferably X2018 is C);

X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W;

X2020 is an amino acid selected from the group consisting of F and W;

X2021 is an amino acid selected from the group consisting of I, L and V;

X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T,

X2023 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y when X2023 is present in the peptide. The peptide comprises a ring structure formed by the linkage between X2007 and X2018, shown in parentheses in formula (V).

The present invention also provides a peptide that binds to TFPI, wherein the peptide comprises the structure of Formula VI: X2001-X2002-F / YKWF / H- [C-X2008-M / V-X2010- X2013-GI / T-X2016-S / TC] -A / VWV-X2022-X2023 (VI) (SEQ ID NO: 3119). In the formula (VI), X2001, X2002 and X2023 are each independently present or absent. X2008, X2010, X2012, X2013, X2016 and X2022 as well as X2001, X2002 and X2023 (when present) are each independently selected from any amino acid. The peptides include ring structures produced by the linkage between X2007 and X2018, shown in parentheses in formula (VI).

In one aspect, the invention provides a peptide that binds to TFPI, wherein the peptide comprises a structure of Formula VIII: X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011 -X3012-X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120). In the formula (VIII), X3001 and X3002 are each independently present or absent. X3001 is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, ; X3002 is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, With respect to the remainder of formula VIII,

X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W and Y;

X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P;

X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;

X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H;

X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;

X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;

X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;

X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H;

X3012 is an amino acid selected from the group consisting of A, C, H, I, K, L and R;

X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I;

X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K;

X3015 is an amino acid selected from the group consisting of A, K, and R;

X3016 is an amino acid selected from the group consisting of A, F, K and R;

X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M;

X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y;

X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I;

X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P;

X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y,

In addition, the present invention provides TFPI-binding peptides comprising a structure of formula IX: X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-H-X3013-X3014 -K / RR-X3017-X3018-X3019-X3020-X3021 (IX) (SEQ ID NO: 3121). Here, X3001, X3002, X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X3011, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid. The invention also encompasses peptides that bind to TFPI, wherein the peptide comprises an amino acid sequence having at least 60% identity to the sequence of formula X: Ac-GYASFPWFVQLHVHKRSWEMA-NH2 (SEQ ID NO: 223). In the context of the present application, any of the peptides included in any of formulas I through X and any TFPI-binding peptides described herein are also referred to as "peptides of the invention" and "peptides described herein."

In some embodiments, the peptides of the invention bind to TFPI-1 (e.g., TFPI-1 alpha) and optionally improve TFPI-regulated thrombin production in the absence of FVIII, FIX, and / or FXI. (E. G., A pharmaceutical composition) comprising a peptide.

The invention also provides methods of using the peptides of the invention. For example, the invention provides a method of inhibiting TFPI comprising contacting TFPI with a peptide as described herein. The present invention also provides a method of enhancing thrombin formation in a coagulation factor-deficient subject, a method of increasing blood clot formation in a subject, and a method of treating blood coagulation disease in a subject. Such methods are also referred to herein in their entirety, for example, as the "inventive method ". The method includes administering to the subject a peptide as described herein in an amount effective to enhance thrombin formation in the subject, an amount effective to enhance blood clot formation, or an amount effective to treat blood clotting disorders. Unless expressly stated to the contrary, the description provided herein with respect to one peptide of the invention or the method of the present invention applies to each and every peptide of the invention and to the method of the invention, respectively. A further aspect of the present invention relates to the use of the peptides of the invention for the manufacture of a medicament, a method of targeting cells displaying TFPI, a method of treating or diagnosing a subject at risk of becoming diseased or diseased, . The preceding methods are also referred to herein in their entirety, for example, as the "inventive method"

Figure 1 is a diagram of a blood coagulation cascade.
Figure 2 is a diagram of the secondary structure of Tissue Factor Pathway Inhibitor-1.
Figure 3 is a plot of the formation of a tetrad complex comprising a tissue factor, Factor Xa (FXa), Factor VIIa (FVIIa), and TFPI.
Figure 4 is a list of amino acid sequences of various TFPI-inhibiting peptides showing amino acid substitutions (coarse and underlined) with respect to peptide JBT0293.
Figure 5 is a plot of mRNA display selection of TFPI-inhibitor peptides.
FIG. 6A is a plot of an EC ₅₀ binding ELISA, and FIG. 6B is a plot of an IC ₅₀ ELISA as described in Example 1. FIG.
Figure 7 is a binding ELISA curve comparing the% OD (y axis) and concentration [nM] (x-axis) to the biotinylated peptide JBT0132.
8A-8D are competitive ELISA curves comparing the% OD (y axis) and concentration [nM] (x axis) for the exemplary peptides of the invention.
9A and 9B are sensorgrams plotting RU (y-axis) versus time (seconds) (x-axis) for peptides JBT0120 and JBT0132.
FIGS. 10A and 10B are Senograms plotting the RU (y-axis) versus time (seconds) (x-axis) for the interaction of tissue factor pathway inhibitor-1 and tissue factor pathway inhibitor-2 with peptide JBT0120.
11A and 11B are graphs comparing the amount of thrombin (nM) (y axis) and time (min) (x axis) generated for peptide JBT0120 and peptide JBT0132 in plasma-based assays.
Figures 12-18 show amino acid sequences of various TFPI-inhibiting peptides; EC ₅₀ and% inhibition of TFPI observed in FXa inhibition assay; EC50 and% inhibition of TFPI observed in an exogenous tenase inhibition assay; (MU / mL) of FEIBA, Factor VIII (FVIII) Immunate, or Factor IX (FIX) in plasma-based assays. " ^* " Represents a negative control group.
Figures 19-21 are tables listing the results of BIAcore analysis of several TFPI-binding peptides. " ^* " Represents a negative control group.
Figures 22-30 show amino acid sequences of various TFPI-binding peptides; EC ₅₀ and% inhibition of TFPI observed in FXa inhibition assay; EC ₅₀ and% inhibition of TFPI observed in exogenous tenaz inhibition assay; And FEIA, FVIII, or FIX equivalent activity (mU / mL) in plasma-based assays. " ^* " Represents a negative control group.
Figure 31 is a graph comparing the pharmacokinetic characteristics of the PEGylated TFPI-binding peptides (concentration of peptide (y axis) vs time after administration (x axis)) to the pharmacokinetic characteristics of the same peptide lacking PEG. Peptides were intravenously administered to C57B16 mice at a dose of 10 mg / kg. Three biological samples were analyzed for the presence of peptides at each time point.
Figures 32-39 are tables listing amino acid sequences and IC ₅₀ or EC ₅₀ values of various peptides of the invention. " ^* " Represents a negative control group.

The present invention provides peptides that block the inhibitory activity of Tissue Factor Pathway Inhibitor-1 (referred to herein as TFPI) within the blood coagulation cascade. Upon vascular injury, the TF complex forms an "extrinsic complex" or "exogenous tnase complex" with Factor VIIa, which activates Factors IX and X (Fig. 1). TFPI is a major natural regulator of TF / FVIIa exogenous complex activity and, by extension, plays a role in controlling thrombin production (Panteleev et al., Eur. J. Biochem., 249, 2016-2031 (2002) . TFPI is a 43 kDa serine protease inhibitor containing three Kunitz-type suppression domains (Figure 2). The Kunitz domain 1 of TFPI binds to FVIIa and the Kunitz domain 2 binds to FXa, allowing the inhibitor to form a quaternary FXa-TFPI-FVIIa-TF complex that blocks the activity of the TF / FVIIa exogenous complex ( 3). TFPI binding of FXa also down-regulates the common pathway of the solidification cascade, while FXa converts prothrombin to thrombin (Audu et al., Anesth. Analg., 103 (4), 841-845 (2006)). The present invention provides TFPI-inhibiting peptides that, for example, block the inhibitory effect of TFPI on blood coagulation cascades, thereby enhancing thrombin formation.

The amino acid sequences of several TFPI-binding peptides are provided herein. Typical amino acids are identified according to their standard 1-letter or 3-letter code as shown in Table 1.

3-character code 1-character code amino acid 3-character code 1-character code amino acid Ala A Alanine Met M Methionine Cys C Cysteine Asn N Asparagine Asp D Aspartic acid Pro P Proline Glu E Glutamic acid Gln Q Glutamine Phe F Phenylalanine Arg R Arginine Gly G Glycine Ser S Serine His H Histidine Thr T Threonine Ile I Isoleucine Val V Balin Lys K Lysine Trp W Tryptophan Leu L Leucine Tyr Y Tyrosine

Non-conventional amino acids and additional peptide building blocks are identified according to the three-letter code provided in Table 2 (except for the typical four-letter abbreviation Ttds).

The amino acid sequence of the peptides provided herein is shown in a typical peptide sequence format as will be appreciated by those skilled in the art. For example, a three-letter code or a one-letter code for a conventional amino acid, or a three-letter code or abbreviation for a non-conventional amino acid, indicates the presence of an amino acid at a specified position in the peptide sequence. The code for each non-conventional amino acid is linked by a hyphen to the code for the next and / or preceding amino acid in the sequence. Adjacent amino acids are linked by chemical bonds (usually amide bonds). Formation of a chemical bond removes a hydroxyl group from the 1-carboxyl group of an amino acid (for example, Hle-adjacent amino acid) when positioned to the left of the adjacent amino acid, and when the amino acid is located to the right of the adjacent amino acid (for example, Lt; RTI ID = 0.0 > amino-Hle) < / RTI > It is understood that both variants apply to the same common amino acid and to adjacent normal amino acids present within the amino acid sequence without explicitly hypothetically exemplifying it. When the amino acid contains more than one amino and / or carboxyl group in the amino acid side chain, a 2- or 3-amino group and / or a 1-carboxyl group is generally used for the formation of the peptide bond. For non-conventional amino acids, a 3-letter code was used, where the first character represents the stereochemistry of the C-a-atom. For example, the first letter of the upper case indicates that the L-type amino acid is present in the peptide sequence, while the first lower case letter indicates that the corresponding amino acid of the D-type exists in the peptide sequence. When a one-letter code is used, the lower case represents the D-amino acid while the upper case represents the L-amino acid. Unless otherwise indicated, the amino acid sequence is presented herein in the N- to C-terminal direction.

C- terminus of some TFPI- binding peptide sequence described herein is illustrated clearly by including abbreviations for specific terminator connected by a hyphen amines OH, NH _2, or the C- terminal amino acid code. The N-terminus of some of the peptides described herein is clearly exemplified by including an abbreviation for hydrogen (relative to the free N-terminus), or a specific terminating carboxylic acid or other chemical group connected via a hyphen to the N-terminal amino acid code.

The present invention provides peptides comprising the amino acid sequence:

X ₇ X ₈ X ₉ X ₁₀ X ₁₁ X ₁₂ X ₁₃ X ₁₄ X ₁₅ X ₁₆ X ₁₇ X ₁₈ X ₁₉ X ₂₀ X ₂₁ (SEQ ID NO: 3109)

Here, using a single character code for the amino acid,

X ₇ is selected from the group consisting of L, P, K, S, W, V, N, and Q;

X ₈ is selected from the group consisting of L, R, N, F, and I;

X ₉ is selected from the group consisting of Y, V, P, and C;

X ₁₀ is selected from the group consisting of F, L, and G;

X ₁₁ is selected from the group consisting of L, W, V, A, M, T and S;

X ₁₂ is selected from the group consisting of T, F, V, R, A, D, L, E, S, and Y;

X ₁₃ is selected from the group consisting of I, M, G, Q, D, and R;

X ₁₄ is selected from the group consisting of G, W, Y, L, M, and H;

X ₁₅ is selected from the group consisting of N, P, F, H, K and Y;

X ₁₆ is selected from the group consisting of M, D, E, V, G, and K;

X ₁₇ is selected from the group consisting of G, I, R, S, T, and L;

X ₁₈ is selected from the group consisting of M, K, L, and I;

X ₁₉ is selected from the group consisting of Y, G, R, and S;

X ₂₀ is selected from the group consisting of A, E, S, C, and Y;

X ₂₁ is selected from the group consisting of A, V, K, and E.

In addition to the core structure (X ₇ -X ₂₁ ) described above, other structures specifically contemplated include those in which one or more additional amino acids are attached to the core structure (e.g., the N-terminus of the amino acid sequence X ₇ -X ₂₁ , C-terminal) structure. Accordingly, the invention includes peptides comprising a core structure and further comprising at least one N-terminal amino acid (s) comprising an amino acid sequence selected from the group consisting of:

X ₆ ,

X ₅ X ₆ ,

X ₄ X ₅ X ₆ ,

X ₃ X ₄ X ₅ X ₆ (SEQ ID NO: 3110),

X ₂ X ₃ X ₄ X ₅ X ₆ (SEQ ID NO: 3111), and

X ₁ X ₂ X ₃ X ₄ X ₅ X ₆ (SEQ ID NO: 3112)

Wherein X ₆ is directly linked to X ₇ of the core structure amino acid sequence,

X < ₁ > is selected from the group consisting of T and G;

X ₂ is selected from the group consisting of F and V;

X ₃ is selected from the group consisting of V, W, Y, and F;

X ₄ is selected from the group consisting of D, Q, and S;

X ₅ is selected from the group consisting of E, T, N, and S;

X ₆ is selected from the group consisting of R, H, K, and A.

The peptides of the invention comprise or consist of the amino acid sequence QSKKNVFVFGYFERLRAK (SEQ ID NO: 1) in one aspect.

In another embodiment, the peptides of the invention comprising a core structure comprise one or more C-terminal amino acid (s) comprising an amino acid sequence selected from the group consisting of:

X ₂₂ ,

X ₂₂ X ₂₃ ,

X ₂₂ X ₂₃ X ₂₄ ,

X ₂₂ X ₂₃ X ₂₄ X ₂₅ (SEQ ID NO: 3113),

X ₂₂ X ₂₃ X ₂₄ X ₂₅ X ₂₆ (SEQ ID NO: 3114), and

X ₂₂ X ₂₃ X ₂₄ X ₂₅ X ₂₆ X ₂₇ (SEQ ID NO: 3115)

Wherein X ₂₂ is directly linked to X ₂₁ of the core structure amino acid sequence,

X ₂₂ is selected from the group consisting of Q, I, E, W, R, L, and N;

X ₂₃ is selected from the group consisting of L, V, M, and R;

X ₂₄ is selected from the group consisting of K, L, A, and Y;

X ₂₅ is F;

X ₂₆ is G;

X ₂₇ is T.

In one aspect, the peptide of the invention comprises or consists of the amino acid sequence VIVFTFRHNKLIGYERRY (SEQ ID NO: 4). It is also contemplated that the peptides of the present invention comprise additional amino acids at both the N-terminus and the C-terminus of the core structure. In this regard, the peptide comprises or consists of the amino acid sequences TFVDERLLYFLTIGNMGMYAAQLKF (SEQ ID NO: 3), GVWQTHPRYFWTMWPDIKGEVIVLFGT (SEQ ID NO: 5), KWFCGMRDMKGTMSCVWVKF (SEQ ID NO: 6), or ASFPLAVQLHVSKRSKEMA (SEQ ID NO: 7).

The present invention further comprises a peptide comprising the amino acid sequence X ₃ X ₄ X ₅ -FX ₇ -NVF-X ₁₁ X ₁₂ -GY-X ₁₅ X ₁₆ -RLRAK-X ₂₂ (SEQ ID NO: 2), wherein X ₃ Is Y or F; X < ₄ > is Q or S; X < ₅ > is N or S; X ₇ is K, N, or Q is; X ₁₁ is V, A, S, or T; X ₁₂ is F, A, D, L, Q, S, or Y; X ₁₅ is F, K, or Y; X ₁₆ is E or D; X ₂₂ is L or N.

The present invention also provides a peptide that binds to TFPI, wherein the peptide comprises a structure of formula (I): X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011- X1013-X1014-X1015-X1016-X1017-X1018-X1019-X1020 (I) (SEQ ID NO: 3116). In formula (I)

X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y;

X1002 is an amino acid selected from the group consisting of G, K and Q;

X1003 is selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Amino acids;

X1004 can be expressed as A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, T, V, W and Y Amino acids selected from the group consisting of;

X1005 is selected from the group consisting of a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, An amino acid selected from the group consisting of Y;

X1006 is an amino acid selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, ego;

X1007 is an amino acid selected from the group consisting of A, F, G, I, K, L, Nmv, P, Q, S, V, W and Y;

X1008 is an amino acid selected from the group consisting of F, H, K, W and Y;

X1009 is an amino acid selected from the group consisting of A, Aib, f, I, K, S, T and V;

X1010 is selected from the group consisting of A, Aib, C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, Amino acids;

X1011 is an amino acid selected from the group consisting of Aib, C, K, G and Nmg;

X1012 is Y;

X1013 is an amino acid selected from the group consisting of A, Aib, C, E, F, G, H, K, L, M, Q, R, W and Y;

X1014 is selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Amino acids;

X1015 is an amino acid selected from the group consisting of (omega-methyl) -R, D, E, K and R;

X1016 is L;

X1017 is (omega-methyl) -R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, Hle, Amino acids selected from the group consisting of L, M, N, Nle, Nva, Opa, Orn, Q, R, S, T, V, W and Y;

X1018 is an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W and Y;

X1019 is an amino acid selected from the group consisting of Bhk, K, R and V.

X1020 is present or absent in Formula I (i.e., in some cases, the peptides of the invention have the structure X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013-X1014 X1015-X1016-X1017-X1018-X1019-X1020 (SEQ ID NO: 3116)). And X is an amino acid selected from the group consisting of Aib, Bhl, C, F, G, H, I, K, L, Nml, Q, R, S, T, V,

For example, the peptides of the invention comprise a structure of formula I, wherein X1001 is an amino acid selected from the group consisting of C, F, I, K, L, Nmf, V, M, W and Y; X1002 is Q; X1003 is an amino acid selected from the group consisting of A, C, D, E, H, K, M, I, N, Q, R, S, T and V; X1004 is selected from the group consisting of A, Aib, C, D, E, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V, Amino acids; X1005 is a group consisting of a, A, Aib, Bal, C, d, E, D, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, Amino acid; X1006 is an amino acid selected from the group consisting of A, Btq, C, D, G, I, K, H, L, M, N, Q, R, S, V and Y; X1007 is an amino acid selected from the group consisting of I, K, L, Q, V and Y; X1008 is an amino acid selected from the group consisting of F, H, and Y; X1009 is an amino acid selected from the group consisting of f, I and V; X1010 is an amino acid selected from the group consisting of A, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, W and Y; X1011 is an amino acid selected from the group consisting of G and Nmg; X1012 is Y; X1013 is an amino acid selected from the group consisting of Aib, C, F, H, L, W and Y; X1014 is an amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, H, I, K, L, M, N, Q, R, S, T, V, W and Y; X1015 is an amino acid selected from the group consisting of E and R; X1016 is L; X1017 is a (omega-methyl) -R, A, Aib, Bhr, C, Cha, Cit, Dab, Dap, Eag, Eew, F, H, Har, Hci, Hle, I, Nle, Nva, Opa, Orn, R, S, T, V and Y; X1018 is an amino acid selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, R, V and W; X1019 is an amino acid selected from the group consisting of K and R; X1020 is an amino acid selected from the group consisting of Aib, Bhl, F, K, L, R and W (when X1020 is present in the peptide).

In one aspect, the peptides of the invention comprise a structure of formula I, wherein X1001 is an amino acid selected from the group consisting of F, L, Y and M; X1002 is Q; X1003 is an amino acid selected from the group consisting of M, Q, R, S, T and C; X1004 is an amino acid selected from the group consisting of Aib, K, L, P, R, E, G, I, Y, M and W; X1005 is an amino acid selected from the group consisting of a, Aib, D, d, G, H, K, k, N, Nmg, p, Q, R, A, E, C and M; X1006 is an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q, R, S and M; X1007 is an amino acid selected from the group consisting of I and V; X1008 is an amino acid selected from the group consisting of F, H, and Y; X1009 is V; X1010 is an amino acid selected from the group consisting of A, D, E, K, M, N, Q, R, F, H, P, S, V, W and Y; X1011 is G; X1012 is Y; X1013 is C or F; X1014 is an amino acid selected from the group consisting of A, C, D, E, K, L, M, N, Q, R, T, V and Aib; X1015 is R; X1016 is L; X1017 is selected from the group consisting of A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nle, Nva, Opa, Orn, R, I, Amino acids; X1018 is an amino acid selected from the group consisting of A, L, N, M and R; X1019 is K; X1020 is K or L.

When the amino acid X1020 is absent in formula I, the peptide of the invention further comprises, in one aspect, the amino acid X1000 at the N-terminus of formula I, wherein the peptide comprises or consists of the structure of formula II: X1000-X1001 -X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013-X1014-X1015-X1016-X1017-X1018-X1019 (II) (SEQ ID NO: 3122). When X1000 is present in the peptide, X1000 is an amino acid selected from the group consisting of A, E, and P, while the amino acid of X1001-X1019 is as defined above.

In a further aspect, the TFPI-binding peptides of the present invention comprise a structure of Formula III: X1001-Q-X1003-X1004-X1005-X1006-I / V-X1008-V- X1010-GYC / F- RL-X1017-X1018-KK / L (III) (SEQ ID NO: 3117). X1001, X1003, X1004, X1005, X1006, X1008, X1010, X1014, X1017 and X1018 in formula (III) are each independently selected from any amino acid. For example, in formula III,

X1001 is an amino acid selected from the group consisting of Bhf, C, D, F, G, H, I, K, L, M, N, Nmf, Q, R, T, V, W and Y, (For example, an amino acid selected from the group consisting of F, L, Y and M) selected from the group consisting of F, I, K, L, Nmf, V, M, W and Y;

X1003 is selected from the group consisting of A, Aib, Bhs, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Is an amino acid selected from the group consisting of A, C, D, E, H, K, M, I, N, Q, R, S, T and V and / Is M, Q, R, S, T, or C;

X1004 may optionally be A, Aib, Bhk, C, D, E, F, G, H, I, K, k, L, M, N, Nmk, P, Q, R, S, , A, Aib, C, D, E, G, H, F, I, K, k, L, M, N, Nmk, P, Q, R, S, V , W and Y (for example, an amino acid selected from the group consisting of Aib, K, L, P, R, E, G, I, Y, M and W);

X1005 may optionally be a, A, Aib, Bal, C, D, d, E, F, G, H, K, k, L, M, N, Nmg, p, Q, R, S, A, Aib, Bal, C, d, E, D, F, G, H, K, k, L, M, N, Nmg, p, and Q are selected from the group consisting of , R, S, T and Y, and / or the amino acid is selected from the group consisting of a, Aib, D, d, G, H, K, , A, E, C or M);

X1006 is optionally selected from the group consisting of A, Aib, Btq, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, Amino acids (for example, A, Btq, C, D, G, I, K, H, L, M, N, Q, R, S, V and Y) An amino acid selected from the group consisting of C, D, G, H, K, N, Q, R, S and M);

X1008 is an amino acid optionally selected from the group consisting of F, H, K, W and Y, for example F, H and Y, and / or;

X1010 is optionally selected from the group consisting of A, Aib, C, D, E, F, G, H, I, K, L, M, N, Nmf, P, Q, R, S, T, V, An amino acid selected from the group consisting of A, D, E, F, G, H, K, L, M, N, P, Q, R, S, T, V, An amino acid selected from the group consisting of A, D, E, K, M, N, Q, R, F, H, P, S, V, W and Y);

X1014 is optionally selected from the group consisting of A, Aib, Bhe, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, The amino acid selected from the group consisting of A, Aib, Bhe, C, D, E, H, I, K, L, M, N, Q, R, S, T, V, W and Y Amino acid (e.g., A, C, D, E, K, L, M, N, Q, R, T, V or Aib);

X1017 is optionally selected from the group consisting of (Omega-methyl) -R, A, Aib, Bhr, C, Cha, Cit, D, Dab, Dap, E, Eag, Eew, F, G, H, Har, Hci, For example, (omega-methyl) -R, A, Aib, or an amino acid selected from the group consisting of L, M, N, Nle, Nva, Opa, Orn, Q, R, S, , Bhr, C, Cha, Cit, Dab, Dap, Eag, Eew, F, H, Har, Hci, I, K, L, M, N, Nle, Nva, Opa, Orn, (For example, A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nle, Nva, Opa, Orn, R, I, L, S and M) and / or;

X1018 is an amino acid selected from the group consisting of A, Bal, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, (For example, A, L, N, M, and M) selected from the group consisting of A, C, D, E, F, I, K, L, M, N, Q, R < / RTI >

In some embodiments, the peptides of the invention comprise at least one additional amino acid residue attached to the N- or C-terminus of the amino acid sequence. For example, a peptide comprising any one of the structures of Formulas I-III further comprises in some embodiments at least one N-terminal amino acid (s) directly linked to X1001, wherein the N-terminal amino acid (s) Comprises an amino acid sequence selected from the group consisting of

X1000,

X999-X1000,

X998-X999-X1000,

X997-X998-X999-X1000 (SEQ ID NO: 3123),

X996-X997-X998-X999-X1000 (SEQ ID NO: 3124),

X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3125),

X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3126),

X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3127)

X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3128)

X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3129), and

X990-X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3130).

When the peptide comprises more than one N-terminal amino acid, X1000 is A or K; X999 is V or K; X998 is Q or K; X997 is L or K; X996 is R or K; X995 is G or K; X994 is V or K; X993 is G or K; X992 is S or K; X991 is K; X990 is K.

In addition to the core structure described in Formulas I-III, another structure specifically contemplated is a structure in which one or more additional amino acids are attached to the C-terminus of the core structure directly linked to X1020. For example, the C-terminal addition optionally comprises an amino acid sequence selected from the group consisting of X1021, X1021-X1022, X1021-X1022-X1023, and X1021-X1022-X1023-X1024 (SEQ ID NO: 3131) K; X1022 is S or K; X1023 and X1024 are K.

The present invention provides a polypeptide having at least 60% identity (e.g., at least 65%, at least 70%, at least 75%, at least 80% identity) to the amino acid sequence Ac-FQSK-Nmg-NVFVDGYFERL-Aib- AKL- %, At least 85%, at least 90%, at least 95% or 100% identity) of a TFPI-binding peptide comprising or consisting of an amino acid sequence. In some cases, the peptides comprise or consist of any one of the amino acid sequences of Formulas I-III as described herein. The present invention provides peptides comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 8-978 (e.g., SEQ ID NOS: 8-741 and 962-972 (e.g., SEQ ID NOS: 8-741, 962-968, 972) and / or a peptide comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 742-961 (e.g. SEQ ID NOs: 744-961) and / or SEQ ID NOs: 973-978) Also included.

The peptides of the present invention include, in some cases, intramolecular disulfide bonds. In this regard, peptides comprising the structure of Formulas I-III contain at least two cysteine residues spaced by at least three amino acid residues such that the cysteines form an intramolecular disulfide bond (e.g., Containing two cysteine residues). In some cases, the cysteines are separated by more than three amino acid residues. For example, in a peptide comprising the structure of formula I, II or III, any two of X1000, X1001, X1003, X1004, X1005, X1006, X1010, X1011, X1013, X1014, X1017, X1018, X1020, The dog is a cysteine which can optionally form disulfide bridges. Thus, in some aspects, the peptide contains two cysteine residues, one of X1000, X1005, X1010 and X1014 is cysteine, and one of X1006, X1010, X1017 and X1021 is cysteine. In the present invention, considering all possible combinations of cysteine pairs, for example, X1000 and X1006 are C; X1000 and X1010 are C; X1000 and X1017 are C; X1005 and X1017 are C; X1010 and X1017 are C; X1010 and X1021 are C; X1014 and X1021 are C.

The present invention further provides a peptide that binds to TFPI, wherein the peptide comprises a structure of formula V: X2001-X2002-X2003-X2004-X2005-X2006- [X2007-X2008-X2009-X2010-X2011-X2012 -X2013-X2014-X2015-X2016-X2017-X2018] -X2019-X2020-X2021-X2022-X2023 (V) (SEQ ID NO: 3118). Wherein the peptide forms a linkage structure between X2007 and X2018 (represented by parentheses in the formula V), for example, a disulfide bond. In Formula V, X2001, X2002, and X2023 are independently present or absent. When present, X2001 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W; X2002 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, Amino acids selected from the group consisting of F, G, I, K, L, R, S, T, V, X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;

X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;

X2005 is W;

X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W;

X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K (e.g. C or Hcy);

X2008 is an amino acid selected from the group consisting of A, G, R, S and T;

X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, Sem and V;

X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;

X2011 is an amino acid selected from the group consisting of D, E, G, S and T;

X2012 is a group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, Sem, T, t, V, v, W and w;

X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;

X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, R, S, T, V and W;

X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W;

X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y;

X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;

X2018 is an amino acid selected from the group consisting of C and D (for example, X2018 is C);

X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W;

X2020 is an amino acid selected from the group consisting of F and W;

X2021 is an amino acid selected from the group consisting of I, L and V;

X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T,

In some cases, in the peptides of the invention comprising a structure of formula V,

X2001 is selected from the group consisting of amino acids selected from the group consisting of A, D, F, G, H, K, L, P and S, for example A, D, F, G, H, K, Is the selected amino acid (when X2001 is present);

X2002 is an amino acid selected from the group consisting of A, F, H, K, L, M, R and S, optionally selected from the group consisting of A, D, F, G, H, K, L, P, (E.g., H, F, M, or R) (when X2002 is present);

X2003 is an amino acid (e. G., F or Y) selected from the group consisting of amino acids selected from the group consisting of A, F, K, L, S and Y, for example F, S and Y;

X2004 is an amino acid (e.g., K) optionally selected from the group consisting of A, D, F, G, K, L and S;

X2005 is optionally W;

X2006 is an amino acid optionally selected from the group consisting of F, H, K and L (e.g., F or H);

X2007 is an amino acid optionally selected from the group consisting of C and HcY (e.g., X2007 is C);

X2008 is an amino acid optionally selected from the group consisting of A, G and S;

X2009 is an amino acid selected from the group consisting of amino acids selected from the group consisting of a, A, K, L, V, M, m, Nle, For example, M, Sem, or V);

X2010 is an amino acid selected from the group consisting of amino acids selected from the group consisting of A, G, K, L, P, R and S such as A, K, L, P, R and S (for example, K, P, or R);

X2011 is an amino acid optionally selected from the group consisting of D, G and S (e.g., D or S);

X2012 is an amino acid selected from the group consisting of A, a, D, d, F, f, G, K, k, L, l, M, m, Nle, P, S and s, (For example, F, L, l, Sem, and M) selected from the group consisting of F, f, G, K, k, L, l, M, Nle, P, ≪ / RTI > amino acid);

X2013 is optionally selected from the group consisting of amino acids selected from the group consisting of A, D, d, F, G, K, L, S and s such as A, D, F, G, K, Amino acids (e.g., D, G, K, or S);

X2014 is an amino acid (e. G., D or G), optionally selected from the group consisting of D, F, G, K, L and S;

X2015 is an amino acid (e.g., I or T) selected from the group consisting of A, D, F, G, I, K, L, M, Nle, S and T;

X2016 is optionally made up of amino acids selected from the group consisting of D, F, K, L, M, Nle, S and Y such as D, F, K, L, M, Nle, S, Amino acid (e.g., D, F, M, Sem, or Y) selected from the group;

X2017 is an amino acid (e.g., S or T), optionally selected from the group consisting of A, D, F, G, K, L, S, T and Y;

X2018 is optionally C;

X2019 is an amino acid (e.g., A or V), optionally selected from the group consisting of A, F, L, S and V;

X2020 is an amino acid (e.g., W), optionally selected from the group consisting of F and W;

X2021 is an amino acid (e.g., V), optionally selected from the group consisting of L and V;

X2022 is selected from the group consisting of amino acids selected from the group consisting of A, D, F, G, K, L, P, R, S and W such as A, F, G, K, L, (E.g., amino acids selected from the group consisting of F, L, K, R, P, and W);

X2023 is selected from the group consisting of amino acids selected from the group consisting of A, D, F, G, K, L, M, S and Y such as A, D, F, G, L, M, (For example, an amino acid sequence selected from the group consisting of A, D, F, M, S and Y) (when X2023 is present).

The present invention further comprises a peptide that binds to TFPI, wherein the peptide comprises a structure of formula VI: X2001-X2002-F / YKWF / H- [C-X2008-M / V-X2010-D-X2012 -X2013-GI / T-X2016-S / TC] -A / VWV-X2022-X2023 (VI) (SEQ ID NO: 3119). In the peptide comprising the structure of formula VI, X2001, X2002 and X2023 are each independently present or absent. When X2001, X2002, and / or X2023 are present, any of X2001, X2002, and X2023 is independently selected from any amino acid. Also, X2008, X2010, X2012, X2013, X2016, and X2022 are each independently selected from any amino acid.

In some aspects, in the peptide of formula VI,

X2001 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W, (For example, an amino acid selected from the group consisting of A, D, F, G, H, K, L and S) selected from the group consisting of H, K, L, When it exists);

X2002 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W, (For example, amino acids selected from the group consisting of A, F, H, K, L, M, R and S) selected from the group consisting of G, H, K, L, M, P, , For example H, F, M, or R) and / or when X2002 is present;

X2008 is an amino acid optionally selected from the group consisting of amino acids selected from the group consisting of A, G, R, S and T, for example A, G and S;

X2010 is selected from the group consisting of amino acids, for example A, G, K, L, P, R and S, optionally selected from the group consisting of A, G, I, K, L, P, (E.g., amino acids selected from the group consisting of A, K, L, P, R and S, such as K, P or R);

X2012 is optionally selected from A, a, D, d, E, e, F, f, G, I, I, K, k, L, l, M, m, Nle, nle, P, a, D, d, F, f, G, K, k, L, l, M and the amino acid selected from the group consisting of SEQ ID NO: (for example, D, d, F, f, G, K, k, L, l, M, Nle, P, S) selected from the group consisting of m, Nle, P, , And Sem, such as F, L, l, Sem, or M);

X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, (For example, amino acids selected from the group consisting of A, D, F, G, K, L, and S, such as amino acids selected from the group consisting of F, G, K, L, G, K, or S);

X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, (For example, amino acids selected from the group consisting of D, F, K, L, M, Nle, S, and Sem) selected from the group consisting of L, M, Nle, S Sem, F, < / RTI > Sem, or M);

X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, (For example, an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W, e.g., amino acid selected from the group consisting of K, L, P, For example F, L, K, R, P or W);

X2023 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, M, S, T, V, W and Y, (For example, amino acids selected from the group consisting of A, D, F, G, L, M, S and Y such as A, D, F, M, S or Y) (when X2023 is present).

The TFPI-binding peptides of the invention comprise, in one aspect, at least 60% identity (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85% %, At least 90%, at least 95% or 100% identity): Ac-FYYKWH [CGMRDMKGTMSC] AWVKF-NH2 (VII) (SEQ ID NO: 1040). Optionally, the peptide comprises or consists of the amino acid sequence of Formulas V-VII as defined herein. The present invention provides a peptide comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 1001-1293 (e.g., a peptide consisting of SEQ ID NOS: 1001-1212 and 1290-1291 (for example, SEQ ID NOS: 1001-120, 1290, or 1291) And / or a peptide comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 1213-1289 and / or SEQ ID NOS: 1292 and 1293).

The present invention further provides TFPI-binding peptides comprising a structure of formula VIII: X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-X3012-X3013-X3014-X3015 -X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120). In formula (VIII), X3001 and X3002 are independently present or absent in the peptide. X3001 is selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y Amino acid; X3002 is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W and Y;

X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, Y and P;

X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;

X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H;

X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;

X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;

X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;

X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;

X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H;

X3012 is an amino acid selected from the group consisting of A, C, H, I, K, L and R;

X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I;

X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K;

X3015 is an amino acid selected from the group consisting of A, K, and R;

X3016 is an amino acid selected from the group consisting of A, F, K and R;

X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M;

X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y;

X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I;

X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P;

X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y,

In some aspects of the invention, the peptide comprises the sequence of formula < RTI ID = 0.0 > VIII &

X3001 is an amino acid selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y, (When X3001 is present) is an amino acid selected from the group consisting of C, D, G, K, L, M, N, P, R, S, T, E, H and Y;

X3002 is an amino acid selected from the group consisting of C, F, H, K, R, S, W, Y, G, I and L, An amino acid selected from the group consisting of (when X3002 is present);

X3003 is an amino acid selected from the group consisting of A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T and W, Amino acid selected from the group consisting of G, H, I, K, L, M, R, S, T and W;

X3004 is an amino acid selected from the group consisting of A, C, D, G, H, I, K, L, M, N, R, S, T, V and P, , I, K, L, M, N, R, S, T and P;

X3005 is selected from the group consisting of amino acids selected from the group consisting of C, F, H, I, K, M, R, T, W and Y such as C, F, H, K, R and W Amino acid;

X3006 is an amino acid optionally selected from the group consisting of P, H and A;

X3007 is an amino acid selected from the group consisting of amino acids selected from the group consisting of C, G, R, W, A and L, for example L, C, R and W;

X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, T, V, W, Y and I, , H, K, R, V, W, Y and I;

X3009 is an amino acid optionally selected from the group consisting of C, I, R, V and K, for example C, R, V and K;

X3010 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, Q, R, S and T, An amino acid selected from the group consisting of:

X3011 is an amino acid selected from the group consisting of A, I, K, L, M, R, S, V, W, C, F and H, , C, F and H;

X3012 is an amino acid (e.g., H), optionally selected from the group consisting of H and R;

X3013 is an amino acid selected from the group consisting of C, K, R, V and I, optionally selected from the group consisting of C, F, K, L, M, R, V and I;

X3014 is an amino acid selected from the group consisting of A, M, C, F, H, I, L, N, R, S, V, W and K, , R and K;

X3015 is optionally K or R;

X3016 is optionally K or R;

X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, H, A and M, Amino acids selected from the group consisting of I, K, L, N, Q, R, S, T, V, H, A and M;

X3018 is an amino acid (e.g., K, C, I, R, or W) optionally selected from the group consisting of A, K, C, I, L, R and W;

X3019 is an amino acid optionally selected from the group consisting of amino acids selected from the group consisting of A, C, E, H, K, N, Q, R and I such as C, E, H, K, ;

X3020 is an amino acid (e.g., C, M, I, or P) optionally selected from the group consisting of C, H, L, M, R, V, I and P;

X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, Y, F and G, , K, L, M, N, Q, R, V, W, F and G.

The present invention further provides peptides that bind to TFPI and include the structure of Formula IX: X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-H- K / RR-X3017-X3018-X3019-X3020-X3021 (IX) (SEQ ID NO: 3121). In Formula IX, X3001 and X3002 are independently present or absent in the peptide. When present, X3001 and / or X3002 are independently selected from any amino acid. Similarly, X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X3011, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid. When present, X3001 is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, For example, amino acids selected from the group consisting of A, C, D, G, I, K, L, M, N, P, Q, R, S, T, W, E, Amino acids selected from the group consisting of A, C, D, G, K, L, M, N, P, R, S, T, E, Similarly, when present, X3002 is optionally an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, (For example, C, K, R, W, Y, G, I and L) selected from the group consisting of C, F, H, K, R, S, W, Y, ≪ / RTI > Also with reference to formula IX,

X3003 is an amino acid optionally selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, (For example, A, C, D, F, G, H, I, K, L, M, N, P, Q, Amino acid selected from the group consisting of G, H, I, K, L, M, R, S, T and W);

X3004 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, (For example, A, C, G, and B) selected from the group consisting of A, C, D, G, H, I, K, L, M, N, R, S, Amino acids selected from the group consisting of H, I, K, L, M, N, R, S, T and P);

X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y, (For example, an amino acid selected from the group consisting of C, F, H, K, R and W) selected from the group consisting of H, I, K, M, R, ;

X3006 is an amino acid optionally selected from the group consisting of amino acids selected from the group consisting of A, W, C, K, P, R and H, for example P, H and A;

X3007 is optionally an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y, , Amino acids selected from the group consisting of A and L (e.g., L, C, R or W) and / or;

X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, (For example, A, C, F, H, and C) selected from the group consisting of C, F, G, H, K, L, M, N, Q, K, R, V, W, Y and I) and / or;

X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K, (E.g., C, R, V, or K) selected from the group consisting of:

X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y, (For example, a group consisting of A, C, K, L, Q, R and S) selected from the group consisting of C, G, H, I, K, L, M, Q, / RTI > and / or;

X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H, (For example, I, K, L, M, R, V, W, C, F and H) selected from the group consisting of K, L, M, R, S, V, W, H) and / or;

X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I such as C, F, K, (For example, C, K, R, V, or I) selected from the group consisting of R, V, and I;

X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, (For example, A, S, C, F, H, I, R and K) selected from the group consisting of C, F, H, I, L, N, R, S, V, Amino acids selected from the group consisting of:

X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M, (For example, C, G, I, C, F, G, I, K, L, N, Q, R, S, T, V, W, An amino acid selected from the group consisting of K, L, N, Q, R, S, T, V, H, A and M);

X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y, for example A, K, C, I, (E.g., K, C, I, R, or W) selected from the group consisting of:

X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I, (E.g., C, E, H, K, R, or I) selected from the group consisting of E, H, K, N, Q, R and I;

X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P, (For example, C, M, I, or P) selected from the group consisting of M, R, V, I and P;

X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y, F and G, (For example, A, C, H, I, K, L, and H) selected from the group consisting of H, I, K, L, M, N, Q, R, V, W, Amino acids selected from the group consisting of M, N, Q, R, V, W, F and G).

In some aspects, the TFPI-binding peptides of the invention have at least 60% identity (e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% , At least 95% or 100% identity): Ac-GYASFPWFVQLHVHKRSWEMA-NH2 (X) (SEQ ID NO: 223). Optionally, the peptide comprises or consists of the amino acid sequence of formula VIII-IX as defined herein. As used herein, "at least 60% identity" and similar terms include any integer, e.g., 60%, 61%, 62%, etc., from 60% to 100%. The term "at least [%] identity" includes any percentage that is at least equal to the total number of amino acids of the peptide of the present invention / number of identical amino acids (at least% identity) The total number of amino acids in the peptide].

The invention encompasses peptides comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 2001-2498 (e.g., SEQ ID NOS: 2001-2296 and 2498 (e.g., SEQ ID NOs: 2001-2126, 2128-2296, or 2498) And / or a peptide comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 2297-2497 (e.g., SEQ ID NO: 2298-2497). The present invention provides a peptide comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 3001-3108 (e.g., SEQ ID NOS: 3001-3064 (e.g., SEQ ID NOS: 3001-3048, 3051-3053, 3055, or 3057-3064 ) And / or comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 3065-3084 (e.g., SEQ ID NOS: 3066-3084) and / or an amino acid sequence selected from the group consisting of SEQ ID NOS: 3085-3108 Peptide). ≪ / RTI >

The peptides of SEQ ID NOs: 1-7 also include, in some aspects, one or more amino acids attached to the N- or C-termini of SEQ ID NOs: 1-7. For example, the present invention can be used in combination with any one or more of the nucleotide sequences of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, Or a peptide comprising or consisting of the amino acid sequence of SEQ ID NO. Exemplary peptides comprising the amino acid sequence of SEQ ID NO: 2 include the amino acids of JBT0294, JBT0295, JBT0296, JBT0297, JBT0298, JBT0299, JBT0300, JBT0301, JBT0302, JBT0303, JBT0304, JBT0305, JBT0306, JBT0307, JBT0308, JBT0309, JBT0310, Or a peptide comprising or consisting of SEQ ID NOs. An exemplary peptide comprising the amino acid sequence of SEQ ID NO: 3 comprises or consists of the amino acid sequence of JBT0049, JBT0053, JBT0057, JBT0190, JBT0193, or JBT0197. The present invention further includes a peptide comprising or consisting of the amino acid sequence of JBT0050, JBT0054, JBT0058, JBT0129, JBT0130, JBT0205, JBT0208, JBT0211, JBT0212, JBT0217, JBT0218, or JBT0219 (all of which include the amino acid sequence of SEQ ID NO: 4) . Exemplary peptides comprising SEQ ID NO: 5 include peptides comprising or consisting of the amino acid sequence of JBT0101, JBT0052, JBT0103, JBT0178, or JBT0182. The present invention further comprises peptides comprising or consisting of the amino acid sequence of JBT0120, JBT0124, JBT0247, JBT0248, JBT0251, or JBT0252, each of which comprises the amino acid sequence of SEQ ID NO: 6. A peptide comprising the amino acid sequence of SEQ ID NO: 7, such as JBT0122, JBT0126. Also provided herein are peptides comprising or consisting of the amino acid sequences of JBT0221, JBT0224, JBT0225, JBT0226, JBT0228, JBT0232, or JBT0233. The peptides described herein are set forth in Table 5 of Example 1 and Figures 12-18.

In certain embodiments, the peptides of the invention comprise an amino acid sequence of JBT0047, JBT0049, JBT0101, JBT0120, or JBT0122, or any of the peptides of the invention described herein (e. G., The amino acid sequence of any one SEQ ID NO: For example, any one of SEQ ID NOS: 8-741, 744-968, 971-978, 1001-1210, 1213-1289, 1290-1293, 2001-2126, 2128-2296, 2298-2498 , 3001-3048, 3051-3053, 3055, 3057-3064, and 3067-3108), or variants of any of the above sequences. "Variant" means a peptide comprising at least one amino acid substitution, amino acid deletion, or amino acid addition to a parent amino acid sequence. The variants may have at least 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75% or more amino acid sequence identity to any amino acid sequence provided herein, having the ability to bind to TFPI and / , 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90% , 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO. In one embodiment, the peptide comprises or consists of the amino acid sequence of JBT0132, JBT0303, JBT0193, JBT0178, JBT0120, or JBT0224.

In one aspect, the peptides of the invention consist of no more than 40 amino acids, for example no more than 35 amino acids. Optionally, the peptides of the invention consist of up to 25 amino acids, or up to 10 amino acids. In various embodiments, the peptides comprise 15-35 amino acid residues (e.g., 15,16, 17,18, 19,20, 21,22, 23,24, 25,26, 27,28, 29,30, 31, 32, 33, 34, or 35 amino acid residues). However, it is also contemplated that the peptides described herein, including one or more deletions, are suitable in the context of the present invention, as long as the peptides block TFPI inhibition of the coagulation cascade and optionally bind TFPI. In one aspect, peptides comprising one or more deletions are suitable in the context of the present invention, as long as the peptides bind to TFPI and optionally block TFPI inhibition of the coagulation cascade. In some aspects, amino acids are removed from within the amino acid sequence at the N-terminus and / or at the C-terminus. Such peptide fragments may comprise 3-14 amino acid residues (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid residues).

Optionally, the peptides of the invention comprise one or more amino acid substitutions (for any amino acid sequence provided herein) that do not destroy the ability of the peptide to bind and / or inhibit TFPI. For example, an amino acid sequence selected from the group consisting of JBT0294, JBT0295, JBT0296, JBT0297, JBT0298, JBT0299, JBT0300, JBT0301, JBT0302, JBT0303, JBT0304, JBT0305, JBT0306, JBT0307, JBT0308, JBT0309, JBT0310, or JBT0311 (The amino acid sequence of SEQ ID NO: 1 directly linked to the lysine residue at the N-terminus and the phenylalanine residue at the C-terminus) (see FIG. 4). Amino acid substitution can be used to (1) reduce susceptibility to proteolysis and / or (2) reduce susceptibility to oxidation and / or (3) alter binding affinity and / or (4) But are not limited to, imparting or modifying other physico-chemical or functional properties. In one aspect, the substitution is a conservative substitution, wherein the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains are defined in the art and include basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid and glutamic acid), uncharged polar side chains (Such as glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan), beta-branched side chains (E.g., threonine, valine, and isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine). However, one skilled in the art will appreciate that the resulting peptide is not limited to generating conservative substitutions so long as it retains the ability to totally or partially down-regulate TFPI activity. The present invention also includes TFPI-inhibiting peptides comprising non-typical, non-natural amino acids known in the art. Exemplary non-natural amino acids include ornithine, citrulline, hydroxyproline, homoserine, phenylglycine, taurine, iodotyrosine, 2,4-diaminobutyric acid,? -Aminoisobutyric acid, Butyric acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, tricyclohexylalanine, tricyclohexylalanine, β-homo-phenylalanine, β-homolysine, β-alanine, fluoro-amino acid, 3-methylamino acid, α-C-methylamino acid, N-methylamino acid, Homoserine, β-homoasparic acid, β-homoasparagine, β-homo asparagine, (S) -cyclohexyl Alanine, (S) -citrate, (S) -2,4-diamine (S) -2-aminobutyric acid, (S) -diaminopropionic acid, (S) -2-propargylglycine, (S) -N (Omega) -nitro-arginine, Phenylalanine, (S) -homo-arginine, (S) -horo-citrulline, (S) -horo-cysteine, (S) -2-amino- S-N-methylalanine, (S) -N-methylalanine, (S) -N-methyl-aspartic acid, (S) -N-methyl-lysine, (S) -N-methyl-leucine, (S) -2-pyridyl-alanine, (S) -ornithine, L-phenylglycine, 4-phenyl- Butyric acid and selenomethionine. Individual amino acids may have L or D stereochemistry where appropriate, but L stereochemistry is commonly used for all amino acids in the peptide.

The present invention further encompasses TFPI-inhibiting peptide variants comprising one or more amino acids inserted within the amino acid sequences provided herein and / or attached at the N-terminus or C-terminus. In one aspect, the peptide is one that facilitates the synthesis, handling, or use of the peptide, including, but not limited to, one or two lysines at the N-terminus and / or the C-terminus to increase the solubility of the peptide Or more amino acids. Suitable fusion proteins include, but are not limited to, proteins comprising one or more polypeptides, polypeptide fragments, or TFPI-inhibiting peptides linked to amino acids that are not generally recognized as being part of the protein sequence. In one aspect, the fusion peptide comprises the entire amino acid sequence of two or more peptides or, alternatively, comprises a portion (fragment) of two or more peptides. In addition to all or part of the TFPI-inhibiting peptides described herein, the fusion protein optionally includes all or a portion of any suitable peptide comprising the desired biological activity / function. Indeed, in some aspects, the TFPI-inhibitory peptides may be, for example, those that have a long circulating half-life, a marker protein, a peptide that facilitates the purification of a TFPI-inhibiting peptide, a peptide sequence that promotes the formation of a multimeric protein, Lt; RTI ID = 0.0 > one < / RTI > In one embodiment, the two or more TFPI-inhibiting peptides are fused together, joined by a multimerization domain, or attached via chemical linkage to produce a TFPI-inhibiting peptide complex. The TFPI-inhibitor peptides may be the same or different.

"Derivatives" are encompassed by the present invention, including TFPI-inhibiting peptides chemically modified in some manner distinct from addition, deletion or substitution of amino acids. In this regard, the peptides of the invention provided herein are chemically coupled to polymers, lipids, other organic moieties, and / or inorganic moieties. Examples of peptide and protein modifications are given in Hermanson, Bioconjugate Techniques, Academic Press, (1996). Derivatives are prepared in some circumstances to increase solubility, stability, absorption, or cycle half-life. Various chemical transformations eliminate or attenuate any undesirable side effects of the material. In this regard, the present invention includes covalently modified TFPI-inhibiting peptides to include one or more water soluble polymer attachments. Useful polymers known in the art include polyethylene glycol (PEG) (e.g., PEG with a size of about 40 kD or 1 kD), polyoxyethylene glycol, polypropylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose , Poly- (N-vinylpyrrolidone) -polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide co-polymer, polyoxyethylated polyol (e.g., glycerol) and polyvinyl alcohol, and But are not limited to, mixtures of any of these materials. In one aspect, the peptides of the invention are PEGylated peptides. For further discussion of water soluble polymer attachment see U.S. Patent 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; And 4,179,337. In another aspect, the peptide derivative comprises a targeting moiety that is specific for a particular cell type, tissue, and / or organ. Alternatively, the peptides are linked to one or more chemical moieties that facilitate purification, detection, quantification, and characterization of peptide activity. An exemplary chemical moiety is biotin. Also, in one aspect, the peptide of the invention is acylated at the N-terminal amino acid of the peptide. In another aspect, the peptide of the invention is amidated at the C-terminal amino acid of the peptide. In yet a further aspect, the peptides of the invention are acylated at the N-terminal amino acid of the peptide and amidated at the C-terminal amino acid of the peptide.

Derivatives also include peptides comprising modified or non-proteinaceous amino acids or modified linker groups (see, e. G., Grant, Synthetic Peptides: A User's Guide, Oxford University Press (1992)). Modified amino acids include, for example, amino acids in which amino and / or carboxyl groups have been replaced with other groups. Non-limiting examples include modified amines including thioamides, ureas, thioureas, acylhydrazides, esters, olefins, sulfonamides, phosphoric amides, ketones, alcohols, boric acid amides, benzodiazepines and other aromatic or non- (See Estiarte et al., Burgers Medicinal Chemistry, 6th edition, Volume 1, Part 4, John Wiley & Sons, New York (2002)). The modified amino acid is often linked to a peptide having at least one of the above-mentioned functional groups instead of an amide bond. Non-protein constituent amino acids include, but are not limited to,? -Alanine (Bal), norvaline (Nva), norleucine (Nle), 4-aminobutyric acid (? -Abu), 2-aminoisobutyric acid (Aib) ? -Ahx), ornithine, hydroxyproline (Hyp), taurine, sarcosine, citrulline (Cit), cysteine acid (Coh), cyclohexylalanine Cha, methionine sulfoxide (Meo), methionine sulfone (Moo), homoserine methyl ester (Hsm), propargylglycine (Eag), 5-fluoro tryptophan (5Fw), 6-fluoro tryptophan (6Fw), 3 ', 4'-dimethoxyphenyl-alanine Earl), 3 ', 4'-difluorophenylalanine (Dff), 4'-fluorophenylalanine (Pff), 1-naphthyl- alanine (1Ni), 1- methyltryptophan (Bf), L-homo-cysteine (Hcy), N-methyl-phenylalanine (Nmf ), 2-thienyl alanine (Thi), 3,3-diphenylalanine (Ebw), homophe Include alanine (Hfe) and S- benzyl -L- cysteine (Ece) is not so limited. These and other non-proteinogenic amino acids may exist as D- or L-isomers. Examples of modified linkers include flexible linkers 4,7,10-trioxa-1,13-tridecanediamine (Ttds), glycine, 6-aminohexanoic acid, beta-alanine (Bal), and Ttds, glycine, 6 - < / RTI > aminohexanoic acid and Bal.

The homologues of the amino acids constituting the peptides of the present invention may be as shown in Table 3.

<Table 3>

In some embodiments, the peptide (CO-NH) linking group linking amino acids within the peptide of the invention associates with a "retro-modified" peptide, ie, in the opposite direction (NH-CO bond) RTI ID = 0.0 &gt; amino acid &lt; / RTI &gt; residues. Retro-modified peptides include the same amino acid chirality as the reference peptides. An " inverso-modified "peptide is a peptide of the invention comprising an amino acid residue associated in the same orientation as the reference peptide, but the chirality of the amino acid is reversed. Thus, when the reference peptide comprises an L-amino acid, the "inverso-modified" peptide comprises a D-amino acid and vice versa. Inverso-modified peptides include CO-NH peptide bonds. A "retro-inverso modified" peptide refers to a peptide comprising amino acid residues that are associated in opposite orientation and have reversed chirality. The retro-insoluble analogue has an inverted terminal and inverted orientation of the peptide bond (i.e., NH-CO) while almost retaining the side chain topology found in the reference peptide. Retro-Inverso peptide mimetics are prepared using standard methods, including those described in Meziere et al., Immunol., 159, 3230-3237 (1997), incorporated herein by reference. A partial retroviral peptide is a peptide in which only a portion of the amino acid sequence is inverted and replaced with an enantiomeric amino acid residue.

The TFPI-binding peptides (e. G., TFPI inhibitor peptides) of the invention are prepared in a variety of ways. In one aspect, peptides are described in Merrifield, J. Am. Chem. Soc., 85, 2149 (1963); [Davis et al., Biochem. Intl., 10, 394-414 (1985); [Larsen et al., J. Am. Chem. Soc., 115, 6247 (1993); [Smith et al., J. Peptide Protein Res., 44, 183 (1994)]; [O'Donnell et al., J. Am. Chem. Soc., 118, 6070 (1996); [Stewart and Young, Solid Phase Peptide Synthesis, Freeman (1969)]; [Finn et al., The Proteins, 3rd ed., Vol. 2, pp. 105-253 (1976); And Erickson et al., The Proteins, 3rd ed., Vol. 2, pp. 257-527 (1976)). Alternatively, a TFPI-binding peptide (e. G., A TFPI-inhibiting peptide) may be conjugated to a nucleic acid encoding a TFPI-binding peptide (e. G., A TFPI-inhibiting peptide) in a host cell, which is cultured to express the peptide And then expressed in a recombinant manner. Such peptides are purified from cell culture fluids using standard protein purification techniques.

The present invention also includes a nucleic acid comprising a nucleic acid sequence encoding a TFPI-inhibiting peptide of the present invention. Methods for making DNA and / or RNA molecules are known in the art. In one aspect, the DNA / RNA molecules encoding the peptides provided herein are generated using chemical synthesis techniques and / or polymerase chain reaction (PCR). If desired, a TFPI-inhibiting peptide coding sequence is introduced into an expression vector. Those skilled in the art will appreciate that any number of expression vectors known in the art, such as, but not limited to, plasmids, plasmid-liposome complexes, and viral vectors are suitable in the context of the present invention. Any of these expression vectors can be obtained, for example, as described in Sambrook et al., Molecular Cloning, a Laboratory Manual, 2d edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989) and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (1994). &Lt; / RTI &gt; Optionally, the nucleic acid is operably linked to one or more regulatory sequences, e. G., A promoter, activator, enhancer, cap signal, polyadenylation signal, or other signal associated with transcription or translation control.

Any TFPI-inhibiting peptide, or nucleic acid encoding a peptide of the invention is also provided in a composition (e. G., A pharmaceutical composition). In this regard, the peptides are formulated using a physiologically acceptable (i.e., pharmaceutically acceptable) carrier, buffer, excipient, or diluent as further described herein. Optionally, the peptide is in the form of a physiologically acceptable salt, which is included in the present invention. "Physiologically acceptable salt" means any pharmaceutically acceptable salt. Some examples of suitable salts include acetate, hydrochloride, hydrobromide, sulfate, citrate, tartrate, glycolate, and oxalate. If desired, the composition comprises one or more additional pharmaceutically active agents.

The peptides provided herein optionally inhibit the activity of down-regulating at least one tissue factor pathway inhibitor-1 (e. G., TFPI-1 alpha) activity, such as, but not limited to, blood coagulation cascade. While not adhering to any particular mechanism of action, the proposed inhibition mechanism may include preventing the formation of the tetrahedron TF-FVIIA-FXA-TFPI complex. The peptide inhibits binding of TFPI Kunitz domain 1 to FXa (e.g., inhibits binding of TFPI Kunitz domain 2 to factor Xa), TF / FVIIa complex (e.g., inhibits binding of TFPI Kunitz domain 1 to TF / FVIIa complex) , TF alone, and / or FVIIa alone. When TFPI activity is attenuated, TF and FVIIa are liberated to activate FX, which in turn enhances the conversion of prothrombin to thrombin.

In one aspect, the peptides of the invention exhibit TFPI antagonistic activity in a model and / or plasma system. An exemplary model system for determining TFPI-inhibiting activity is an exogenous Tnase assay, which tests the ability of a candidate peptide to restore exogenous complex-mediated FX activation in the presence of TFPI, which is a natural inhibitor of FX activation response (See, for example, Lindhout et al., Thromb. Haemost., 74, 910-915 (1995)). Another model system for characterizing TFPI-inhibiting activity is the FXa inhibition assay, wherein FXa activity is measured in the presence of TFPI (see Sprecher et al., PNAS, 91, 3353-3357 (1994) . The exogenous tenase assay and the FXa inhibition assay are further described in Example 3. Optionally, the peptide of the present invention is 1 x 10 ^-4 M or less, 1 x 10 ^-5 M or less, 1 x 10 ^-6 M or less, or 1 x 10 ^-7 M half-maximum effective concentration (EC below in the presence of TFPI ₅₀ ) to improve FX activation.

In one aspect, TFPI-antagonistic activity is characterized by plasma-based assays. Thrombin formation is triggered in plasma which is substantially free of FVIII or FIX activity in the presence of the candidate peptide (e. G., Residual coagulation factor activity is less than 1%). Thrombin formation can be detected using a fluorescent or chromogenic substrate as described in Example 4. &lt; RTI ID = 0.0 &gt; A system for measuring thrombin activity is provided by Thrombinoscope BV (Maastricht, The Netherlands). Prothrombin conversion is measured, for example, using a Thrombograph ™ (Thermo Scientific, Waltham, Mass., USA), and the resulting data is analyzed using a Thrombinoscope, available from Trombinskopov, ) &Lt; / RTI &gt; software to generate a calibrated automatic thrombogram. In certain embodiments, TFPI-inhibiting peptides increase the amount of peak thrombin produced during the assay and / or reduce the time required to achieve peak thrombin formation. For example, the peptide improves TFPI-regulated thrombin production in the absence of FVIII (e.g., in FVIII-deficient plasma) to at least 1% of the level of TFPI-dependent thrombin production in normal plasma. Typically, normal (untreated) plasma contains about 0.5 U / mL to about 2 U / mL Factor VIII. Thus, in some cases, the TFPI-inhibitor peptide will enhance thrombin formation in the absence of FVIII to at least about 1% of that observed in the presence of 0.5 U / mL to 2 U / mL FVIII. In a further embodiment, the peptide inhibits thrombin formation in the absence of Factor VIII by at least about 2%, at least about 3%, at least about 3%, at least about 5%, at least about 5% 5%, at least about 7%, or at least about 10%. In various aspects, the peptides are administered to animal models of thrombin deficiency or hemophilia to characterize TFPI inhibitory activity in vivo. Such in vivo models are known in the art and include, for example, mice that have received anti-FVIII antibodies to induce hemophilia A (Tranholm et al., Blood, 102, 3615-3620 (2003)); (FVIII knock-out mice (Bi et al., Nat. Genet., 10 (1), 119-121 (1995)) and FIX knock- Out mice (Wang et al., PNAS, 94 (21), 11563-66 (1997)); Rabbit-induced hemophilia-A (Shen et al., Blood, 42 (4), 509-521 (1973)); And Chapel Hill HA dogs (Lozier et al., PNAS, 99, 12991-12996 (2002)).

Without being bound to any particular theory or mechanism, the peptides of the invention provided herein can inhibit TFPI activity by blocking (either competitively or in an allosteric manner) the binding of TFPI and FXa. Alternatively or additionally, the peptides can inhibit the binding of TFPI to the tissue factor (TF) / Factor VIIa complex. Thus, in certain aspects, the peptide binds specifically to TFPI. Various peptides from any source, including but not limited to mice, rats, rabbits, dogs, cats, cows, horses, pigs, guinea pigs, and primates, bind to TFPI. In one embodiment, the peptide binds human TFPI. Optionally, the TFPI-inhibiting peptide binds to TFPI from more than one species (i. E., The peptide is cross-reactive between multiple species). In a particular aspect, the peptide binds to TFPI with 1 x 10 ^-4 M or less, 1 x 10 ^-5 M or less, 1 x 10 ^-6 M or less, or 1 x 10 ^-7 dissociation constant (K _D) of less than M . Affinity may be determined, for example, and without limitation using any one, two or more of a variety of techniques, such as affinity ELISA analysis, competitive ELISA analysis, and / or surface plasmon resonance (BIAcore) analysis. Competition (IC ₅₀ ) When characterized using an ELISA assay, the peptides of the invention optionally display an IC ₅₀ of about 50,000 nM or less. For example, the peptide represents the IC _50, for example, about 5,000 nM or less, about 1,000 nM or less, or IC ₅₀ of less than about 500 nM up to about 10,000 nM. In one aspect, the peptide exhibits an IC ₅₀ of about 250 nM or less, about 100 nM or less, or about 50 nM or less. Exemplary peptides and their IC ₅₀ values are provided in Figures 32-39; In some cases, the peptides are grouped into groups A, B, C, D, E, F, and G (see Table 4 in Example 1) based on IC ₅₀ values. In various aspects, the invention provides peptides belonging to Groups A, B, C, D, E, F, and / or G as set forth in Table 4. The affinity can also be determined by a kinematic method or by an equilibrium / solution method. Such methods are described in further detail herein or are known in the art.

As with all binding materials and binding assays, those skilled in the art know that it would be both tedious and impractical to list the various moieties that a binding agent should not detectably combine to be biologically (e.g., therapeutically) effective. Thus, the term "specifically binds" refers to the ability of a peptide to bind to TFPI with greater affinity than to bind to non-related control proteins other than TFPI. For example, the peptides can bind to TFPI with an affinity that is at least 5, 10, 15, 25, 50, 100, 250, 500, 1000, or 10,000 times greater affinity for the control protein. In some embodiments, the peptides bind to TFPI with greater affinity than "anti-target" (the binding of the peptides to it in proteins or other naturally occurring substances in humans that may cause deleterious effects). Some classes of peptides or proteins are potential anti-targets. Because TFPI-inhibitory peptides exert their activity in the bloodstream and / or endothelium, plasma proteins are potential anti-targets. Proteins containing the Kunitz domain (KD) are potential anti-targets, since the KDs of different proteins share significant similarities. Tissue factor pathway inhibitor-2 (TFPI-2) is very similar to TFPI-1α and contains KD similar to TFPI-1α (Sprecher et al., PNAS, 91, 3353-3357 (1994)). Thus, in one aspect, the peptides of the invention bind to TFPI with an affinity that is at least 5, 10, 15, 25, or 50 times greater than the affinity for an anti-target, e.g., TFPI-2.

The present invention further includes a method of inhibiting TGF-1 (TFPI). The method comprises contacting the TFPI with a TFPI-binding peptide as described herein. Any degree of TFPI-active inhibition is contemplated. For example, a TFPI-inhibiting peptide reduces TFPI-inhibition of an exogenous pathway by at least about 5% (e.g., at least about 10%, at least about 25%, or at least about 30%). In some embodiments, the TFPI-inhibiting peptide reduces TFPI activity in the exogenous pathway by at least about 50%, at least about 75%, or at least about 90%, relative to TFPI activity in the absence of the peptide.

The present invention further includes a method of targeting a biological structure (e.g., cell surface and endothelial lining, for example) in which TFPI is located. The method includes contacting the TFPI-binding peptide described herein conjugated to a moiety that imparts additional functionality to the peptide, optionally with a biological structure (including, for example, cells that display TFPI on the cell surface, but not limited to) do. The moiety may be a dye (e.g., a fluorescent dye), a radionuclide or a radionuclide-containing complex, a protein (e.g., an enzyme, a toxin, or an antibody) or a cytotoxic agent. For example, the peptides are linked or conjugated to effector moieties that facilitate peptide detection and / or purification and / or contain therapeutic properties. In one aspect, a TFPI-binding peptide or peptide conjugate is administered to a mammal to target cells that display TFPI in the mammal. Optionally, the method further comprises detecting binding of the TFPI-binding peptide to TFPI. The method is useful for the treatment and diagnosis of diseases in which TFPI is a suitable diagnostic marker or in which the TFPI-expressing cells are the target for treatment options.

In some aspects, peptide-TFPI binding is indirectly detected. In this regard, the peptide is contacted with an interacting partner that binds to the peptide of the present invention without significantly inhibiting the peptide-TFPI binding, and an interaction partner is detected. Exemplary interaction partners include, but are not limited to, antibodies, antigen-binding antibody fragments, anticalines and antibody mimetics, aptamers and spiegelmers. Optionally, the interaction partner comprises a detection moiety to facilitate detection of the interaction partner-peptide complex. For example, methods for detecting antibodies and fragments thereof are well understood in the art. Similarly, detection moieties are widely used in the art for identification of biological materials and include, for example, dyes (e. G., Fluorescent dyes), radionuclides and radionuclide-containing complexes, and enzymes.

Accordingly, the present invention provides a method of diagnosing a subject afflicted with or at risk of developing a disease or disorder associated with or caused by abnormal TFPI activity. The method comprises administering to the subject a TFPI-binding peptide of the invention and detecting the TFPI-peptide complex. In some cases, the peptides of the invention are conjugated to a detectable moiety, and the method includes detecting a detectable moiety. In other cases, the method comprises administering to the subject a TFPI-binding peptide interaction partner that binds to the TFPI-binding peptide and detecting the interaction partner. If desired, the interaction partner includes or is coupled to a detectable moiety, and a detectable moiety is detected. The presence of a detectable moiety is indicative of the presence of TFPI and thereby may be ameliorated or prevented by a disease or disorder associated with TFPI (e.g., (i) by inhibiting TFPI, or (ii) A disease or condition that includes a symptom). Where administration of the peptide to a subject is undesirable, a biological sample is obtained from the subject, contacted with a TFPI-binding peptide as described herein, and a TFPI-peptide complex is detected.

The peptides of the invention bind to TFPI and are thus useful for purifying TFPI or recombinant TFPI from biological samples (e.g., biological fluids, such as serum), fermentation extracts, tissue preparations, culture media, The invention encompasses methods of using TFPI-linkages in commercial production of TFPI or in methods for characterization of TFPI molecules. For example, the invention includes a method of purifying TFPI. The method comprises contacting a sample containing TFPI with a peptide as defined herein under appropriate conditions to form a complex between TFPI and the peptide; Removing the complex from the sample; Optionally dissociating the complex to release TFPI. Appropriate exemplary conditions for complexing between TFPI and peptides are disclosed in the Examples, and such conditions can be readily modified to dissociate the TFPI-peptide complex. In some embodiments, the peptide is immobilized on a support, e. G., A solid support, to facilitate recovery of TFPI. For example, in one embodiment, the peptide is immobilized on a chromatographic stationary phase (e.g., silica, affinity chromatography beads, or chromatographic resin) and a sample containing TFPI is applied to a stationary phase to form a TFPI- The complex is formed, the remaining sample is removed from the stationary phase, and TFPI is eluted from the stationary phase. In this regard, the peptides of the invention are suitable for use in affinity chromatography techniques in one aspect.

A method of enhancing thrombin formation in a coagulation factor-deficient subject is also provided. The method comprises administering to the subject a peptide provided herein under conditions effective to inhibit TFPI. In this regard, TFPI-inhibiting peptides are administered under effective conditions effective to enhance thrombin formation in a subject. By "clotting factor-deficiency" is meant that the subject suffers from a deficiency of one or more blood factors, such as FVIII, FIX, or FXI, required for thrombin formation. Indeed, in one embodiment, the subject lacks FVIII. Alternatively or additionally, the subject lacks factor IX. A deficiency of coagulation factor is confirmed by examining the amount of the factor in the clinical sample. Those skilled in the art will classify hemophilia according to the magnitude of the coagulation factor deficiency. Subjects with mild hemophilia have a normal amount (1 U / ml) of Factor VIII or about 5% to 30% of Factor IX. Moderate hemophilia is characterized by about 1% to 5% of normal Factor VIII, Factor IX, or Factor XI levels whereas a subject with severe hemophilia has less than 1% of normal Factor VIII, Factor IX, or Factor XI . The deficiency can be confirmed indirectly by an activated partial thromboplastin time (APTT) test. The APTT test measures the length of time required for a blood clot to form, and this time is significantly reduced compared to patients with normal coagulation factor levels, such as Factor VIII deficiency (haemophilia A), factor LX deficiency (haemophilia B), and factor XI deficiency It is longer for patients with hemophilia C). Nearly 100% of patients with severe and moderate factor VIII deficiency can be diagnosed using APTT. The present invention further includes enhancing thrombin formation in a subject not suffering from a coagulation factor deficiency. The method includes administering to a subject (e.g., a subject having a normal, physiological level of coagulation factor) a peptide provided herein under conditions effective to enhance thrombin formation.

In one aspect, TFPI-inhibiting peptides are used to increase blood clot formation in a subject. A method of increasing blood clot formation comprises administering to a subject a peptide as described herein, under effective conditions effective to increase blood clot formation. It will be appreciated that the method does not require a complete restoration of the solidification cascade to achieve beneficial (e.g., therapeutic) effects. Any improvement or increase in thrombin or blood clot formation that reduces the incidence or severity of symptoms associated with a coagulation factor deficiency is contemplated. Methods for determining the efficacy of the method in promoting thrombin formation and blood coagulation are known in the art and described herein.

The present invention provides a method of treating a blood clotting disorder in a subject comprising administering to the subject one or more TFPI-inhibiting peptides, e. G., Any one or more of the peptides described herein, The method further comprises a method of treating the disease. In one aspect, the peptides are not natural peptides that inhibit TFPI activity. "Coagulation disorders" include bleeding disorders caused by lack of blood coagulation factor activity and lack of platelet activity. Blood clotting factors include, but are not limited to Factor V (FV), FVII, FVIII, FIX, FX, FXI, FXIII, FII (the cause of hypoprothrombinemia), and von Willebrand factor. Factor deficiency is caused by, for example, the shortened in vivo half-life of the factor, the altered binding characteristics of the factor, the genetic defect of the factor, and the reduced plasma concentration of the factor. Coagulation disorders can be congenital or acquired. Potential genetic defects include deletions, additions and / or substitutions in the nucleotide sequence coding for the coagulation factor, and their absence, presence and / or substitution each negatively affect the activity of the coagulation factor. Coagulation disorders also result from the generation of inhibitors or autoimmunity (e. G., Antibodies) to coagulation factors. In one example, the coagulation disorder is hemophilia A. Alternatively, the coagulation disorder is hemophilia B or hemophilia C.

Platelet disorders are caused by a lack of platelet function in the circulatory system or by abnormally low platelet counts. Low platelet counts may be due to, for example, lack of production, platelet isolation, or uncontrolled patent destruction. Thrombocytopenia (platelet deficiency) may exist for a variety of reasons, including chemotherapy and other pharmacotherapy, radiation therapy, surgery, blood loss due to accident, and other disease states. Exemplary disease states involving thrombocytopenia include: Aplastic anemia; Idiopathic or immune thrombocytopenia (ITP), including idiopathic thrombocytopenic purpura associated with breast cancer; HIV-associated ITP and HIV-related thrombotic thrombocytopenic purpura; Metastatic tumors causing thrombocytopenia; Neonatal lupus syndrome systemic lupus including spleen enlargement; Fanconi syndrome; Vitamin B12 deficiency; Folate deficiency; May-Hegglin anomaly; Wiscott-Aldrich syndrome; Chronic liver disease; Myelodysplastic syndrome associated with thrombocytopenia; Paroxysmal nocturnal hemoglobinuria; Acute primary thrombocytopenia after C7E3 Fab (abciximab) therapy; Allogeneic immune thrombocytopenia including maternal allogeneic immune thrombocytopenia; Thrombocytopenia associated with anti-phospholipid antibodies and thrombosis; Autoimmune thrombocytopenia; Drug-induced immune thrombocytopenia including carboplatin-induced thrombocytopenia and heparin-induced thrombocytopenia; Fetal thrombocytopenia; Gestational thrombocytopenia; Hughes syndrome; Lupus positive thrombocytopenia; Accidental and / or massive blood loss; Myeloproliferative disorders; Thrombocytopenia in patients with malignant tumors; Thrombotic thrombocytopenic purpuric fever including thrombotic microangiopathy which appears as thrombotic thrombocytopenic purpuric / hemolytic uremic syndrome in cancer patients; Purpura (PTP) after transfusion; Autoimmune hemolytic anemia; Factory diverticulum not visible to the naked eye; True erythrocyte anemia; Autoimmune thrombocytopenia; Pandemic nephropathy; Rifampicin-associated acute renal failure; Paris-Trousseau thrombocytopenia; Neonatal allogeneic immune thrombocytopenia; Paroxysmal nocturnal hemoglobinuria; Hematological changes in stomach cancer; Hemolytic uremic syndrome (e. G., Urinary toxic conditions in children); And hematologic features associated with viral infection including hepatitis A virus and CMV-associated thrombocytopenia. Platelet disorders also include, but are not limited to von Willebrand disease, adrenal hyperplasia, Glanzman platelet hypoplasia, and Bernard-Soulier disease. Additional bleeding disorders that can be treated with TFPI-inhibiting peptides include trauma-induced bleeding conditions; Deficiencies of one or more contact factors such as FXI, FXII, precuricle crane and high molecular weight kininogen (HMWK); Vitamin K deficiency; Fibrinogen diseases such as fibrinogenemia, hypofibrinogenemia and abnormal fibrinogenemia; And alpha 2-antiplasmin deficiency. In one embodiment, the TFPI-inhibiting peptides are used for the treatment of excessive bleeding, such as surgery, trauma, intracerebral hemorrhage, liver disease, renal disease, thrombocytopenia, platelet dysfunction, hematoma, internal bleeding, hemorrhagic arthropathy, It is used to treat excessive bleeding caused by pregnancy and dengue hemorrhagic fever. All of the above disorders are considered "blood clotting disorders" in the context of the disclosure herein.

In one aspect, the TFPI-inhibiting peptides of the invention are used to reverse (in whole or in part) the effect of one or more anticoagulants in a subject. Numerous anticoagulants are known in the art and include, for example, heparin; Coumarin derivatives such as warfarin or dicumarol; TFPI; AT III; Lupus anticoagulants; Nematocide antagonist peptide (NAPc2); FVIIa inhibitors; Active-site blocked FVIIa (FVIIai); Active-site blocked FIXa (FIXai); FIXa inhibitors; FXa inhibitors such as Fondaparinux, HydraPhynux, DX-9065a, and Lactic acid (DPC906); Active-site blocked FXa (FXai); Inhibitors of FVa or FVIIIa, such as activated protein C (APC) and soluble trombomodulin; Thrombin inhibitors such as hirudin, bivalirudin, argatroban and ximelagatran; And an antibody that binds to a coagulation factor (e.g., FV, FVII, FVIII, FIX, FX, FXIII, FII, FXI, FXII, von Willebrand factor, precursor crane, or high molecular weight kininogen (HMWK) Antibody fragments.

As used herein, "treating" and "treatment" refer to the severity and / or any reduction in the severity of symptoms associated with blood clotting disorders. Thus, "treating" and "treatment" include treatment and prevention. Those skilled in the art will appreciate that any degree of protection or remediation from blood coagulation disorders or conditions associated therewith is beneficial to a subject, e.g., a human patient. The quality of life of the patient is improved by reducing the depth of symptoms to an arbitrary degree in the subject and / or delaying the appearance of symptoms. Thus, in one aspect, the method may be performed as soon as possible after the subject is determined to be at risk for developing a blood coagulation disorder (e.g., a deficiency of a coagulation factor (e.g., FVIII, FIX, or FXI) (E. G., Hemophilia A, haemophilia B, or haemophilia C) is detected. In a further aspect, the peptide is administered wholly or in part to protect against damage or excessive blood loss during surgery.

In view of the above, the present invention provides peptides for use in a method for the treatment of a subject, e. G., A method for the treatment of diseases wherein inhibition of TFPI is beneficial. In one aspect, the disease or disorder is a blood clotting disorder. A subject is at risk of developing a disease or disease or suffering from a disease or disorder (or a harmful biological event, such as excessive blood loss). The method comprises administering to a subject a peptide of the invention under conditions effective in an effective amount to treat or prevent, in whole or in part, a disease or disorder. The present invention further provides a peptide for use in the manufacture of a medicament. For example, the peptides may be used in the manufacture of a medicament for the treatment of blood coagulation disorders as described in detail herein.

In some embodiments, it is advantageous to administer a nucleic acid comprising a nucleic acid sequence encoding a TFPI-binding peptide (e. G., A TFPI-inhibiting peptide) of the invention to a subject. The nucleic acid is provided in place of or in addition to the TFPI-inhibiting peptide in one aspect. Expression vectors, nucleic acid control sequences, methods of administration, and the like are further described herein and described in U.S. Patent Publication 20030045498.

Particular dosing regimens for a particular subject will depend in part on the amount of TFPI-inhibiting peptide of the present invention, the amount of TFPI-binding peptide (e.g., TFPI-inhibiting peptide) administered, the route of administration, the particular disease being treated, , And the cause and extent of any side effects. The amount of peptide administered to a subject (e. G., A mammal, e. G., A human being) and the conditions of administration (e. G., Time of administration, route of administration, route of administration) It is enough for. The dosage will usually depend on a variety of factors, such as the particular TFPI-inhibiting peptide used, the age and weight of the subject, and the presence and depth of any disease or disorder in the subject. The size of the dose will also be determined by the route, timing and frequency of administration. Therefore, the clinician can titrate dosages and modify the route of administration to obtain optimal therapeutic effects, and conventional range search techniques are well known to those skilled in the art. By way of pure example, in one aspect, the method comprises administering, for example, from about 0.1 [mu] g / kg to about 100 mg / kg or more according to the above-mentioned factors. In another embodiment, the dosage is from 1 [mu] g / kg to about 75 mg / kg; Or 5 [mu] g / kg to about 50 mg / kg; Or from 10 [mu] g / kg to about 20 mg / kg. In certain embodiments, the dosage ranges from about 0.5 mg / kg to about 20 mg / kg (e.g., about 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.3 mg / 5 mg / kg, 5.5 mg / kg, 6 mg / kg, 6.5 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / mg / kg, or 10 mg / kg). Given the chronic nature of many blood clotting disorders, it is believed that subjects will receive TFPI-inhibiting peptides over a course of weeks, months, or years, and may require daily or weekly dosing at least once . In another embodiment, the TFPI-inhibiting peptides are administered in combination with a relatively short duration of treatment to treat acute conditions (e. G., Bleeding caused by surgery or trauma, or an agent inhibitor / autoimmune episodes in a subject receiving a coagulation- , For example, for 1 to 14 days.

Suitable methods for administering physiologically acceptable compositions, e. G. Pharmaceutical compositions, comprising the peptides described herein are known in the art. Although more than one route may be used to administer the peptide, a particular route may provide a more immediate and more effective response than other routes. Depending on the circumstances, the pharmaceutical composition may be applied or injected into the body cavity and / or absorbed through the skin or mucosa, ingested and / or inhaled and / or introduced into the circulatory system. In one aspect, a composition comprising a TFPI-inhibiting peptide is administered intravenously, intra-arterially, or intraperitoneally to introduce a peptide of the invention into the circulatory system. Non-intravenous administration is also particularly appropriate in connection with low molecular weight therapeutics. In certain circumstances, pharmaceutical compositions comprising a TFPI-inhibiting peptide are administered orally, topically, sublingually, parenterally, rectally; Through injection by intracerebral (intraventricular), intracerebral, intramuscular, intraocular, intralesional, intralesional, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intrathecal, urethral, or intestinal means; By a delayed release system; Or by a transplantation device. If desired, TFPI-inhibiting peptides may be administered region-wise through the femoral artery for delivery to the leg, for example, via intra-arterial or intravenous administration to the area of interest. In one embodiment, the peptides are described in, for example, U.S. Patent Nos. 5,439,686 and 5,498,421, and U.S. Patent Publications 2003/0059474, 2003/0064033, 2004/0043077, 2005/0048127, 2005/0170005, 2005/0142205, 2005/142201, 2005/0233945, 2005/0147689. 2005/0142206, 2006/0024379, 2006/0260777, 2007/0207210, 2007/0092452, 2007/0281031, and 2008/0026068. Alternatively, the composition is administered via implantation of a membrane, sponge, or other suitable material onto which the desired molecule is absorbed or encapsulated. Where an implant is used, the device is implanted from one side into any suitable tissue, and delivery of the desired molecule is accomplished in various aspects through diffusion, timed-release bolus, or continuous administration. In another aspect, the TFPI-inhibiting peptide is administered directly to the tissue exposed during the surgical procedure or treatment of the impairment, or through transfusion of the blood procedure. Therapeutic delivery schemes are well known to those skilled in the art, some of which are further described, for example, in U.S. Patent 5,399,363.

To facilitate administration, the TFPI-binding peptide (e.g., a TFPI-inhibiting peptide) may be formulated into a physiologically acceptable composition comprising a carrier (i.e., a vehicle, adjuvant, buffer or diluent) do. The particular carrier employed is limited only by chemical-physical considerations, for example by a lack of solubility and reactivity with the peptide, and by the route of administration. Physiologically acceptable carriers are known in the art. Exemplary pharmaceutical forms suitable for injectable use include, but are not limited to, sterile aqueous solutions or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (see, for example, U.S. Patent No. 5,466,468). Injectable formulations are described, for example, in Pharmaceutics and Pharmacy Practice, J.B. Lippincott Co., Philadelphia. Pa., Banker and Chalmers, eds., Pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., Pages 622-630 (1986). Pharmaceutical compositions comprising the peptides provided herein are optionally placed in a container with a filler material providing instructions regarding the use of such pharmaceutical compositions. Generally, such instructions include a reliable expression describing the reagent concentration, and the relative amounts of the excipient component or diluent that may be required to constitute the pharmaceutical composition in certain embodiments.

Where appropriate, TFPI-binding peptides of the invention (e. G., TFPI-inhibiting peptides) are administered in combination with other agents and / or other therapeutic modalities to achieve additional or increased biological effects. The co-therapeutic agent may be a plasma-derived or recombinant coagulation factor, a hemophilia prophylactic agent, an immunosuppressant, a plasma factor-inhibiting antibody antagonist (i.e., an anti-inhibitor), an antifibrinolytic agent, an antibiotic, a hormone therapy, - steroidal anti-inflammatory drugs (NSAIDs) or steroidal anti-inflammatory agents), coagulation enhancers and analgesics. In one aspect, the method can be performed on a subject such as, for example, FXIII, FXII, FXI (eg, HEMOLEVEN® (Labora et al., Laboratoire francais du Fractionnement et FIS (for example, BENEFIX) coagulation factor IX (for example, &lt; RTI ID = 0.0 &gt; ALPHANINE SD (Grifols, Los Angeles, Calif., USA); MONONINE (CSL Behring, King 's of Pennsylvania, USA); Wyeth (Madison, NJ USA); ALPHANINE SD (PROFILNINE) SD (Grifolis, Los Angeles, CA); or PROPLEX &lt; RTI ID = 0.0 &gt; T ™ (Baxter, Illinois, USA) (HELIXATE) FS (CS Elvering, King of Prussia, Pennsylvania, USA); REFACTO (Field &lt; RTI ID = 0.0 &gt; XYNTHA ™ (Wired, USA Medison, NJ), KOGENATE® and Cogenate® FS (Bayer, Pittsburgh, Pa., USA); Alpha® HEMOPHIL M ™ (Baxter, DEERFIELD, IL.); K0ATE®-DVI (Tarecris Bio-Surfactics - US) FVIIa (e. G., NOVOSEVEN® FVIIa (FVIIa)), FVIIa (e. G., Talcris Biotherapeutics-USA, Research Triangle Park, North Carolina, USA); or MONARC-M (Baxter, Novo Nordisk, USA FVI, FII, and / or Fill), and FVII concentrate (Baxter Bioscience, Vienna, Austria) or Bio Products Laboratories (Hertfordshire Elstry, UK) Is an add-on therapy for traditional alternative therapy. In some cases, the subject is also administered a FEIBA VH Immuno (TM) (Baxter Bioscience, Vienna, Austria), a lyophilized sterile human plasma fraction with factor VIII inhibitor bypass activity. FEIBA VH Immuno ™ contains approximately the same units of Factor VIII inhibitor detoxification activity and prothrombin complex factors (Factors II, VII, IX, and X and Protein C). Other exemplary co-therapeutics include, but are not limited to, precurin crane, high molecular weight kininogen (HMWK), von Willebrand factor, tissue factor, and thrombin. Alternatively or additionally, the TFPI-inhibiting peptide is co-formulated with one or more different TFPI-inhibiting peptides.

Accordingly, the present invention provides a method of treating a subject, comprising administering to the subject a TFPI-binding peptide (e.g., a TFPI-inhibiting peptide) (or multiple TFPI-inhibiting peptides) of the invention, In combination with suitable substance (s). The administration strategy may include simultaneous administration (i. E., Substantially concurrent administration) of the TFPI-inhibiting peptide and one or more additional suitable substance (s) and non-concurrent administration (i. E., Administration in any order (folded or not) . It will be understood that the different components are optionally administered within the same or separate compositions and by the same or different routes of administration.

In some embodiments, the peptides of the invention are conjugated to a moiety, e. G., A therapeutic or diagnostic moiety, e. G., A detection moiety, and the co-treatment described above. Alternatively or in addition, the peptide may be conjugated to a moiety that is (a) bound to a peptide and (b) is therapeutically active and / or provides additional functionality to an interacting partner (e.g., therapeutic, diagnostic or detection agent) Is administered in combination with an acting partner (e. G., An antibody, antibody fragment, anticalyne, aptamer, or spigelmer). Suitable moieties include, but are not limited to, dyes, radionuclides, radionuclide-containing complexes, enzymes, toxins, antibodies, antibody fragments, and cytotoxic agents, and in some cases the moiety has therapeutic activity To achieve the desired biological effect). The peptide conjugate or peptide-interacting partner pair is suitable for use in any of the methods described herein, for example, in a method of treating a subject afflicted with or at risk of developing a disease or disorder.

All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each individual disclosure or patent application were specifically and individually indicated to be incorporated by reference. It is also to be understood that the entire document is intended to relate as an integrated disclosure and that all combinations of features described herein are also contemplated if combinations of features are not found in the same sentence, paragraph, or clause of the document do. For example, where protein therapy is described, embodiments involving polynucleotide therapy (using polynucleotides / vectors encoding proteins) are specifically contemplated and vice versa. While the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, certain changes and modifications may be made to the invention without departing from the scope of the appended claims, And will be readily apparent to those skilled in the art. The invention encompasses all embodiments of the invention in which the range is narrower in any way than the specifically mentioned variation, for example. With respect to aspects of the invention described as genus, all individual species are individually considered as distinct aspects of the present invention. It is to be understood that, unless the context clearly dictates a more limited meaning, with respect to aspects of the claimed invention that are either used to describe the singular ("a" or "an" do. It should be understood that, for elements described in more than one of the sets, all combinations within the set are considered.

Example

Example  One

The following examples illustrate the production of peptides, identification, and screening for binding to TFPI.

Peptide candidates were obtained from commercial suppliers (e.g., PolyPeptide Laboratories SAS (Strasbourg, France) and JPT Peptide Technologies GmbH (Berlin, Germany)). A method for synthesizing a candidate peptide is provided above. The candidate peptide was synthesized as a trifluoroacetate (TFA) salt with a purity> 90% or> 60%. All peptides were dissolved in DMSO at a stock solution concentration of 10 mM. TFPI-binding peptide sequences were identified using an mRNA display library. mRNA display technology is superior to other library screening techniques because it allows for the diversity of 10 ¹⁴ different sequences within the starting pool and avoids the in vivo steps required for phage display, for example. Briefly, the technique involves direct linking of the mRNA to its coded candidate peptide through the furomycin molecule (Figure 5). mRNA display methods are further described in International Patent Application Publication No. WO 2005/051985 and Liu et al., Methods in Enzymology, 318, 268-293 (2000). TFPI was immobilized to the solid support via biotin and exposed to the candidate peptide-RNA complex. The TFPI-linked candidate peptide-RNA complex was isolated and RNA reverse transcription was performed to obtain the coding DNA. A high affinity binder was obtained after 6 to 10 rounds of selection using a competitive elusion strategy. Many candidate peptides were 31 amino acids in length (27 randomly selected amino acids and 2 amino acids adjacent to both ends).

Selected peptides were synthesized and applied to peptide optimization using microarray-based scan analysis to identify peptide fragments carrying TFPI-binding affinity. For example, a microarray-based scan of JBT0047 was performed using a series of 20 amino acid fragments of peptides whose sequences were overlapped by 19 amino acids. N- and C-terminal cleavage assays were performed to supplement the scan analysis. Microarray scan results showed that peptide JBT0293 binds to TFPI in the highest affinity. A series of substitution mutants based on the amino acid sequence of JBT0293 was generated and tested for TFPI binding properties.

The affinity of the subset peptides for TFPI was demonstrated by enzyme linked immunosorbant assay (ELISA) -like analysis (conjugation (EC ₅₀ ) ELISA) performed using biotinylated peptides. In 96 well Maxi-soap (Maxisorp) 3 ㎍ / mL TFPI in the plate (neongkeu (Nunc)) coating buffer _{(15 mM Na 2 CO 3,} 35 mM NaHCO 3, pH 9.6) were coated overnight. The plate was washed three times with 350 μL wash buffer (HNaT: 175 mM NaCl, 25 mM HEPES, 5 mM CaCl ₂ , 0.1% Tween 80, pH 7.35) and subsequently 200 μl of 2% yeast extract in HNaT . Plates were then washed three times with 350 [mu] l HNaT. The biotinylated candidate peptide was diluted 1/200 in HNaT from the DMSO stock solution. If no precipitate appeared during 1/200 dilution of the 10 mM peptide stock solution, the initial peptide concentration was 50 μM. When a precipitate is formed, a pre-dilution of the peptide stock solution in DMSO is performed. The diluted peptides were applied to maxisophile plates, serial dilutions (1/3) were generated, and the dilutions were incubated at room temperature for 1.5 hours. Three wash steps (350 [mu] l HNaT) were performed after incubation. The bound peptides were incubated (1 hour) with horseradish peroxidase-conjugated streptavidin followed by three washing steps with HNaT and with the addition of TMB (3,3 ', 5,5'-tetra Methylbenzidine) by subsequent color conversion. The analysis is illustrated in Figure 6a.

In general, peptide binding to immobilized TFPI was significantly higher than in the background. The EC ₅₀ values for biotinylated peptides are given in Figures 32-39. The binding curve of one TFPI-binding peptide, JBT0132, is shown in Fig. The EC ₅₀ of JBT0132 was calculated to be about 2.2 nM.

In addition, competition (IC ₅₀ ) ELISAs were performed using biotinylated TFPI-binding peptides as "tracers" to compete with non-biotinylated candidate peptides for TFPI-binding. The analysis principle is shown in FIG. 6B. The 96 well maxi soap plates were coated overnight with 3 μg / mL TFPI in coating buffer (15 mM Na ₂ CO ₃ , 35 mM NaHCO ₃ , pH 9.6). The plate was washed three times with 350 ㎕ wash buffer (HNaT: 175 mM NaCl, 25 mM HEPES, 5 mM CaCl ₂ , 0.1% Tween 80, pH 7.35) and blocked with 200 2 of 2% yeast extract in HNaT for 2 hours . Plates were then washed three times with 350 [mu] l HNaT. Biotinylated tracer peptides were applied at concentrations corresponding to their respective EC ₉₀ values (median if n> 2) determined in the binding ELISA. Peptide competitor stock solutions (10 mM) were diluted 1 / 33.3 in HNaT without HSA and serial 1/3 dilutions in HNaT with 3% DMSO. The diluent was further diluted with biotinylated tracer peptides at a ratio of 1: 6 (20 [mu] l competitor diluent and 100 [mu] l tracer peptide). A mixture of competitor and tracer peptides was applied to TFPI-coated microtiter plates and incubated for 1.5 hours. The plate was washed three times with 350 [mu] l HNaT. Peptide-TFPI binding was determined by applying HRP-conjugated streptavidin to microtiter plates, incubating the mixture for 1 hour, washing the plate 3 times with 350 [mu] l HNaT and incubating TMB (3,3 ', 5,5' -Tetramethylbenzidine) was applied and detected by detecting the subsequent color conversion of TMB by HRP. IC ₅₀ graphs for representative non-biotinylated peptides are provided in Figures 8a-8d. The IC ₅₀ readings of the peptides JBT0303, JBT0120 and JBT0224 are presented in Table 3.

Peptides IC ₅₀ [[mu] M] n SD Tracer peptide Tracer concentration [μM] JBT0303 0.119 2 0.064 JBT0131 0.0409 JBT0120 0.0189 3 0.0044 JBT0124 0.0718 JBT0224 n.a. One JBT0126 0.240

In addition to competitive ELISA (IC ₅₀ ) assays, screening assays were used to measure a greater number of peptides in parallel. The screening ELISA was similar to the competitive IC ₅₀ ELISA except that only three different concentrations of competitor (300 nM, 100 nM and 33.3 nM for the JBT0047 class, and 50000 nM, 16667 nM and 5556 nM for the JBT0122 class) Do. In some cases, the screening results were expressed as% inhibition of the tracer signal relative to competitive peptides (competitive peptide JBT0477 for the JBT0047 family, and competitive peptide JBT1697 for the JBT0122 family). Competitive IC ₅₀ assay results and screening assay results of peptides prepared and screened according to the methods presented herein are provided in Figures 32-39. The mean IC ₅₀ values shown in Figures 32-39 are based on a greater number of assays than the values given in Table 3, and therefore the values may be slightly different. The results of the screening ELISA are presented as percent inhibition of the tracer peptide JBT0131 binding. Some peptides analyzed using IC ₅₀ ELISA were sorted in Figures 32-39 according to their binding affinities shown in Table 4.

TFPI Competition ELISA IC ₅₀ [nM] group <50 nM A 50 < x &lt; 100 nM B 100 < x &lt; 250 nM C 250? X < 1000 nM D 1000 < x &lt; 5000 nM E 5000 < x &lt; 10000 nM F 10000 < x &lt; 50000 nM G

Exemplary TFPI-binding peptides identified using the methods described herein are set forth in Table 5. Some peptides are biotinylated and many include N- and C-terminal lysines to promote solubility. Some peptides showed TFPI-inhibiting activity in the model and / or plasma assay system as described below.

This example provides an exemplary method for generating and characterizing TFPI-inhibiting peptides. All of the peptides in Table 5 were found to bind to human TFPI-la. Mutagenic assays have demonstrated that at least one amino acid can be substituted within the TFPI-binding peptide while maintaining affinity for TFPI. The peptides of Table 5 tested in ELISA assays were bound to TFPI-1 alpha with an EC _{50 of} less than 10 μM (1 × 10 ^-5 M) and an IC ₅₀ of less than 50 μM.

Example  2

Selected TFPI-binding peptides were further characterized in terms of "anti-target" binding. This example demonstrates that TFPI-inhibiting peptides exhibit reduced affinity for non-TFPI-1 protein.

Because of the similarity to TFPI-1, TFPI-2 was selected as an anti-target. (R & D Systems (R & D Systems, Minneapolis, Minn., USA; catalog number 2974-PI), human TFPI-1 (residues 29-282 fused at the C- terminus to the 10 His- tag; MW 41 kDa Binding peptide (TFPI-binding peptide) to TFPI-2 (R & D Systems, Minneapolis, Minn., USA) at the C-terminus was fused to residues 29-289; MW 41 kDa (R & D Systems; catalog number 2975- Were investigated using BIAcore 3000 (TM) surface plasmon resonance assay (GE Healthcare, Charlotte St. Giles, UK). TFPI protein was immobilized on C1 chip (Order Code: BR-1005-40) by amine coupling chemistry targeting 500 RU. Several TFPI-binding peptides were used as analytes for interaction with immobilized TFPI proteins. A flow rate of 30 l / min was used. After 180 seconds, 180 [mu] l of the peptide solution was injected at 6 different concentrations ranging from 3.84 nM to 656.25 nM and allowed a dissociation time of 480 seconds. The chip was regenerated using 45 [mu] l 10 mM NaOH. Four measurements were taken before and after each coupling experiment using HBS-P buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% P20) + 1% DMSO and 0.8% P80. Data was analyzed using BIAevaluation® Version 4.1 software (geo-healthcare). Sensograms were fitted to a 1: 1 Langmuir binding curve to determine k _on and k _off and calculate K _D.

The binding constants from several tested peptides bound to blank cells, such as JBT0050, JBT0121, JBT0205 and JBT0211, and its Sensogram, could not be determined. JBT0133 showed weak binding to TFPI-1. Sensograms from other peptides provide reliable binding constants. The results of BIAcore analysis of several TFPI-inhibiting peptides are provided in Table 6 and Figures 19-21. Each of the peptides listed in Table 6 presented a K _D of less than 10 μM. Sensograms of two peptides in the peptide are provided in Figures 9a and 9b.

The interaction with the TFPI-2 anti-target was also examined. The maximum signal generated from human TFPI-2 and candidate peptide interaction was much lower than the signal obtained using TFPI-1 as an interaction partner. Velocity analysis for low TFPI-2 coupled signals was error prone; Therefore, the binding affinity was estimated using the visual comparison of the sensograms. Sensograms illustrating JBT0120 binding to TFPI-1 and TFPI-2 are provided in Figures 10a and 10b. JBT0120 binds to TFPI-2 with a 10-fold lower affinity than its binding affinity for TFPI-1. It was also found that JBT0132 showed at least a 10-fold greater affinity for TFPI-1 than TFPI-2.

The data provided in this example confirms that TFPI-inhibiting peptides specifically bind to TFPI-1.

Example  3

The following examples illustrate the characterization of the TFPI-inhibiting activity of selected peptides identified in Example 1 using FXa inhibition and an exogenous tenazase inhibition assay. Both analyzes predict activity in the plasma system. Exogenous tenacity assays provide insights into the effects of (a) the interaction of FXa and TFPI and (b) the effect of peptides on the interaction of the FXa-TFPI complex and the TF-FVIIa complex. The FXa inhibition assay only measures the effect of peptides on the interaction of FXa and TFPI.

The exogenous tenacity complex is responsible for FX and FIX activation at the onset of the coagulation process. The exogenous complex consists of FVIIa, tissue factor (TF), and FX substrate. Coupled enzyme assays were established to determine the effect of peptides on TFPI-mediated inhibition of exogenous tenazy complexes. The peptide was diluted 1 / 6.25 (from DMSO) from the 10 mM stock solution and further diluted by serial 1/4 dilution in DMSO to prevent unwanted precipitation. A TFPI HNaCa-HSA was diluted in (25mM HEPES; pH 7.35 175mM NaCl ; 5mM CaCl 2;; 0.1% HSA). (DiaPharma, available from West Chester, Ohio) (all HNaCa &lt; (R) &gt;), FVIIa, lipidated TF, phospholipid vesicle (DOPC / POPS 80/20), and FXa specific chromogenic substrate -HSA) was added to the 96-well plate. After the incubation period, TFPI and peptide dilutions were added to give a final concentration of 2.5% DMSO FX activation was initiated by adding FX to the wells. FXa- The amount of FXa produced at a particular time point was calculated from the OD readout. The FXa produced 20 minutes after the initiation of the reaction was compared to the peptide concentration versus the peptide concentration A plot of inhibition (%) of TFPI was taken into account for the calculation of the EC ₅₀ .

In addition, functional inhibition of TFPI was investigated using FXa inhibition assay. The FXa-specific chromogenic substrate (S-2222) and TFPI (both diluted in HNaCa-HSA) were added to a 96 well plate. The peptide was diluted 1 / 6.25 (from DMSO) from the 10 mM stock solution and further diluted by serial 1/4 dilution in DMSO to prevent unwanted precipitation. The peptide dilution (2.5 L) was added to a 96 well plate to give a final concentration of 2.5% DMSO. The conversion of the chromogenic substrate was triggered by the addition of FXa and the kinetics of the conversion were measured in a micro-plate reader. TFPI is so slow inhibit FXa, was taken into account for the calculation of EC ₅₀ values OD read after 115 minutes from the plot of the peptide concentration to TFPI inhibition (%) of.

The results of the exogenous tenase assay and the FXa inhibition assay are provided in Table 7 and Figures 22-27.

FXa inhibition assay Exogenous tenaje analysis EC ₅₀ [[mu] M] Inhibition at 2.5 μM% EC ₅₀ [[mu] M] Inhibition at 2.5 μM% JBT0120 0.9 45 0.9 45 JBT0132 1.2 36 0.1 10 JBT0224 n.a. 26 3.5 18 JBT0303 1.2 61 n.a. 8

Looking at Table 7, JBT0120, JBT0132, and JBT0224 restored exogenous complex-mediated FX activation to <2 μM EC ₅₀ in the presence of TFPI-1, inhibiting TFPI activity from about 20% to about 60%. JBT0047 (EC ₅₀ = 1.4 μM), JBT0131 (EC ₅₀ = 2.2 μM), and JBT0293 (EC ₅₀ = 2.9 μM) also restored exogenous complex activity in the presence of TFPI-1. In addition, JBT0120, JBT0132, JBT0224 and JBT0303 restored FXa activity to <5 μM EC ₅₀ in the presence of TFPI-1 and inhibited TFPI activity from about 5% to about 50% in the FXa inhibition assay. _{JBT0047 (EC 50 = 0.7 μM)} , JBT0131 (EC 50 = 8.2 μM), JBT0293 (EC 50 = 1.3 μM), JBT0297 (EC 50 = 0.6 μM), and JBT0305 (EC ₅₀ = 2.3 μM) also FXa inhibition assay Lt; RTI ID = 0.0 &gt; TFPI-1. &Lt; / RTI &gt; This example confirms that the peptides of the invention are TFPI antagonists.

Example  4

In this example, the TFPI inhibitory activity of the peptides is established using plasma-based assays.

The effect of peptides on thrombin generation was determined by automated thrombolysis calibrated in a Fluoroskan Ascent (R) reader (Thermo Labsystems, Helsinki, Finland; filters of 390 nm excitation and 460 nm emission) followed by thrombin- (Hemker, Pathophysiol. Haemost. Thromb., 33, 4-15 (2003)) of Z-Gly-Gly-Arg-AMC. Plasma of patients with FVIII or FIX deficiency (George King Bio-Medical Inc., Overland Park, KS, USA) was obtained for testing. The residual coagulation factor activity for each plasma was less than 1%. As a model for antibody-mediated FVIII deficiency, a high-temperature, heat-inactivated, anti-human FVIII plasma (4490 &lt; RTI ID = 0.0 &gt; BU / ml; Baxter Bioscience, Vienna, Austria). Plasma was mixed with corn trypsin inhibitor (CTI) (Hematologic Technologies, Inc., Essex Junction, Vt., USA) to inhibit factor XIIa contamination to a final concentration of 40 [mu] g / mL .

Pre-warmed (37 ° C) plasma (80 μl) was added to each well of a 96 well microplate (Immulon 2HB, clear U-shaped bottom; Thermo Electron, Waltham, Mass., USA) . (12 pM) recombinant human tissue factor and phospholipid vesicles (48 [mu] M) (phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine) (Trombinskov Vivi, Maastricht, Netherlands) to induce thrombin production by tissue factor Lt; RTI ID = 0.0 &gt; of PPP &lt; / RTI &gt; reagent. The peptide was diluted 1 / 7.5 in DMSO from 10 mM stock and further diluted 1 / 8.33 with Aqua-Dest to give a concentration of 0.5% DMSO in the final assay mixture at a concentration of 12% DMSO. 5 [mu] l HEPES buffered saline containing 5 mg / ml human serum albumin (Sigma-Aldrich Corporation, St. Louis, MO, USA) prior to placing the plates in pre-warmed (37 ° C) After addition of 12% DMSO in Dest, a peptide dilution or reference protein (FVIII Immunate Reference Standard (Baxter Bioscience, Vienna, Austria); Factor VIII Inhibitor Activity Barrier Reference (FEIBA) Reference Standard (Baxter Bioscience, Vienna, And purified human plasma FIX (Enzyme Research Laboratories, South Bend, Ill., USA) were added to each well. Fluorescent substrates and HEPES - dispensing 20 [mu] l FluCa reagent (Trombinskov Vive, Maastricht, Netherlands) containing buffer CaCl ₂ (100 mM) The fluorescence intensity was recorded at 37 ° C.

The parameters of the resulting thrombin production curve were calculated using a thrombin calculator to calibrate the Trombinoscopy ™ software (Trombinskov Vive, Maastricht, Netherlands) and internal filter and substrate consumption effects (Hemker, Pathophysiol. Haemost. Thromb., 33, 4-15 (2003)). (Peak thrombin, nM) at the peak of each thrombin generation curve is calculated as a standard value, in order to calculate the thrombin generating activity of a specific peptide concentration equivalent to the reference protein (for example, FVIII Immunate 참조 reference standard, FEIBA reference standard) Plotted against the concentration, and fitted by a non-linear algorithm. Based on the above calibration, FVIII imitate, FIX, FEIBA or Novoseven equivalent activity was calculated. Results for various peptides are provided in Figures 12-18 and 28-30. Representative results are shown in Table 8 (* indicates that FVIII-deficient plasma was obtained from different donors).

FVIII-equivalent activity in plasma lacking FVIII at 10 [mu] M peptide The FEIBA-equivalent activity [mU / ml] in FVIII-inhibited plasma at 10 [mu] M peptide JBT0120 37.4 ^* 298 JBT0132 5.3 41 JBT0224 16.2 191 JBT0303 20.8 253

Referring to Table 8, JBT0120, JBT0132, JBT0224, and JBT0303 showed that TFPI-dependent thrombin production in FVIII-deficient plasma exceeded 1% of the level of thrombin production (% FVIII-equivalent activity) in plasma containing FVIII . The tested peptides showed about 5% -40% FVIII-equivalent activity in FVIII-deficient plasma. JBT0120 and JBT0132 improved the peak thrombin and peak time in a dose-dependent manner as shown in Figs. 11A and 11B.

Example  5

The following examples demonstrate that the peptides of the present invention can be modified by the addition of moieties that enhance the physicochemical or pharmacokinetic properties of the peptides. As illustrated below, the addition of 40 kDa PEG to the peptides described herein dramatically improved the pharmacokinetic behavior of the peptides.

Methods for conjugating chemical or biological moieties to peptides are known in the art. To add PEG (polyethylene glycol) to the peptides described herein, a functional group (AOA = aminooxyacetate) was added to the N-terminus of the peptide for coupling to aldehydes and ketones. Alternatively, cysteine was added to the C-terminal portion of the peptide for coupling with maleimide (Hermanson, Bioconjugate Techniques, Academic Press (1996)). (SEQ ID NO: 166) and (JBT1587) Ac-FQSKGNVFVDGYFERL-Aib-AKLC-NH2 (SEQ ID NO: 167) were used for N-terminal and C-terminal modifications using PEG, respectively Respectively. AOA-FQSKGNVFVDGYFERL-Aib-AKL-NH2 (SEQ ID NO: 166) and Ac-FQSKGNVFVDGYFERL-Aib-AKLC-NH2 (SEQ ID NO: 167) were dissolved in an excess amount of 40 kDa mPEG-propionaldehyde (SUNBRIGHT ME-400AL2, NOF, was incubated with mPEG-maleimide (SUNBRIGHT ME-400MA, NOF, Japan). The resulting PEGylated peptides JBT1853 and JBT1855 show a similar affinity compared to the starting structure Ac-FQSKGNVFVDGYFERL-Aib-AKL-NH2 (JBT0740) (SEQ ID NO: 66).

The resulting PEGylated peptides exhibited significantly increased plasma stability and sustained plasma half-life in mice. Figure 31 shows the free peptide JBT0740 (Ac-FQSKGNVFVDGYFERL-Aib-AKL-NH2) (SEQ ID NO: 25) relative to the PEGylated peptide JBT1855 (Ac-FQSKGNVFVDGYFERL-Aib-AKLC 66). &Lt; / RTI &gt; Unlike unpegylated peptides, PEGylated peptides are present in high concentrations in mouse plasma 100 minutes after administration. Non-PEGylated peptides are rapidly cleared from plasma.

                         SEQUENCE LISTING &Lt; 110 > Dockal, et al.   <120> TFPI INHIBITORS AND METHODS OF USE <130> 31315 / 44241A <150> 61 / 139,272 <151> 2008-12-19 <160> 3145 <170> PatentIn version 3.5 <210> 1 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 1 Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu Arg 1 5 10 15 Ala Lys          <210> 2 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is selected from the group consisting of Val, Trp, Tyr, and        Phe <220> <221> MOD_RES <222> (2) (2) <223> Xaa is selected from the group consisting of Asp, Gln, and Ser <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected from the group consisting of Glu, Thr, Ans, and        Ser <220> <221> MOD_RES &Lt; 222 > (5) &Lt; 223 > Xaa is selected from the group consisting of Leu, Pro, Lys, Ser,        Trp, Val, Asn and Gln <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is selected from the group consisting of Leu, Trp, Val, Ala,        Met, Thr, and Ser <220> <221> MOD_RES &Lt; 222 > (10) &Lt; 223 > Xaa is selected from the group consisting of Thr, Phe, Val, Arg,        Ala, Asp, Leu, Glu, Ser, and Tyr <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is selected from the group consisting of Asn, Pro, Phe, His,        Lys, and Tyr <220> <221> MOD_RES &Lt; 222 > (14) &Lt; 223 > Xaa is selected from the group consisting of Met, Asp, Glu, Val,        Gly, and Lys <220> <221> MOD_RES &Lt; 222 > (20) &Lt; 223 > Xaa is selected from the group consisting of Gln, Ile, Gle, Trp,        Arg, Leu, and Asn <400> 2 Xaa Xaa Xaa Lys Xaa Asn Val Phe Xaa Xaa Gly Tyr Xaa Xaa Arg Leu 1 5 10 15 Arg Ala Lys Xaa             20 <210> 3 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 3 Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met 1 5 10 15 Gly Met Tyr Ala Ala Gln Leu Lys Phe             20 25 <210> 4 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 4 Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly Tyr Glu Arg 1 5 10 15 Arg Tyr          <210> 5 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 5 Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp Pro Asp 1 5 10 15 Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr             20 25 <210> 6 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 6 Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val 1 5 10 15 Trp Val Lys Phe             20 <210> 7 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 7 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met Ala              <210> 8 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (35) <223> C-terminal amidation <400> 8 Lys Lys Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys 1 5 10 15 Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu Arg Ala Lys Leu Thr             20 25 30 Ser Lys Lys         35 <210> 9 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 9 Lys Lys Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys 1 5 10 15 Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu Arg Ala Lys Lys Lys             20 25 30 <210> 10 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 10 Lys Lys Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys Asn Val Phe 1 5 10 15 Val Phe Gly Tyr Phe Glu Arg Leu Arg Ala Lys Leu Thr Ser Lys Lys             20 25 30 <210> 11 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 11 Lys Lys Gln Val Ala Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly 1 5 10 15 Tyr Phe Glu Arg Leu Arg Ala Lys Leu Thr Ser Lys Lys             20 25 <210> 12 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 12 Lys Lys Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu 1 5 10 15 Arg Leu Arg Ala Lys Leu Thr Ser Lys Lys             20 25 <210> 13 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 13 Lys Lys Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu 1 5 10 15 Arg Leu Arg Ala Lys Leu Lys Lys             20 <210> 14 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 14 Lys Lys Ala Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe 1 5 10 15 Glu Arg Leu Arg Ala Lys Leu Lys Lys             20 25 <210> 15 <211> 36 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (2) (2) <223> Xaa is Carboxyfluorescein <220> <221> MOD_RES &Lt; 222 > (36) <223> C-terminal amidation <400> 15 Lys Xaa Lys Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys 1 5 10 15 Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu Arg Ala Lys Leu             20 25 30 Thr Ser Lys Lys         35 <210> 16 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 16 Phe Gln Ser Lys Asn Asn Val Phe Val Asp Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 17 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 17 Phe Gln Ser Lys Asn Asn Val Phe Val Gln Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 18 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 18 Phe Gln Ser Lys Asn Asn Val Phe Val Ser Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 19 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 19 Phe Gln Ser Lys Asn Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 20 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 20 Phe Gln Ser Lys Asp Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 21 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 21 Phe Gln Ser Lys Lys Asn Val Phe Val Glu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 22 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 22 Phe Gln Ser Lys Lys Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 23 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 23 Phe Gln Ser Lys Lys Asn Val Phe Val His Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 24 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 24 Phe Gln Ser Lys Lys Asn Val Phe Val Met Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 25 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 25 Phe Gln Ser Lys Lys Asn Val Phe Val Asn Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 26 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 26 Phe Gln Ser Lys Gly Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 27 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 27 Phe Gln Ser Lys Gly Asn Val Phe Val Asn Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 28 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 28 Phe Gln Ser Lys Gly Asn Val Phe Val His Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 29 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 29 Phe Gln Ser Lys Gly Asn Val Phe Val Lys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 30 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 30 Phe Gln Ser Lys Gly Asn Val Phe Val Glu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 31 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 31 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 32 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 32 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 33 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 33 Phe Gln Ser Lys Asp Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 34 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 34 Phe Gln Ser Lys Asp Asn Val Phe Val Asn Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 35 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 35 Phe Gln Ser Lys Asp Asn Val Phe Val His Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 36 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 36 Phe Gln Ser Lys Asp Asn Val Phe Val Lys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 37 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 37 Phe Gln Ser Lys Asp Asn Val Phe Val Glu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 38 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 38 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 39 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 39 Phe Gln Ser Lys Asn Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 40 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 40 Phe Gln Ser Lys Asn Asn Val Phe Val Asn Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 41 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 41 Phe Gln Ser Lys Asn Asn Val Phe Val His Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 42 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 42 Phe Gln Ser Lys Asn Asn Val Phe Val Lys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 43 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 43 Phe Gln Ser Lys Asn Asn Val Phe Val Glu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 44 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 44 Phe Gln Ser Lys Gln Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 45 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 45 Phe Gln Ser Lys Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 46 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 46 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 47 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 47 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 48 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 48 Phe Gln Ser Lys Gly Asn Val His Val Lys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 49 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 49 Phe Gln Ser Lys Gly Asn Val His Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 50 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 50 Phe Gln Ser Pro Gly Asn Val His Val Lys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 51 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 51 Phe Gln Ser Pro Gly Asn Val His Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 52 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 52 Phe Gln Ser Lys Gly Asn Ile Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 53 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 53 Phe Gln Ser Lys Ala Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 54 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 54 Phe Gln Ser Lys Ala Asn Val Phe Val Thr Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 55 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 55 Phe Gln Ser Lys Gly Ala Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 56 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is (S) -Diaminopropionic acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 56 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 57 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) <223> (S) -Ornithine <220> <221> misc_feature &Lt; 222 > (17) <223> Xaa can be any naturally occurring amino acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 57 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 58 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is (S) -2-Amino-pentanoic acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 58 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 59 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 59 Phe Gln Ser Lys Ala Asn Val Phe Val Ala Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 60 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 60 Phe Gln Ser Lys Ala Ala Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 61 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 61 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 62 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 62 Phe Gln Ser Lys Gly Asn Val Phe Val Thr Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 63 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> (S) -Homo-Citrulline <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 63 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 64 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) (S) -Homo-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 64 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 65 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) (S) -2-Pyridyl-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 65 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 66 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is 2-Amino-isobutryic acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 66 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 67 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 67 Phe Gln Ser Lys Gly Ala Val Phe Val Thr Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 68 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) (S) -N (omega) -nitro-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 68 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 69 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 69 Phe Gln Ser Lys Gly Asn Val Phe Val Thr Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 70 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 70 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 71 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 71 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 72 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 72 Phe Gln Ser Lys Gly Ala Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 73 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 73 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 74 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 74 Phe Gln Ser Lys Gly Asn Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 75 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 75 Phe Gln Ser Glu Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 76 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 76 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 His Ala Lys Leu             20 <210> 77 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 77 Phe Gln Ser Ile Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 78 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 78 Phe Gln Ser Lys Gly Asn Ile Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 79 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 79 Phe Gln Ser Lys Ala Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 80 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 80 Phe Gln Ser Lys Gly Lys Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 81 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 81 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Lys Ala Lys Leu             20 <210> 82 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) (S) -2-Propargylglycine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 82 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Gly Ala Lys Leu             20 <210> 83 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 83 Phe Gln Ser Leu Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 84 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 84 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Leu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 85 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is (S) -2,4-Diaminobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 85 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 86 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 86 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Leu Ala Lys Leu             20 <210> 87 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 87 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Leu Lys Leu             20 <210> 88 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 88 Met Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 89 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 89 Phe Gln Met Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 90 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 90 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Met Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 91 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 91 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Met Lys Leu             20 <210> 92 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) (S) -Cyclohexylalanine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 92 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 93 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 93 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Asn Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 94 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 94 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Asn Lys Leu             20 <210> 95 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 95 Phe Gln Ser Pro Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 96 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) (S) -2-Amino-5-methyl-hexanoic acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 96 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 97 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 97 Phe Gln Gln Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 98 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 98 Phe Gln Ser Lys Gly Gln Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 99 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 99 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Gln Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 100 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 100 Phe Gln Arg Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 101 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 101 Phe Gln Ser Arg Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 102 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 102 Phe Gln Ser Lys Gly Arg Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 103 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 103 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Arg Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 104 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 104 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 105 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 105 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Arg Lys Leu             20 <210> 106 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 106 Phe Gln Ser Lys Ala Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 107 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 107 Phe Gln Ser Lys Gly Ser Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 108 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 108 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Thr Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 109 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 109 Phe Gln Ser Lys Gly Ala Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 110 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 110 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Val Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 111 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 111 Tyr Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 112 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 112 Phe Gln Ser Lys Gly Asn Val Tyr Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 113 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 113 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 114 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Carboxyfluorescein <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 114 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 115 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 115 Phe Gln Ser Lys Lys Ala Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 116 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 116 Phe Gln Ser Lys Gly Ala Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 117 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Asp <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 117 Phe Gln Ser Lys Asp Ala Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 118 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 118 Phe Gln Ser Lys Lys Ala Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 119 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 119 Phe Gln Ser Lys Asp Ala Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 120 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 120 Phe Gln Ser Lys Lys Ala Val Phe Val Lys Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 121 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 121 Phe Gln Ser Lys Asp Ala Val Phe Val Lys Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 122 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 122 Phe Gln Ser Lys Lys Ala Val Phe Val Thr Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 123 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Asp <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 123 Phe Gln Ser Lys Asp Ala Val Phe Val Thr Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 124 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Carboxyfluorescein <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 124 Xaa Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu             20 <210> 125 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 125 Phe Gln Ser Lys Gly Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 126 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 126 Phe Gln Ser Lys Ala Asn Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 127 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 127 Phe Gln Ser Lys Ala Asn Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 128 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Pro <220> <221> MOD_RES &Lt; 222 > (20) C-terminal N-ethyl <400> 128 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 129 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 129 Phe Gln Ser Lys Pro Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 130 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 130 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu Cys             20 <210> 131 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 131 Phe Gln Ser Lys Gly Asn Val Phe Val Ser Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 132 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 132 Phe Gln Ser Lys Gly Asn Val Phe Val Val Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 133 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 133 Phe Gln Ser Lys His His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 134 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 134 Phe Gln Ser Arg Arg Gly Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 135 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 135 Phe Gln Cys Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 136 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 136 Phe Gln Ser Lys Gly Cys Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 137 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 137 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Cys Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 138 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 138 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Cys Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 139 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 139 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 140 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 140 Phe Gln Ser Lys Ala Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 141 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 141 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Met Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 142 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 142 Phe Gln Ser Lys Asp Asn Val Phe Val His Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 143 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 143 Tyr Gln Ser Lys Asn Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 144 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 144 Phe Gln Ser Lys Gly His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 145 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 145 Phe Gln Ser Lys Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 146 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 146 Phe Gln Ser Lys Glu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 147 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 147 Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 148 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 148 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 149 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 149 Phe Gln Ser Lys Asn Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 150 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 150 Phe Gln Ser Lys Asp His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 151 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 151 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 152 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 152 Phe Gln Ser Lys His His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 153 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 153 Phe Gln Ser Lys His Asn Val Tyr Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 154 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 154 Phe Gln Ser Arg Arg Gly Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 155 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 155 Tyr Gln Ser Lys Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 156 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 156 Phe Gln Ser Glu His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 157 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 157 Phe Gln Ser Lys Asn Asp Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 158 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 158 Phe Gln Ser Lys Arg Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 159 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 159 Phe Gln Ser Pro Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 160 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 160 Phe Gln Ser Gly Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 161 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 161 Phe Gln Ser Lys Gly Asn Val Phe Val Ala Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 162 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (4) (4) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 162 Phe Gln Ser Xaa Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 163 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 163 Phe Gln Ser Lys Xaa Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 164 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 164 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 165 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 165 Phe Gln Ser Lys Gly Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 166 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Aminooxy acetate <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 166 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 167 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (14) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 167 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu Cys             20 <210> 168 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (14) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is 2-Amino-isobutryic acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 168 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Cys Arg Leu 1 5 10 15 Xaa Ala Lys Leu Cys             20 <210> 169 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 169 Phe Gln Ser Lys Gly Asn Ile Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 His Ala Lys Leu             20 <210> 170 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 170 Phe Gln Ser Lys Asn Asn Val Phe Val Asp Gly Tyr Phe Lys Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 171 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 171 Tyr Gln Thr Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 172 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 172 Phe Gln Thr Lys Asp Asn Val His Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 173 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 173 Leu Gln Gln Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 174 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal pegylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 174 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 175 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal pegylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 175 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 176 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (21) <223> PEGYLATION <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 176 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu Cys             20 <210> 177 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Pro <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 177 Phe Gln Ser Lys Pro Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 178 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Pro <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 178 Phe Gln Ser Lys Pro Asn Val His Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 179 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 179 Pro Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu             20 <210> 180 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 180 Pro Glu Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu 1 5 10 15 Arg Leu Arg Ala Lys Leu             20 <210> 181 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (6) (S) -N-methyl-Glu <220> <221> MOD_RES <222> (18). (18) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 181 Pro Phe Gln Ser Lys Glu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg 1 5 10 15 Leu Xaa Ala Lys Leu             20 <210> 182 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 182 Lys Lys Ala Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe 1 5 10 15 Glu Arg Leu Arg Ala Lys Leu Thr Lys Lys             20 25 <210> 183 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 183 Phe Gln Ser Lys Asn Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 184 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 184 Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 185 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 185 Phe Gln Ser Lys Lys Asn Val Phe Val Ser Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 186 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 186 Phe Gln Ser Lys Asn Asn Val Phe Val Tyr Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 187 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 187 Phe Gln Ser Lys Asn Asn Val Phe Val Phe Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 188 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 188 Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 189 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Carboxyfluorescein <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 189 Ala Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys             20 <210> 190 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 190 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 191 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 191 Phe Gln Ser Lys Lys Asn Val Phe Val Val Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 192 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 192 Phe Gln Ser Lys Lys Asn Val His Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 193 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 193 Phe Gln Ser Lys Lys Asn Val Phe Val Lys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 194 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 194 Phe Gln Ser Lys Lys Asn Val Phe Val Pro Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 195 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 195 Phe Gln Ser Lys Lys Asn Val Phe Val Arg Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 196 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 196 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Glu Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 197 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 197 Phe Gln Ser Lys Gln Asn Val Phe Val Asn Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 198 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 198 Phe Gln Ser Lys Gln Asn Val Phe Val His Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 199 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 199 Phe Gln Ser Lys Gln Asn Val Phe Val Lys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 200 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 200 Phe Gln Ser Lys Gln Asn Val Phe Val Glu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 201 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) (S) -N-methyl-phenylalanine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 201 Ala Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 202 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (4) (4) (S) -N-methyl-lysine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 202 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 203 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> beta-Homoarginine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 203 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 204 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> beta-Homoleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 204 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 205 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 205 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Lys Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 206 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 206 Phe Gln Ser Lys Gly Ala Val Phe Val Phe Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 207 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 207 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 208 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 208 Phe Gln Ser Lys Gly Asn Val Phe Val Asn Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 209 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 209 Phe Gln Ser Lys Gly Asn Val Phe Val Lys Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 210 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 210 Phe Gln Ser Lys Gly Asn Val Phe Val Glu Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 211 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 211 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Lys Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 212 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 212 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 213 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 213 Phe Gln Ser Lys Gly Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 214 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 214 Phe Gln Ser Lys Ala Ala Val Phe Val Thr Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 215 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 215 Phe Gln Ser Lys Ala Asn Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 216 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 216 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ile Ala Lys Leu             20 <210> 217 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 217 Phe Gln Ser Lys Ala Asn Val Phe Val Phe Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 218 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 218 Phe Gln Ser Lys Gly Ala Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 219 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 219 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Val Ala Lys Leu             20 <210> 220 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 220 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Trp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 221 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 221 Phe Gln Ser Lys Asp Ala Val Phe Val Asp Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 222 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 222 Phe Gln Ser Lys Gly Ala Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 223 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 223 Phe Gln Ser Lys Asp Ala Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 224 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 224 Phe Gln Ser Lys Gly Ala Val Phe Val Lys Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 225 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 225 Phe Gln Ser Lys Asp Ala Val Phe Val Lys Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 226 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 226 Phe Gln Ser Lys Gly Ala Val Phe Val Thr Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 227 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 227 Phe Gln Ser Lys Asp Ala Val Phe Val Thr Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 228 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) C-terminal N-methyl <400> 228 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 229 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 229 Phe Gln Ser Lys Phe Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 230 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 230 Phe Gln Ser Lys Gly Asn Val Phe Val Ala Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 231 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 231 Phe Gln Ser Lys Gly Asn Val Phe Val Met Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 232 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 232 Phe Gln Ser Lys Gly Asn Val Phe Val Pro Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 233 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 233 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Met Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 234 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 234 Tyr Gln Ser Lys Asn Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 235 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 235 Phe Gln Ser Lys Gly His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 236 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 236 Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 237 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 237 Phe Gln Thr Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 238 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 238 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 239 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 239 Phe Gln Ser Lys Asn Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 240 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 240 Phe Gln Ser Lys Asp His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 241 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 241 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Arg Lys Leu             20 <210> 242 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 242 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 243 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 243 Phe Gln Ser Lys Leu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 244 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 244 Phe Gln Ser Val Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ser Ala Lys Leu             20 <210> 245 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 245 Phe Gln Ser Tyr Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 246 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 246 Phe Gln Ser Gly Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 247 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 247 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Xaa Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 248 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (14) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 248 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Xaa Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 249 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 249 Phe Gln Ser Tyr Lys His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 250 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 250 Phe Gln Ser Lys Gly Ile Val Phe Val Asp Gly Tyr Phe Lys Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 251 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 251 Phe Gln Ser Tyr Lys Arg Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 252 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (21) <223> PEGYLATION <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 252 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu Cys             20 <210> 253 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 253 Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys Asn Val 1 5 10 15 Phe Val Phe Gly Tyr Phe Glu Arg Leu Arg Ala Lys Leu Thr Ser             20 25 30 <210> 254 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 254 Lys Lys Ala Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe 1 5 10 15 Glu Arg Leu Arg Ala Lys Lys Lys             20 <210> 255 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 255 Lys Lys Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu Thr Lys Lys             20 <210> 256 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 256 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 257 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 257 Tyr Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 258 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 258 Phe Gln Ser Lys Lys Asn Val Phe Val Ala Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 259 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 259 Phe Gln Ser Lys Lys Asn Val Phe Val Leu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 260 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 260 Phe Gln Ser Lys Lys Asn Val Phe Val Gln Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 261 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 261 Phe Gln Ser Lys Lys Asn Val Phe Val Tyr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 262 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 262 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 263 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <400> 263 Phe Gln Ser Lys Asn Asn Val Phe Val Ala Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 264 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 264 Phe Gln Ser Lys Lys Asn Gln Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 265 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 265 Phe Gln Ser Pro Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 266 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 266 Phe Gln Ser Lys Lys Asn Val Phe Val Gly Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 267 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 267 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Leu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 268 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) Xaa is 13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 268 Xaa Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu             20 <210> 269 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (11) <223> N-methyl-Gly <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 269 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 270 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> beta-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 270 Phe Gln Ser Lys Ala Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 271 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (6) <223> beta-Homoasparagin <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 271 Phe Gln Ser Lys Gly Asp Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 272 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (14) <223> beta-Homoaspartic acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 272 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 273 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is (S) -Citrullin <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 273 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 274 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 274 Phe Gln Ser Gly Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 275 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 275 Phe Gln Ser Lys Lys Gly Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 276 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 276 Phe Gln Lys Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 277 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 277 Phe Gln Ser Lys Lys Lys Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 278 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 278 Phe Gln Ser Lys Lys Asn Lys Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 279 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 279 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Lys Ala Lys Leu             20 <210> 280 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 280 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Lys Lys Leu             20 <210> 281 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 281 Phe Gln Asp Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 282 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 282 Phe Gln Ser Lys Lys Asp Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 283 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <400> 283 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 284 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 284 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 285 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 285 Gly Ser Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu 1 5 10 15 Arg Leu Arg Ala Lys Leu             20 <210> 286 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 286 Phe Gln Ser Lys Gly Asn Leu Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 287 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 287 Phe Gln Ser Lys Gly Asn Val Phe Ile Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 288 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 288 Phe Gln Ser Lys Lys Ala Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 289 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 289 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 290 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (4) (4) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 290 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 291 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 291 Phe Gln Ser Lys Lys Asn Val Phe Phe Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 292 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 292 Phe Gln Ser Lys Gly Asn Val Phe Val His Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 293 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> omega-methyl-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 293 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 294 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 294 Phe Gln Ala Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 295 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 295 Phe Gln Ser Ala Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 296 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 296 Phe Gln Ser Asp Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 297 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 297 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Asp Lys Leu             20 <210> 298 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 298 Phe Gln Glu Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 299 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 299 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Glu Lys Leu             20 <210> 300 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 300 Phe Gln Ser Lys Ala Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 301 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 301 Phe Gln Ser Phe Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 302 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 302 Phe Gln Ser Lys Ala Ala Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 303 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 303 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Phe Ala Lys Leu             20 <210> 304 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 304 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Phe Lys Leu             20 <210> 305 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 305 Phe Gln Ser Lys Ala Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 306 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 306 Phe Gln His Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 307 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 307 Phe Gln Ser His Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 308 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 308 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe His Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 309 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 309 Ile Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 310 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 310 Phe Gln Ile Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 311 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 311 Phe Gln Ser Lys Gly Ile Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 312 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 312 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Ile Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 313 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 313 Phe Gln Ser Lys Gly Leu Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 314 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 314 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Leu Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 315 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 315 Phe Gln Asn Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 316 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 316 Phe Gln Ser Asn Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 317 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 317 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Asn Ala Lys Leu             20 <210> 318 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 318 Phe Gln Ser Gln Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 319 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 319 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Gln Lys Leu             20 <210> 320 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 320 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Arg Leu             20 <210> 321 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 321 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Arg             20 <210> 322 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 322 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Ser Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 323 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 323 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Thr Ala Lys Leu             20 <210> 324 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 324 Val Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 325 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 325 Phe Gln Val Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 326 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 326 Phe Gln Ser Val Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 327 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 327 Phe Gln Ser Lys Gly Val Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 328 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 328 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Val Lys Leu             20 <210> 329 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 329 Trp Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 330 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 330 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Trp Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 331 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 331 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Trp Lys Leu             20 <210> 332 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 332 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Trp             20 <210> 333 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 333 Phe Gln Ser Lys Gly Tyr Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 334 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 334 Phe Gln Ser Lys Gly Asn Tyr Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 335 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 335 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Tyr Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 336 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 336 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Tyr Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 337 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 337 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Tyr Ala Lys Leu             20 <210> 338 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 338 Phe Gln Ser Lys Xaa Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 339 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 339 Phe Gln Ser Lys Ala Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 340 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 340 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 341 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 341 Phe Gln Ser Lys Leu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 342 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 342 Phe Gln Ser Lys Arg Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 343 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 343 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 344 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 344 Phe Gln Ser Lys Gly Asn Val Phe Val Gly Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 345 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 345 Phe Gln Ser Lys Gly Asn Val Phe Val Trp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 346 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 346 Phe Gln Ser Lys Gly Asn Val Phe Val Tyr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 347 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 347 Phe Gln Ser Lys Ala Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 348 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 348 Phe Gln Ser Arg Glu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 349 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 349 Phe Gln Ser Lys Asp Asn Val Phe Val His Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 350 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 350 Phe Gln Ser Lys Glu Arg Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 351 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 351 Phe Gln Ser Lys Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ile Lys Leu             20 <210> 352 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 352 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Val Lys Leu             20 <210> 353 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 353 Phe Gln Ser Arg Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 354 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 354 Phe Gln Ser Arg Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 355 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 355 Phe Gln Ser Lys Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 356 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 356 Phe Gln Ser Ser Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 357 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 357 Phe Gln Ser Lys Glu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 358 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 358 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 359 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 359 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Arg Leu             20 <210> 360 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 360 Phe Gln Ser Lys His Asn Val Tyr Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 361 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 361 Phe Gln Ser Lys Tyr Asn Ile Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 362 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 362 Phe Gln Ser Lys Asn Asp Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 363 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 363 Phe Gln Ser Gly Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 364 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 364 Phe Gln Ser Pro Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 365 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 365 Phe Gln Ser Pro Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 366 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 366 Phe Gln Ser Arg Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 367 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 367 Phe Gln Ser Lys Lys Arg Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 368 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 368 Phe Gln Ser Ile Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 369 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 369 Cys Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 370 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 370 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Cys Lys Leu             20 <210> 371 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 371 Phe Gln Ser Lys Phe Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 372 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 372 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Gly Tyr His Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 373 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 373 Phe Gln Ser Ser His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 374 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 374 Phe Gln Ser Arg Glu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 375 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 375 Phe Gln Ser Cys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 376 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 376 Phe Gln Asp Pro Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 377 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 377 Phe Gln Ser Lys Thr Asn Ile Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 378 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 378 Phe Gln Ser His Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 379 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 379 Phe Gln Ser Arg Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 380 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 380 Phe Gln Ser Ser Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 381 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 381 Phe Gln Ser His His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 382 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 382 Phe Gln Thr Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 383 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 383 Phe Gln Ser Lys Ala Asn Val His Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 384 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 384 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Arg Lys Leu             20 <210> 385 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 385 Phe Gln Ser Lys Ser Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 386 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 386 Phe Gln Ser His Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 387 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 387 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Phe             20 <210> 388 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 388 Phe Gln Ser Lys Met Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 389 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 389 Phe Gln Ser Ala Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 390 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 390 Phe Gln Ser Lys His Val Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 391 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 391 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Arg Leu             20 <210> 392 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 392 Phe Gln Ser Lys Lys His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 393 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 393 Phe Gln Ser Asn Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 394 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 394 Phe Gln Ser Glu Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 395 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 395 Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Phe Lys Leu             20 <210> 396 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 396 Phe Gln Ser Lys Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ser Ala Lys Leu             20 <210> 397 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 397 Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ser Ala Lys Leu             20 <210> 398 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 398 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ser Ala Lys Leu             20 <210> 399 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 399 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ser Ala Lys Leu             20 <210> 400 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 400 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Xaa             20 <210> 401 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 401 Phe Gln Ser Lys Gly Asn Val Phe Val Cys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu Cys             20 <210> 402 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (1) (17) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 402 Cys Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg 1 5 10 15 Leu Cys Ala Lys Leu             20 <210> 403 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (1) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES <222> (18). (18) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 403 Cys Phe Gln Ser Lys Gly Asn Val Phe Val Cys Gly Tyr Phe Glu Arg 1 5 10 15 Leu Xaa Ala Lys Leu             20 <210> 404 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> DISULFID <222> (1) (7) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (18). (18) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 404 Cys Phe Gln Ser Lys Gly Cys Val Phe Val Glu Gly Tyr Phe Glu Arg 1 5 10 15 Leu Xaa Ala Lys Leu             20 <210> 405 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 405 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Phe Ala Lys Leu             20 <210> 406 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 406 Lys Lys Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Lys Lys             20 <210> 407 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 407 Phe Gln Asn Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 408 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 408 Phe Gln Ser Lys Lys Asn Val Phe Ala Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 409 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 409 Phe Gln Ser Lys Lys Asn Val Phe Ser Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 410 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 410 Phe Gln Ser Lys Lys Asn Val Phe Thr Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 411 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 411 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Lys Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 412 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 412 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Tyr Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 413 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Carboxyfluorescein <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 413 Xaa Ala Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu 1 5 10 15 Arg Leu Arg Ala Lys             20 <210> 414 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 414 Phe Gln Ser Lys Lys Asn Ala Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 415 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 415 Phe Gln Ser Lys Lys Asn Pro Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 416 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 416 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Val Leu             20 <210> 417 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) (S) -N-methyl-Val <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 417 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 418 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (10) (S) -N-methyl-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 418 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 419 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) (S) -N-methyl-Leu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 419 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 420 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Beta-Homophenylalanine <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 420 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 421 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (3) <223> beta-Homoserine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 421 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 422 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (4) (4) <223> beta-Homolysine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 422 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 423 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> beta-Ala <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 423 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Ala Lys Leu             20 <210> 424 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> beta-Homolysine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 424 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 425 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 425 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 426 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 426 Gly Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 427 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 427 Phe Gly Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 428 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 428 Phe Gln Gly Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 429 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 429 Phe Gln Ser Lys Lys Asn Gly Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 430 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 430 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Gly Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 431 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 431 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Gly Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 432 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 432 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Gly Lys Leu             20 <210> 433 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 433 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Gly             20 <210> 434 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 434 Lys Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 435 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 435 Phe Lys Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 436 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 436 Phe Gln Ser Lys Lys Asn Val Lys Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 437 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 437 Phe Gln Ser Lys Lys Asn Val Phe Lys Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 438 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 438 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Lys Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 439 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 439 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Lys Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 440 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 440 Phe Gln Ser Lys Lys Asn Phe Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 441 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 441 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Phe Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 442 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 442 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Phe             20 <210> 443 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 443 Asp Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 444 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 444 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Asp Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 445 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 445 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Asp Lys Leu             20 <210> 446 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 446 Phe Gln Ser Lys Lys Asn Leu Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 447 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 447 Phe Gln Ala Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 448 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 448 Phe Gln Ser Ala Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 449 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 449 Phe Gln Ser Lys Ala Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 450 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 450 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 451 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 451 Phe Gln Pro Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 452 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 452 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Pro Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 453 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 453 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Pro 1 5 10 15 Arg Ala Lys Leu             20 <210> 454 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 454 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Pro             20 <210> 455 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 455 Phe Gln Ser Ser Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 456 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 456 Phe Gln Ser Lys Lys Ser Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 457 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 457 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Ser Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 458 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 458 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ser Lys Leu             20 <210> 459 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 459 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Ser Leu             20 <210> 460 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 460 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Leu Leu             20 <210> 461 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (10) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 461 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 462 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES (12). (12) <223> D-Tyr <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 462 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 463 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (14) <223> D-Glu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 463 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 464 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (15) <223> D-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 464 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 465 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> D-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 465 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 466 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) <223> D-Phe <220> <221> MOD_RES <222> (2) (2) <223> D-Gln <220> <221> MOD_RES &Lt; 222 > (3) <223> D-Ser <220> <221> MOD_RES <222> (4) (4) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Lys <220> <221> MOD_RES <222> (6) <223> D-Asn <220> <221> MOD_RES <222> (7) (7) <223> D-Val <220> <221> MOD_RES &Lt; 222 > (8) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Val <220> <221> MOD_RES &Lt; 222 > (10) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (11) <223> D-Gly <220> <221> MOD_RES (12). (12) <223> D-Tyr <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (14) <223> D-Glu <220> <221> MOD_RES &Lt; 222 > (15) <223> D-Arg <220> <221> MOD_RES &Lt; 222 > (16) <223> D-Leu <220> <221> MOD_RES &Lt; 222 > (17) <223> D-Arg <220> <221> MOD_RES <222> (18). (18) <223> D-Ala <220> <221> MOD_RES <222> (19). (19) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> D-Leu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 466 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 467 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) <223> D-Leu <220> <221> MOD_RES <222> (2) (2) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (3) <223> D-Ala <220> <221> MOD_RES <222> (4) (4) <223> D-Arg <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Leu <220> <221> MOD_RES <222> (6) <223> D-Arg <220> <221> MOD_RES <222> (7) (7) <223> D-Glu <220> <221> MOD_RES &Lt; 222 > (8) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Tyr <220> <221> MOD_RES &Lt; 222 > (10) <223> D-Gly <220> <221> MOD_RES &Lt; 222 > (11) <223> D-Phe <220> <221> MOD_RES (12). (12) <223> D-Val <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (14) <223> D-Val <220> <221> MOD_RES &Lt; 222 > (15) <223> D-Asn <220> <221> MOD_RES &Lt; 222 > (16) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (17) <223> D-Lys <220> <221> MOD_RES <222> (18). (18) <223> D-Ser <220> <221> MOD_RES <222> (19). (19) <223> D-Gln <220> <221> MOD_RES &Lt; 222 > (20) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 467 Leu Lys Ala Arg Leu Arg Glu Phe Tyr Gly Phe Val Phe Val Asn Lys 1 5 10 15 Lys Ser Gln Phe             20 <210> 468 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (15) <223> omega-methyl-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 468 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 469 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 469 Ala Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 470 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 470 Phe Ala Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 471 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 471 Phe Gln Ser Lys Gly Asn Ala Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 472 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 472 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Ala Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 473 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 473 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Ala Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 474 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 474 Phe Gln Asp Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 475 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 475 Phe Gln Ser Lys Gly Asp Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 476 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 476 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Asp Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 477 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 477 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Asp Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 478 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 478 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Asp Ala Lys Leu             20 <210> 479 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 479 Glu Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 480 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 480 Phe Gln Ser Lys Gly Glu Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 481 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 481 Phe Gln Ser Lys Gly Asn Glu Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 482 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 482 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Glu Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 483 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 483 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Glu Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 484 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 484 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Glu Ala Lys Leu             20 <210> 485 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 485 Phe Phe Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 486 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 486 Phe Gln Phe Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 487 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 487 Phe Gln Ser Lys Gly Phe Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 488 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 488 Phe Gln Ser Lys Gly Asn Phe Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 489 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 489 Phe Gln Ser Lys Gly Asn Val Phe Phe Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 490 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 490 Phe Gln Ser Lys Ala Ala Val Phe Val Ala Gly Tyr Phe Ala Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 491 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 491 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Phe Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 492 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 492 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Phe Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 493 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 493 Phe Gly Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 494 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 494 Phe Gln Gly Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 495 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 495 Phe Gln Ser Gly Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 496 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 496 Phe Gln Ser Lys Gly Gly Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 497 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 497 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Gly Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 498 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 498 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Gly Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 499 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 499 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Gly Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 500 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 500 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Gly Ala Lys Leu             20 <210> 501 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 501 His Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 502 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 502 Phe Gln Ser Lys Gly His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 503 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 503 Phe Gln Ser Lys Gly Asn His Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 504 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 504 Phe Gln Ser Lys Gly Asn Val Phe Val Asp His Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 505 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 505 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr His Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 506 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 506 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg His Lys Leu             20 <210> 507 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 507 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys His             20 <210> 508 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 508 Phe Ile Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 509 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 509 Phe Gln Ser Lys Gly Asn Val Phe Ile Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 510 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 510 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Ile Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 511 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 511 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ile Lys Leu             20 <210> 512 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 512 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Ile             20 <210> 513 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 513 Lys Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 514 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 514 Phe Gln Lys Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 515 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 515 Phe Gln Ser Lys Gly Asn Val Phe Lys Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 516 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 516 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Lys Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 517 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 517 Leu Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 518 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 518 Phe Gln Leu Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 519 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 519 Phe Gln Ser Lys Gly Asn Leu Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 520 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 520 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Leu Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 521 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 521 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Leu Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 522 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 522 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Leu Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 523 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 523 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Met Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 524 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 524 Asn Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 525 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 525 Phe Asn Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 526 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 526 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Asn Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 527 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 527 Phe Gln Ser Lys Gly Asn Pro Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 528 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 528 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Pro Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 529 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 529 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Pro Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 530 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 530 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Pro Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 531 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 531 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Pro Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 532 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 532 Gln Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 533 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 533 Phe Gln Ser Lys Gly Asn Gln Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 534 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 534 Phe Gln Ser Lys Gly Asn Val Phe Gln Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 535 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 535 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gln Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 536 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 536 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Gln Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 537 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 537 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Gln Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 538 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 538 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Gln Ala Lys Leu             20 <210> 539 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 539 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Gln             20 <210> 540 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 540 Arg Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 541 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 541 Phe Arg Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 542 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 542 Phe Gln Ser Lys Gly Asn Arg Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 543 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 543 Phe Gln Ser Lys Gly Asn Val Arg Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 544 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 544 Phe Gln Ser Lys Gly Asn Val Phe Arg Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 545 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 545 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Arg Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 546 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 546 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Arg 1 5 10 15 Arg Ala Lys Leu             20 <210> 547 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 547 Phe Ser Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 548 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 548 Phe Gln Ser Ser Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 549 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 549 Phe Gln Ser Lys Gly Asn Ser Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 550 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 550 Phe Gln Ser Lys Gly Asn Val Phe Ser Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 551 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 551 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Ser Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 552 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 552 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Ser Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 553 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 553 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ser Ala Lys Leu             20 <210> 554 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 554 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ser Lys Leu             20 <210> 555 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 555 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Ser             20 <210> 556 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 556 Thr Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 557 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 557 Phe Gln Thr Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 558 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 558 Phe Gln Ser Thr Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 559 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 559 Phe Gln Ser Lys Gly Thr Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 560 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 560 Phe Gln Ser Lys Gly Asn Thr Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 561 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 561 Phe Gln Ser Lys Gly Asn Val Phe Thr Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 562 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 562 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Thr Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 563 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 563 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Thr Lys Leu             20 <210> 564 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 564 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Thr             20 <210> 565 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 565 Phe Gln Ser Lys Ala Ala Val Phe Val Phe Gly Tyr Phe Ala Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 566 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 566 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Val Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 567 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 567 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Val 1 5 10 15 Arg Ala Lys Leu             20 <210> 568 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 568 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Val             20 <210> 569 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 569 Phe Gln Trp Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 570 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 570 Phe Gln Ser Lys Gly Trp Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 571 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 571 Phe Gln Ser Lys Gly Asn Trp Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 572 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 572 Phe Gln Ser Lys Gly Asn Val Trp Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 573 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 573 Phe Gln Ser Lys Gly Asn Val Phe Trp Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 574 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 574 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Trp Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 575 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 575 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Trp 1 5 10 15 Arg Ala Lys Leu             20 <210> 576 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 576 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Trp Ala Lys Leu             20 <210> 577 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 577 Phe Gln Tyr Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 578 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 578 Phe Gln Ser Lys Gly Asn Val Phe Tyr Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 579 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 579 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Tyr Lys Leu             20 <210> 580 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 580 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Tyr             20 <210> 581 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 581 Phe Gln Ser Lys Glu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 582 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 582 Phe Gln Ser Lys Ile Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 583 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 583 Phe Gln Ser Lys Pro Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 584 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 584 Phe Gln Ser Lys Ser Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 585 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 585 Phe Gln Ser Lys Thr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 586 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 586 Phe Gln Ser Lys Val Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 587 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 587 Phe Gln Ser Lys Trp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 588 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 588 Phe Gln Ser Lys Gly Asn Val Phe Val Ile Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 589 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 589 Phe Gln Ser Lys Gly Asn Val Phe Val Leu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 590 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 590 Phe Gln Ser Lys Gly Asn Val Phe Val Gln Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 591 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 591 Phe Gln Ser Lys Phe Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 592 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 592 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Gly Tyr His Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 593 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 593 Phe Gln Ser Ser His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 594 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 594 Phe Gln Ser Ala Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 595 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 595 Phe Gln Ser Phe Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 596 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 596 Phe Gln Asp Pro Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 597 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 597 Phe Gln Ser Lys Val Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 598 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 598 Phe Gln Ser Ile Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 599 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 599 Phe Gln Ser Lys Thr Asn Ile Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 600 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 600 Phe Gln Ser His Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 601 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 601 Phe Gln Ser Lys Glu Asn Val Phe Val Asp Gly Tyr Phe Asp Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 602 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 602 Phe Gln Ser His His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 603 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 603 Phe Gln Ser Tyr Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 604 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 604 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Phe Lys Leu             20 <210> 605 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 605 Phe Gln Ser Phe Lys His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 606 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 606 Phe Gln Ser Lys Ala Asn Val His Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 607 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 607 Phe Gln Ser Lys Ser Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 608 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 608 Phe Gln Ser His Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 609 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 609 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Phe             20 <210> 610 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 610 Phe Gln Ser Lys Met Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 611 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 611 Phe Gln Ser Ala Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 612 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 612 Phe Gln Ser Lys Gly Asn Trp Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 613 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 613 Phe Gln Ser Ala Lys Asn Val Phe Val Asp Gly Tyr Phe Val Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 614 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 614 Phe Gln Ser Lys Thr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 615 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 615 Phe Gln Ser Lys His Val Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 616 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 616 Phe Gln Ser Lys Lys His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 617 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 617 Phe Gln Ser Asp Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 618 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 618 Phe Gln Ser Asn Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 619 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 619 Phe Gln Ser His Lys Asn Val Phe Val Glu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 620 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 620 Phe Gln Ser Tyr Lys Asp Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Thr Lys Leu             20 <210> 621 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 621 Phe Gln Ser Lys Asn Asn Phe Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Arg Leu             20 <210> 622 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 622 Phe Gln Ser Glu Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 623 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 623 Phe Gln Ser Glu His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 624 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 624 Phe Gln Ser Glu Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 625 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 625 Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Phe Lys Leu             20 <210> 626 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 626 Phe Gln Ser Lys Arg Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 627 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 627 Phe Gln Ser Gly Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 628 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 628 Phe Gln Ser Tyr Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Phe Ala Lys Leu             20 <210> 629 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 629 Phe Cys Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 630 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 630 Phe Gln Ser Cys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 631 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 631 Phe Gln Ser Lys Gly Asn Cys Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 632 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 632 Phe Gln Ser Lys Gly Asn Val Phe Val Cys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 633 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 633 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Cys Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 634 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 634 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Cys 1 5 10 15 Arg Ala Lys Leu             20 <210> 635 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 635 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Cys             20 <210> 636 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 636 Phe Gln Ser Phe Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 637 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 637 Phe Gln Ser Lys Val Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 638 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 638 Phe Gln Ser Ile Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 639 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 639 Phe Gln Ser Lys Glu Arg Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 640 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 640 Phe Gln Ser Lys Glu Asn Val Phe Val Asp Gly Tyr Phe Asp Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 641 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 641 Phe Gln Ser Lys Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ile Lys Leu             20 <210> 642 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 642 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Val Lys Leu             20 <210> 643 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 643 Phe Gln Ser Tyr Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 644 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 644 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Phe Lys Leu             20 <210> 645 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 645 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 646 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 646 Phe Gln Ser Phe Lys His Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 647 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 647 Leu Gln Ser Lys Thr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 648 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 648 Phe Gln Ser Lys Cys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 649 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 649 Phe Gln Ser Lys Phe Asn Val Phe Val Asp Gly Tyr Thr Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 650 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 650 Phe Gln Ser Val Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 651 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 651 Phe Gln Ser Lys Gly Asn Trp Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 652 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 652 Phe Gln Ser Lys Val Ala Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 653 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 653 Phe Gln Ser Cys Lys Asn Val Phe Val Asp Gly Tyr Phe Val Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 654 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 654 Phe Gln Ser Lys Thr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 655 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 655 Phe Gln Ser Lys Lys Asp Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 656 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 656 Phe Gln Ser Lys Ser Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Arg Leu             20 <210> 657 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 657 Phe Gln Ser Asp Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 658 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 658 Phe Gln Ser His Lys Asn Val Phe Val Glu Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 659 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 659 Phe Gln Ser Lys Pro Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 660 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 660 Phe Gln Ser Tyr Lys Asp Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Thr Lys Leu             20 <210> 661 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 661 Phe Gln Ser Lys Leu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 662 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 662 Phe Gln Ser Lys Asn Asn Phe Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Arg Leu             20 <210> 663 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 663 Phe Gln Ser Lys Tyr Asn Ile Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 664 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 664 His Gln Gln Phe Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 665 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (3) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 665 Phe Gln Xaa Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 666 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 666 Phe Gln Ser Lys Gly Xaa Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 667 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 667 Phe Gln Ser Lys Gly Asn Val Phe Xaa Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 668 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> misc_feature &Lt; 222 > (10) <223> Xaa can be any naturally occurring amino acid <220> <221> MOD_RES &Lt; 222 > (11) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 668 Phe Gln Ser Lys Gly Asn Val Phe Val Xaa Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 669 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (11) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 669 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Xaa Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 670 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (5) (17) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 670 Phe Gln Ser Lys Cys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 671 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 671 Phe Gln Ser Lys Gly Asn Val Phe Val Cys Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 672 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 672 Phe Gln Ser Lys Lys Asn Asn Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 673 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 673 Phe Gln Ser Lys Lys Asn Val Val Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 674 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 674 Phe Gln Ser Lys Lys Asn Val Phe Gln Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 675 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (3) (S) -N-methyl-Ser <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 675 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 676 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (9) (S) -N-methyl-Val <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 676 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 677 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (13) (S) -N-methyl-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 677 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 678 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (14) (S) -N-methyl-Glu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 678 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 679 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (18). (18) (S) -N-methyl-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 679 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 680 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (2) (2) <223> beta-Homoglutamine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 680 Phe Glu Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 681 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (8) <223> Beta-Homophenylalanine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 681 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 682 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (10) <223> Beta-Homophenylalanine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 682 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 683 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (13) <223> Beta-Homophenylalanine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 683 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 684 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (16) <223> beta-Homoleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 684 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 685 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is (S) -Citrullin <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 685 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Xaa Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 686 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 686 Phe Gln Ser Lys Lys Asn Val Gly Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 687 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 687 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Gly 1 5 10 15 Arg Ala Lys Leu             20 <210> 688 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 688 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Gly Leu             20 <210> 689 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 689 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Lys Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 690 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 690 Phe Gln Ser Lys Phe Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 691 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 691 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Phe Lys Leu             20 <210> 692 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 692 Leu Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 693 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 693 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Leu Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 694 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 694 Phe Gln Ser Lys Gly Asn Val Phe Leu Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 695 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 695 Phe Ala Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 696 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 696 Phe Gln Ser Lys Lys Pro Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 697 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 697 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Ser Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 698 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 698 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Leu Lys Leu             20 <210> 699 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (3) <223> D-Ser <220> <221> MOD_RES &Lt; 222 > (20) <223> N-terminal acetylation <400> 699 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 700 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 700 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 701 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 701 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Gly Lys Leu             20 <210> 702 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 702 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Lys Lys Leu             20 <210> 703 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 703 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Lys             20 <210> 704 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 704 Phe Gln Ser Lys Ala Asn Val Phe Val Thr Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 705 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 705 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Gly Ala Lys Leu             20 <210> 706 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 706 Phe Gln Ser Val Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 707 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 707 Phe Gln Ser Lys Val Ala Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 708 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 708 Phe Gln Ser Lys Glu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Tyr Lys Leu             20 <210> 709 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 709 Phe Gln Ser Thr Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 710 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 710 Phe Xaa Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 711 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 711 Phe Gln Ser Lys Gly Asn Xaa Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 712 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 712 Lys Lys Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu Arg 1 5 10 15 Ala Lys Leu Thr Ser Lys Lys             20 <210> 713 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 713 Phe Ser Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 714 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES (12). (12) (S) -N-methyl-Tyr <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 714 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 715 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 715 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Lys 1 5 10 15 Arg Ala Lys Leu             20 <210> 716 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 716 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Asp Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 717 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 717 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Asp Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 718 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 718 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Asp Leu             20 <210> 719 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 719 Phe Gln Ser Lys Lys Asn Val Leu Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 720 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 720 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 721 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 721 Ala Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 722 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 722 Phe Gln Ser Lys Pro Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 723 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 723 Phe Gln Ser Lys Lys Asn Val Phe Pro Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 724 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 724 Phe Gln Ser Lys Lys Asn Ser Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 725 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 725 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Leu Ala Lys Leu             20 <210> 726 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 726 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 727 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (2) (2) <223> D-Gln <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 727 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 728 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (6) <223> D-Asn <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 728 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 729 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) <223> D-Val <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 729 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 730 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (8) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 730 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 731 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 731 Phe Gln Ser Lys Gly Asn Val Phe Ala Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 732 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 732 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Ala             20 <210> 733 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 733 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Asn             20 <210> 734 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 734 Ser Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 735 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 735 Phe Gln Ser Lys Lys Asn Val Phe Phe Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 736 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 736 Phe Gln Ser Lys Lys Asp Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 737 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 737 Phe Gln Ser Lys Ser Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Arg Leu             20 <210> 738 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 738 Phe Gln Ser Thr Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 739 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 739 Tyr Gln Ser Lys Gln Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 740 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 740 Phe Gln Ser Phe Glu Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 His Ala Lys Leu             20 <210> 741 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 741 Xaa Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 742 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 742 Val Val Glu Lys Leu Thr Phe Val Gln Leu Ser Phe Leu Asn Arg Arg 1 5 10 15 Arg Phe Ser Gln Tyr Ala Gly Phe Lys Gly Ala Gly Lys Val             20 25 30 <210> 743 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 743 Arg Val Phe Leu Tyr Phe Ser Gly Lys Ala Gly Gly Leu Val Lys Leu 1 5 10 15 Val Glu Arg Gln Ala Phe Gln Thr Asn Val Ser Lys Phe Arg             20 25 30 <210> 744 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 744 Lys Lys Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys 1 5 10 15 Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu Lys Lys             20 25 <210> 745 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 745 Lys Lys Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys 1 5 10 15 Asn Val Phe Val Phe Gly Tyr Phe Lys Lys             20 25 <210> 746 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 746 Lys Lys Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys 1 5 10 15 Asn Val Phe Val Phe Lys Lys             20 <210> 747 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 747 Phe Gln Ser Lys Gln Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 748 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 748 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Asn             20 <210> 749 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 749 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys              <210> 750 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 750 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Leu Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 751 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (8) (S) -methyl-Phe <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 751 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 752 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (15) (S) -methyl-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 752 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 753 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (16) (S) -N-methyl-Leu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 753 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 754 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) (S) -N-methyl-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 754 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 755 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) (S) -N-methyl-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 755 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 756 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) <223> beta-Leu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 756 Phe Gln Ser Lys Gly Asn Leu Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 757 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (9) <223> beta-Leu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 757 Phe Gln Ser Lys Gly Asn Val Phe Leu Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 758 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (11) <223> beta-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 758 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Ala Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 759 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES (12). (12) <223> beta-Tyr <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 759 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 760 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (15) <223> beta-Homoarginine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 760 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 761 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (15) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 761 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Xaa Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 762 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 762 Phe Gln Ser Lys Lys Asn Val Phe Gly Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 763 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 763 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Gly Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 764 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 764 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Gly Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 765 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 765 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Lys             20 <210> 766 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 766 Phe Phe Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 767 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 767 Phe Gln Phe Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 768 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 768 Phe Gln Ser Phe Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 769 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 769 Phe Gln Ser Lys Lys Phe Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 770 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 770 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Phe Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 771 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 771 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Phe Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 772 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 772 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Phe Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 773 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 773 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Phe 1 5 10 15 Arg Ala Lys Leu             20 <210> 774 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 774 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Phe Ala Lys Leu             20 <210> 775 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 775 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Phe Leu             20 <210> 776 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 776 Phe Asp Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 777 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 777 Phe Gln Ser Asp Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 778 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 778 Phe Gln Ser Lys Lys Asn Asp Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 779 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 779 Phe Gln Ser Lys Lys Asn Val Asp Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 780 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 780 Phe Gln Ser Lys Lys Asn Val Phe Asp Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 781 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 781 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Asp Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 782 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 782 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Asp 1 5 10 15 Arg Ala Lys Leu             20 <210> 783 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 783 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Asp Ala Lys Leu             20 <210> 784 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 784 Phe Leu Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 785 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 785 Phe Gln Leu Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 786 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 786 Phe Gln Ser Leu Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 787 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 787 Phe Gln Ser Lys Leu Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 788 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 788 Phe Gln Ser Lys Lys Leu Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 789 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 789 Phe Gln Ser Lys Lys Asn Val Phe Leu Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 790 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 790 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Leu Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 791 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 791 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Leu Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 792 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 792 Phe Gln Ser Lys Lys Asn Val Ala Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 793 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 793 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Ala Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 794 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 794 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Ala Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 795 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 795 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Ala Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 796 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 796 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Ala Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 797 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 797 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Ala 1 5 10 15 Arg Ala Lys Leu             20 <210> 798 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 798 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Ala Leu             20 <210> 799 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 799 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Ala             20 <210> 800 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 800 Pro Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 801 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 801 Phe Pro Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 802 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 802 Phe Gln Ser Lys Lys Asn Val Pro Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 803 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 803 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Pro Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 804 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 804 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Pro Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 805 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 805 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Pro Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 806 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 806 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Pro Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 807 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 807 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Pro Ala Lys Leu             20 <210> 808 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 808 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Pro Lys Leu             20 <210> 809 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 809 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Pro Leu             20 <210> 810 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 810 Ser Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 811 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 811 Phe Gln Ser Lys Ser Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 812 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 812 Phe Gln Ser Lys Lys Asn Val Ser Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 813 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 813 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Ser Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 814 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 814 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Ser Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 815 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 815 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Ser Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 816 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 816 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Ser 1 5 10 15 Arg Ala Lys Leu             20 <210> 817 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 817 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ser Ala Lys Leu             20 <210> 818 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 818 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Ser             20 <210> 819 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (16) <223> D-Leu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 819 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 820 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (18). (18) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 820 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 821 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 821 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 822 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> D-Leu <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 822 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 823 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (15) <223> omega-methyl-Arg <220> <221> MOD_RES &Lt; 222 > (17) <223> omega-methyl-Arg <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 823 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 824 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 824 Phe Gln Ser Lys Gly Asn Val Ala Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 825 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 825 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Ala Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 826 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 826 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Ala Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 827 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 827 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Ala 1 5 10 15 Arg Ala Lys Leu             20 <210> 828 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 828 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Ala Leu             20 <210> 829 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 829 Asp Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 830 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 830 Phe Asp Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 831 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 831 Phe Gln Ser Lys Gly Asn Asp Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 832 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 832 Phe Gln Ser Lys Gly Asn Val Asp Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 833 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 833 Phe Gln Ser Lys Gly Asn Val Phe Asp Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 834 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 834 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Asp Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 835 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 835 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Asp Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 836 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 836 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Asp 1 5 10 15 Arg Ala Lys Leu             20 <210> 837 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 837 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Asp Leu             20 <210> 838 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 838 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Asp             20 <210> 839 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 839 Phe Glu Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 840 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 840 Phe Gln Ser Lys Gly Asn Val Glu Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 841 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 841 Phe Gln Ser Lys Gly Asn Val Phe Glu Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 842 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 842 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Glu Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 843 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 843 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Glu Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 844 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 844 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Glu 1 5 10 15 Arg Ala Lys Leu             20 <210> 845 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 845 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Glu Leu             20 <210> 846 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 846 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Glu             20 <210> 847 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 847 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Phe Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 848 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 848 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Phe Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 849 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 849 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Phe 1 5 10 15 Arg Ala Lys Leu             20 <210> 850 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 850 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Phe Leu             20 <210> 851 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 851 Gly Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 852 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 852 Phe Gln Ser Lys Gly Asn Gly Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 853 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 853 Phe Gln Ser Lys Gly Asn Val Gly Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 854 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 854 Phe Gln Ser Lys Gly Asn Val Phe Gly Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 855 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 855 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Gly Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 856 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 856 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Gly 1 5 10 15 Arg Ala Lys Leu             20 <210> 857 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 857 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Gly Leu             20 <210> 858 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 858 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Gly             20 <210> 859 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 859 Phe His Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 860 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 860 Phe Gln Ser Lys Gly Asn Val Phe His Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 861 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 861 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly His Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 862 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 862 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu His Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 863 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 863 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg His 1 5 10 15 Arg Ala Lys Leu             20 <210> 864 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 864 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala His Leu             20 <210> 865 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 865 Phe Gln Ser Lys Gly Asn Val Ile Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 866 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 866 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Ile Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 867 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 867 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Ile Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 868 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 868 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Ile Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 869 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 869 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Ile 1 5 10 15 Arg Ala Lys Leu             20 <210> 870 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 870 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Ile Leu             20 <210> 871 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 871 Phe Lys Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 872 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 872 Phe Gln Ser Lys Gly Asn Lys Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 873 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 873 Phe Gln Ser Lys Gly Asn Val Lys Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 874 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 874 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Lys Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 875 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 875 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Lys Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 876 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 876 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Lys Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 877 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 877 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Lys 1 5 10 15 Arg Ala Lys Leu             20 <210> 878 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 878 Phe Leu Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 879 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 879 Phe Gln Ser Lys Gly Asn Val Leu Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 880 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 880 Phe Gln Ser Lys Gly Asn Val Phe Leu Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 881 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 881 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Leu Leu             20 <210> 882 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 882 Phe Gln Ser Lys Gly Asn Met Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 883 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 883 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Met 1 5 10 15 Arg Ala Lys Leu             20 <210> 884 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 884 Phe Gln Ser Lys Gly Asn Asn Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 885 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 885 Phe Gln Ser Lys Gly Asn Val Asn Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 886 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 886 Phe Gln Ser Lys Gly Asn Val Phe Asn Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 887 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 887 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Asn Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 888 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 888 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Asn Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 889 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 889 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Asn 1 5 10 15 Arg Ala Lys Leu             20 <210> 890 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 890 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Asn Leu             20 <210> 891 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 891 Pro Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 892 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 892 Phe Pro Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 893 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 893 Phe Gln Pro Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 894 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 894 Phe Gln Ser Lys Gly Pro Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 895 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 895 Phe Gln Ser Lys Gly Asn Val Pro Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 896 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 896 Phe Gln Ser Lys Gly Asn Val Phe Pro Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 897 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 897 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Pro Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 898 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 898 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Pro 1 5 10 15 Arg Ala Lys Leu             20 <210> 899 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 899 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Pro Ala Lys Leu             20 <210> 900 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 900 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Pro Lys Leu             20 <210> 901 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 901 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Pro Leu             20 <210> 902 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 902 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Pro             20 <210> 903 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 903 Phe Gln Ser Lys Gly Asn Val Gln Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 904 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 904 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Gln Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 905 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 905 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Gln 1 5 10 15 Arg Ala Lys Leu             20 <210> 906 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 906 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Gln Leu             20 <210> 907 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 907 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Arg Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 908 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 908 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Arg Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 909 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 909 Phe Gln Ser Lys Gly Asn Val Ser Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 910 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 910 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Ser Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 911 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 911 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Ser Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 912 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 912 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Ser 1 5 10 15 Arg Ala Lys Leu             20 <210> 913 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 913 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Ser Leu             20 <210> 914 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 914 Phe Thr Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 915 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 915 Phe Gln Ser Lys Gly Asn Val Thr Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 916 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 916 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Thr Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 917 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 917 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Thr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 918 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 918 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Thr Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 919 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 919 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Thr 1 5 10 15 Arg Ala Lys Leu             20 <210> 920 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 920 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Thr Leu             20 <210> 921 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 921 Phe Val Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 922 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 922 Phe Gln Ser Lys Gly Asn Val Val Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 923 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 923 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Val Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 924 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 924 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Val Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 925 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 925 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Val Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 926 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 926 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Val Leu             20 <210> 927 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 927 Phe Trp Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 928 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 928 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Trp Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 929 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 929 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Trp Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 930 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 930 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Trp Leu             20 <210> 931 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 931 Phe Tyr Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 932 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 932 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Tyr Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 933 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 933 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Tyr Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 934 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 934 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Tyr 1 5 10 15 Arg Ala Lys Leu             20 <210> 935 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 935 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Tyr Leu             20 <210> 936 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Val <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 936 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 937 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 937 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Asp             20 <210> 938 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 938 Leu Gln Ser Lys Thr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 939 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 939 Phe Gln Ser Lys Phe Asn Val Phe Val Asp Gly Tyr Thr Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 940 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 940 Phe Gln Ser Lys His Asn Val Phe Val Asp Gly His Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 941 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 941 Phe Gln Ser Val His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Pro 1 5 10 15 Ala Ala Lys Leu             20 <210> 942 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 942 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Glu Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 943 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 943 Phe Gln Ser Lys Pro Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 944 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 944 His Gln Gln Phe Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Ala Ala Lys Leu             20 <210> 945 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 945 Phe Gln Ser Lys His Asn Val Phe Val Asp Ala Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 946 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 946 Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Ser Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 947 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 947 Phe Gln Ser Lys Gly Asn Val Cys Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 948 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 948 Phe Gln Ser Lys Gly Asn Val Phe Cys Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 949 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 949 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Cys Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 950 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 950 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Cys Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 951 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 951 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Cys Leu             20 <210> 952 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation &Lt; 400 > 952 Phe Gln Ser Cys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 953 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 953 Phe Gln Ser Ala Tyr Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 954 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 954 Phe Gln Ser Val His Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Pro 1 5 10 15 Cys Ala Lys Leu             20 <210> 955 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 955 Phe Gln Ser Lys Tyr Asn Val Phe Val Asp Glu Tyr Phe Glu Arg Leu 1 5 10 15 Cys Ala Lys Leu             20 <210> 956 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (8) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 956 Phe Gln Ser Lys Gly Asn Val Xaa Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 957 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES (12). (12) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 957 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Xaa Phe Glu Arg Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 958 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 958 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Xaa Leu 1 5 10 15 Xaa Ala Lys Leu             20 <210> 959 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES <222> (19). (19) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 959 Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Xaa Ala Xaa Leu             20 <210> 960 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (11) <223> C-terminal amidation <400> 960 Asp Gly Tyr Phe Glu Arg Leu Arg Ala Lys Leu 1 5 10 <210> 961 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) <223> C-terminal amidation <400> 961 Phe Gln Ser Lys Lys Asn Val 1 5 <210> 962 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 962 Xaa Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys Asn 1 5 10 15 Val Phe Val Phe Gly Tyr Phe Glu Arg Leu Arg Ala Lys Leu Thr Ser             20 25 30 <210> 963 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (33) <223> Xaa is Lysin (biotin) <220> <221> MOD_RES &Lt; 222 > (33) <223> C-terminal amidation <400> 963 Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys Asn Val 1 5 10 15 Phe Val Phe Gly Tyr Phe Glu Arg Leu Arg Ala Lys Leu Thr Ser Xaa             20 25 30 Xaa      <210> 964 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 964 Xaa Ala Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu 1 5 10 15 Arg Leu Arg Ala Lys             20 <210> 965 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 965 Xaa Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu             20 <210> 966 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES <222> (2) (2) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 966 Xaa Xaa Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu Thr             20 <210> 967 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 967 Xaa Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys              <210> 968 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 968 Xaa Lys Lys Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe 1 5 10 15 Glu Arg Leu Arg Ala Lys Leu Lys Lys             20 25 <210> 969 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 969 Xaa Gly Lys Asn Ala Lys Phe Tyr Leu Phe Glu Ser Leu Arg Gln Val 1 5 10 15 Lys Phe Val Phe Arg             20 <210> 970 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 970 Xaa Tyr Lys Phe Ser Phe Asn Lys Glu Leu Phe Lys Gln Ala Arg Leu 1 5 10 15 Arg Phe Val Gly Val             20 <210> 971 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 971 Xaa Ser Gly Val Gly Arg Leu Gln Val Ala Phe Gln Ser Lys Lys Asn 1 5 10 15 Val Phe Val Phe Gly             20 <210> 972 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 972 Xaa Phe Gln Ser Lys Lys Asn Val Phe Val Asp Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu             20 <210> 973 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 973 Xaa Phe Gln Ser Lys Asn Asn Val Phe Val Phe Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu             20 <210> 974 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> C-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 974 Xaa Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Asp Arg 1 5 10 15 Leu Arg Ala Lys Leu             20 <210> 975 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 975 Phe Gln Ser Lys Lys Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 976 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 976 Phe Gln Ser Lys Asp Asn Val Phe Val Asp Gly Tyr Phe Asp Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 977 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 977 Xaa Phe Gln Ser Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg 1 5 10 15 Leu Arg Ala Lys Leu             20 <210> 978 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) C-terminal N-propyl <400> 978 Phe Gln Ser Lys Gly Asn Val Phe Val Phe Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 979 <400> 979 000 <210> 980 &Lt; 400 > 980 000 <210> 981 <400> 981 000 <210> 982 <400> 982 000 <210> 983 <400> 983 000 <210> 984 <400> 984 000 <210> 985 <400> 985 000 <210> 986 <400> 986 000 <210> 987 <400> 987 000 <210> 988 <400> 988 000 <210> 989 <400> 989 000 <210> 990 <400> 990 000 <210> 991 <400> 991 000 <210> 992 <400> 992 000 <210> 993 <400> 993 000 <210> 994 <400> 994 000 <210> 995 <400> 995 000 <210> 996 <400> 996 000 <210> 997 <400> 997 000 <210> 998 <400> 998 000 <210> 999 <400> 999 000 <210> 1000 <400> 1000 000 <210> 1001 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (12) (23) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (35) <223> C-terminal amidation <400> 1001 Lys Lys Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp 1 5 10 15 Met Lys Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg Tyr Asp Thr             20 25 30 Ser Lys Lys         35 <210> 1002 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (28) <223> C-terminal amidation &Lt; 400 > 1002 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg Tyr             20 25 <210> 1003 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1003 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1004 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1004 Ser Arg Tyr Lys Trp Phe Cys Ala Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1005 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal amidation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1005 Ser Arg Tyr Lys Trp Phe Cys Ala Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1006 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1006 Ser Arg Tyr Lys Trp Phe Cys Gly Met Pro Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1007 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1007 Asp Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1008 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1008 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Asp Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1009 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1009 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Asp             20 <210> 1010 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1010 Ser Phe Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1011 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1011 Ser Arg Phe Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1012 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1012 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Phe Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1013 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1013 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Phe 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1014 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1014 Gly Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1015 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1015 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Gly Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1016 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1016 Lys Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1017 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1017 Ser Arg Tyr Lys Trp Phe Cys Gly Met Lys Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1018 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1018 Leu Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1019 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1019 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Leu Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1020 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1020 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Leu             20 <210> 1021 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1021 Ser Arg Tyr Lys Trp Phe Cys Ser Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1022 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1022 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Ser Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1023 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1023 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Pro Phe             20 <210> 1024 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1024 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1025 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES (12). (12) <223> D-Leu <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1025 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Leu Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1026 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1026 Ser Met Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Tyr 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1027 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1027 Phe His Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Tyr 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1028 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1028 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Ile Met 1 5 10 15 Ser Cys Ala Trp Val Lys Phe             20 <210> 1029 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1029 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Ile Met 1 5 10 15 Ser Cys Val Trp Val Lys Tyr             20 <210> 1030 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1030 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Ile Asp 1 5 10 15 Ser Cys Val Trp Val Arg Phe             20 <210> 1031 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1031 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Ile Met 1 5 10 15 Ser Cys Val Trp Val Lys Ala             20 <210> 1032 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1032 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Thr Cys Val Trp Val Lys Phe             20 <210> 1033 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1033 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Ser             20 <210> 1034 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1034 Ser His Tyr Lys Trp His Cys Ala Met Arg Asp Met Lys Gly Thr Tyr 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1035 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1035 Ser Tyr Tyr Lys Trp His Cys Gly Val Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Ser             20 <210> 1036 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1036 Gly His Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Phe 1 5 10 15 Ser Cys Val Trp Val Phe             20 <210> 1037 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1037 Ala Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Leu Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Ser             20 <210> 1038 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1038 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Tyr 1 5 10 15 Ser Cys Val Trp Val Lys Met             20 <210> 1039 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1039 Ser His Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Ile Met 1 5 10 15 Ser Cys Val Trp Val Phe             20 <210> 1040 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1040 Phe Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Ala Trp Val Lys Phe             20 <210> 1041 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1041 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Asp 1 5 10 15 Ser Cys Val Trp Val Trp Tyr             20 <210> 1042 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1042 Ser His Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Ala Trp Val Lys Phe             20 <210> 1043 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1043 His Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Ser             20 <210> 1044 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1044 Ser Tyr Tyr Lys Trp His Cys Ala Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Thr Cys Val Trp Val Lys Phe             20 <210> 1045 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1045 Ser Tyr Tyr Lys Trp His Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Leu Phe             20 <210> 1046 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1046 Ser His Tyr Lys Trp His Cys Ala Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Ala Trp Val Lys Phe             20 <210> 1047 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 1047 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg Tyr Asp Thr Ser             20 25 30 <210> 1048 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1048 Ala Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1049 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1049 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Ala Trp Val Lys Phe             20 <210> 1050 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (6) (17) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation &Lt; 400 > 1050 Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser 1 5 10 15 Cys Val Trp Val Lys Phe             20 <210> 1051 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES (12). (12) <223> D-Met <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1051 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1052 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1052 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Asp Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1053 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1053 Phe Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1054 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1054 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Phe Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1055 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1055 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Gly Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1056 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1056 Ser Lys Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1057 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1057 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Lys Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1058 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1058 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Lys Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1059 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1059 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Lys 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1060 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1060 Ser Leu Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1061 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1061 Ser Arg Tyr Lys Trp Leu Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1062 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1062 Ser Arg Tyr Lys Trp Phe Cys Gly Met Leu Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1063 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1063 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Leu Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1064 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1064 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Leu 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1065 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1065 Ser Ser Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1066 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1066 Ser Arg Ser Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1067 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1067 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Ser Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1068 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1068 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Ser Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1069 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1069 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Ser 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1070 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1070 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Ser Phe             20 <210> 1071 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1071 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Ser             20 <210> 1072 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1072 Pro Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1073 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> DISULFID <222> (6) (17) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1073 Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser 1 5 10 15 Cys Val Trp Val Lys Phe             20 <210> 1074 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES (12). (12) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1074 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Phe Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1075 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (28) <223> C-terminal amidation <400> 1075 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg Tyr             20 25 <210> 1076 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (28) <223> C-terminal amidation <400> 1076 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe Arg Tyr Asp Thr Ser             20 25 <210> 1077 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES (12). (12) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (16) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1077 Ser Arg Tyr Lys Trp Phe Cys Gly Xaa Arg Asp Xaa Lys Gly Thr Xaa 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1078 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1078 Ser Ala Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1079 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1079 Ser Arg Tyr Lys Trp Phe Cys Gly Met Ala Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1080 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation &Lt; 400 > 1080 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Ala Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1081 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1081 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Ala Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1082 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1082 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Ala Phe             20 <210> 1083 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1083 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Ala             20 <210> 1084 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1084 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Pro Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1085 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1085 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Asp Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1086 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1086 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Asp 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1087 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1087 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Phe Trp Val Lys Phe             20 <210> 1088 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1088 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Gly Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1089 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1089 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Gly Phe             20 <210> 1090 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1090 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Gly             20 <210> 1091 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1091 Ser Arg Tyr Lys Trp Lys Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1092 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1092 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Leu Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1093 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1093 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Leu Trp Val Lys Phe             20 <210> 1094 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1094 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Leu Lys Phe             20 <210> 1095 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1095 Ser Arg Tyr Lys Trp Phe Cys Gly Met Ser Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1096 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1096 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Ser Ser Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1097 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1097 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Ser Trp Val Lys Phe             20 <210> 1098 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <400> 1098 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1099 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <400> 1099 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1100 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Pro <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1100 Ser Arg Tyr Lys Trp Phe Cys Gly Pro Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1101 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES (12). (12) <223> D-Asp <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1101 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Asp Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1102 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES (12). (12) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1102 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Lys Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1103 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 1103 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met Ser Cys Val Trp Val Lys             20 25 <210> 1104 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES (12). (12) &Lt; 223 > Xaa is (S) -Noreleucine <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is (S) -Noreleucine <220> <221> MOD_RES <222> (19). (19) &Lt; 223 > Xaa is (S) -Noreleucine <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 1104 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Xaa Arg Asp Xaa Lys 1 5 10 15 Gly Thr Xaa Ser Cys Val Trp Val Lys Phe Arg Tyr Asp Thr Ser             20 25 30 <210> 1105 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1105 Ser Arg Ala Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1106 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> D-Ala <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is Norleucine <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1106 Ser Arg Tyr Ala Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1107 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1107 Ser Arg Tyr Lys Trp Phe Cys Gly Ala Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1108 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1108 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Ala Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1109 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (5) <223> N-methyl-Gly <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1109 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Ala 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1110 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1110 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ala Cys Val Trp Val Lys Phe             20 <210> 1111 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (5) (16) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 1111 Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys 1 5 10 15 Val Trp Val Lys Phe             20 <210> 1112 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) <223> Homo-Cys <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1112 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1113 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Met <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1113 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1114 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1114 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1115 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (9) <223> Cys residues linked via disulfide bond <400> 1115 Gly Ser Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly 1 5 10 15 Thr Met Ser Cys Val Trp Val Lys Phe             20 25 <210> 1116 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1116 Ser Asp Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1117 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1117 Ser Arg Tyr Asp Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1118 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1118 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Asp Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1119 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1119 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Asp Cys Val Trp Val Lys Phe             20 <210> 1120 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1120 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Asp Phe             20 <210> 1121 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1121 Ser Arg Tyr Phe Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1122 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1122 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Phe Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1123 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1123 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Phe Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1124 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1124 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Phe Cys Val Trp Val Lys Phe             20 <210> 1125 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1125 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Phe Val Lys Phe             20 <210> 1126 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1126 Ser Gly Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1127 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1127 Ser Arg Tyr Gly Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1128 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1128 Ser Arg Tyr Lys Trp Phe Cys Gly Met Gly Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1129 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1129 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Gly Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1130 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1130 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Gly 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1131 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1131 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Gly Cys Val Trp Val Lys Phe             20 <210> 1132 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1132 Ser Arg Lys Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1133 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1133 Ser Arg Tyr Lys Trp Phe Cys Gly Lys Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1134 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1134 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Lys Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1135 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1135 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Lys Cys Val Trp Val Lys Phe             20 <210> 1136 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1136 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Lys             20 <210> 1137 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1137 Ser Arg Leu Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1138 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1138 Ser Arg Tyr Leu Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1139 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1139 Ser Arg Tyr Lys Trp Phe Cys Gly Leu Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1140 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1140 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Leu Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1141 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1141 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Leu Cys Val Trp Val Lys Phe             20 <210> 1142 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1142 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Leu Phe             20 <210> 1143 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1143 Ser Arg Tyr Ser Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1144 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1144 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Ser Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1145 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1145 Ser Pro Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1146 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1146 Ser Arg Tyr Lys Trp Phe Cys Gln Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1147 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1147 Ser Arg Tyr Lys Trp Phe Cys Arg Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1148 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (5) (16) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1148 Ser Arg Tyr Lys Trp Phe Cys Thr Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1149 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 1149 Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys 1 5 10 15 Val Trp Val Lys Phe             20 <210> 1150 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1150 Ser Arg Tyr Lys Trp Phe Cys Gly Ala Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1151 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES (12). (12) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1151 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Ala Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1152 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES (12). (12) <223> D-Ser <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1152 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Ser Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1153 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Asp <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1153 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Asp Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1154 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Ser <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1154 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Ser Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1155 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (4) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 1155 Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val 1 5 10 15 Trp Val Lys Phe Arg Tyr Asp Thr Ser             20 25 <210> 1156 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (4) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1156 Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val 1 5 10 15 Trp Val Lys Phe             20 <210> 1157 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1157 Ser Arg Tyr Lys Trp Phe Ala Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1158 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1158 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Ala Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1159 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1159 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Ala Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1160 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1160 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Ala Val Trp Val Lys Phe             20 <210> 1161 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1161 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Ala Lys Phe             20 <210> 1162 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1162 Ser Arg Tyr Lys Trp Phe Gly Met Arg Cys Asp Met Lys Gly Cys Thr 1 5 10 15 Met Ser Val Trp Val Lys Phe             20 <210> 1163 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES <222> (18). (18) <223> Homo-Cys <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1163 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1164 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1164 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Lys Gly Thr Met Ser 1 5 10 15 Cys Val Trp Val Lys Phe             20 <210> 1165 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1165 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Gly Thr Met Ser 1 5 10 15 Cys Val Trp Val Lys Phe             20 <210> 1166 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1166 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Met Ser 1 5 10 15 Cys Val Trp Val Lys Phe             20 <210> 1167 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES <222> (7) (7) <223> d-Cys <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 1167 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1168 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (11) <223> D-Asp <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1168 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1169 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (15) <223> D-Thr <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1169 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1170 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (17) <223> D-Ser <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1170 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1171 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES <222> (18). (18) <223> D-Cys <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1171 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1172 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1172 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Pro Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1173 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1173 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Pro Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1174 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1174 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Pro Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1175 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1175 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Pro 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1176 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1176 Ser Arg Asp Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1177 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1177 Ser Arg Tyr Lys Trp Phe Cys Gly Asp Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1178 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1178 Ser Arg Tyr Lys Trp Phe Cys Gly Phe Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1179 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1179 Ser Arg Tyr Lys Trp Phe Cys Gly Met Phe Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1180 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1180 Ser Arg Gly Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1181 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1181 Ser Arg Tyr Lys Trp Phe Cys Gly Gly Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1182 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1182 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Gly Trp Val Lys Phe             20 <210> 1183 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1183 Ser Arg Tyr Lys Trp Phe Cys Lys Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1184 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1184 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Lys Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1185 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1185 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Leu Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1186 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1186 Ser Arg Tyr Lys Trp Phe Cys Gly Ser Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1187 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1187 Ser Arg Pro Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1188 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1188 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Pro             20 <210> 1189 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1189 Ser Arg Tyr Lys Trp Phe Cys Met Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1190 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1190 Ser Arg Tyr Lys Trp Phe Cys Asn Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1191 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1191 Ser Arg Tyr Lys Trp Phe Cys Trp Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1192 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1192 Ser Arg Tyr Lys Trp Phe Cys Gly Phe Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1193 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Lys <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1193 Ser Arg Tyr Lys Trp Phe Cys Gly Lys Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1194 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Leu <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1194 Ser Arg Tyr Lys Trp Phe Cys Gly Leu Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1195 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Ser <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1195 Ser Arg Tyr Lys Trp Phe Cys Gly Ser Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1196 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES (12). (12) <223> D-Pro <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1196 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Pro Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1197 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Ala <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1197 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Ala Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1198 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Phe <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1198 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Phe Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1199 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Leu <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1199 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Leu Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1200 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (13) <223> D-Pro <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1200 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Pro Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1201 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 1201 Lys Lys Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly 1 5 10 15 Thr Met Ser Cys Val Trp Lys Lys             20 <210> 1202 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 1202 Lys Lys Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser 1 5 10 15 Cys Val Trp Val Lys Phe Lys Lys             20 <210> 1203 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (4) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1203 Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val 1 5 10 15 Trp Val Lys Phe             20 <210> 1204 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 1204 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Ser Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met Ser Ser Val Trp Val Lys Phe Arg Tyr Asp Thr Ser             20 25 30 <210> 1205 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1205 Lys Trp Phe Ser Gly Xaa Arg Asp Xaa Lys Gly Thr Xaa Ser Ser Val 1 5 10 15 Trp Val Lys Phe             20 <210> 1206 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1206 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp             20 <210> 1207 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1207 Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val 1 5 10 15 Trp Val Lys Phe             20 <210> 1208 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES (12). (12) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES <222> (19). (19) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 1208 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Ser Gly Xaa Arg Asp Xaa Lys 1 5 10 15 Gly Thr Xaa Ser Ser Val Trp Val Lys Phe Arg Tyr Asp Thr Ser             20 25 30 <210> 1209 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (4) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1209 Lys Trp Phe Cys Gly Xaa Arg Asp Xaa Lys Gly Thr Xaa Ser Cys Val 1 5 10 15 Trp Val Lys Phe             20 <210> 1210 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES (12). (12) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (16) &Lt; 223 > Xaa is (S) -Norleucine <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1210 Ser Arg Tyr Lys Trp Phe Ser Gly Xaa Arg Asp Xaa Lys Gly Thr Xaa 1 5 10 15 Ser Ser Val Trp Val Lys Phe             20 <210> 1211 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 1211 Arg Lys Arg Asp Val Ser Gly Lys Met Cys Trp Ser Gly Phe Gly Ser 1 5 10 15 Lys Trp Phe Arg Cys Ala Asp Met Met Thr Tyr Tyr Ser Val Thr             20 25 30 <210> 1212 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 1212 Arg Trp Ser Gly Lys Ser Thr Tyr Ser Cys Asp Ala Met Val Arg Arg 1 5 10 15 Met Gly Met Lys Cys Phe Ser Phe Gly Trp Thr Asp Val Tyr Lys             20 25 30 <210> 1213 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 1213 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg Tyr Asp Thr Ser             20 25 30 <210> 1214 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 1214 Lys Lys Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp 1 5 10 15 Met Lys Gly Thr Met Ser Lys Lys             20 <210> 1215 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 1215 Lys Lys Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp 1 5 10 15 Val Lys Phe Arg Tyr Asp Lys Lys             20 <210> 1216 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 1216 Lys Lys Met Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp Val Lys 1 5 10 15 Phe Arg Tyr Asp Thr Ser Lys Lys             20 <210> 1217 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (10) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1217 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met Ser Cys Val             20 <210> 1218 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 1218 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met              <210> 1219 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (1) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1219 Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp Val Lys 1 5 10 15 Phe Arg Tyr Asp Thr Ser             20 <210> 1220 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 1220 Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg Tyr 1 5 10 15 Asp Thr Ser              <210> 1221 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 1221 Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg Tyr 1 5 10 15 Asp Thr Ser              <210> 1222 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1222 Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys 1 5 10 15 Gly Thr Met Ser             20 <210> 1223 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1223 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp             20 <210> 1224 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (1) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1224 Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp Val Lys 1 5 10 15 Phe Arg Tyr Asp             20 <210> 1225 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1225 Met Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg 1 5 10 15 Tyr Asp Thr Ser             20 <210> 1226 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1226 Met Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg 1 5 10 15 Tyr Asp Thr Ser             20 <210> 1227 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1227 Cys Gly Met Arg Asp Met Lys Gly Thr Met Ser Cys Val Trp Val Lys 1 5 10 15 Phe Arg Tyr Asp             20 <210> 1228 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1228 Lys Trp Phe Ser Gly Met Arg Asp Met Lys Gly Thr Met Ser Ser Val 1 5 10 15 Trp Val Lys Phe             20 <210> 1229 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1229 Ser Arg Tyr Lys Trp Phe Ser Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Ser Val Trp Val Lys Phe             20 <210> 1230 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1230 Ser Arg Tyr Lys Ala Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1231 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1231 Ser Arg Tyr Lys Trp Ala Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1232 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1232 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Ala Val Lys Phe             20 <210> 1233 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (9). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1233 Ser Arg Tyr Lys Trp Phe Gly Met Cys Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1234 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (11) .. (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1234 Ser Arg Tyr Lys Trp Phe Gly Met Arg Asp Cys Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1235 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (13). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1235 Ser Arg Tyr Lys Trp Phe Gly Met Arg Asp Met Lys Cys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1236 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1236 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Cys 1 5 10 15 Met Ser Val Trp Val Lys Phe             20 <210> 1237 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID &Lt; 222 > (7) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1237 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Cys Gly Thr 1 5 10 15 Met Ser Val Trp Val Lys Phe             20 <210> 1238 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1238 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Cys Met Lys Gly Thr 1 5 10 15 Met Ser Val Trp Val Lys Phe             20 <210> 1239 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (8) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1239 Ser Arg Tyr Lys Trp Phe Gly Cys Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Cys Ser Val Trp Val Lys Phe             20 <210> 1240 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (9). (16) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1240 Ser Arg Tyr Lys Trp Phe Gly Met Cys Arg Asp Met Lys Gly Thr Cys 1 5 10 15 Met Ser Val Trp Val Lys Phe             20 <210> 1241 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) <223> Homo-Cys <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES <222> (18). (18) <223> Homo-Cys <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1241 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1242 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is (S) -Diaminopropionic acid <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1242 Ser Arg Tyr Lys Trp Phe Xaa Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Asp Val Trp Val Lys Phe             20 <210> 1243 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1243 Ser Arg Tyr Lys Trp Phe Lys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Asp Val Trp Val Lys Phe             20 <210> 1244 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7) (17) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 1244 Ser Arg Tyr Lys Trp Phe Cys Met Arg Asp Met Lys Gly Thr Met Ser 1 5 10 15 Cys Val Trp Val Lys Phe             20 <210> 1245 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (10) <223> D-Arg <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1245 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1246 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (16) <223> D-Met <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1246 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1247 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1247 Ser Arg Tyr Lys Trp Phe Cys Pro Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1248 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1248 Ser Arg Tyr Lys Trp Phe Cys Gly Pro Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1249 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1249 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Pro Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1250 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1250 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Pro Cys Val Trp Val Lys Phe             20 <210> 1251 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1251 Ser Arg Tyr Lys Asp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1252 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1252 Ser Arg Tyr Lys Trp Asp Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1253 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1253 Ser Arg Tyr Lys Trp Phe Cys Asp Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1254 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1254 Ser Arg Tyr Lys Trp Phe Cys Gly Met Asp Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1255 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1255 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Asp Trp Val Lys Phe             20 <210> 1256 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1256 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Asp Val Lys Phe             20 <210> 1257 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1257 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Asp Lys Phe             20 <210> 1258 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1258 Ser Arg Tyr Lys Phe Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1259 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1259 Ser Arg Tyr Lys Trp Phe Cys Phe Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1260 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1260 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Phe Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1261 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1261 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Phe Lys Phe             20 <210> 1262 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1262 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Phe Phe             20 <210> 1263 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1263 Ser Arg Tyr Lys Gly Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1264 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1264 Ser Arg Tyr Lys Trp Gly Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1265 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1265 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Gly Val Lys Phe             20 <210> 1266 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1266 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Gly Lys Phe             20 <210> 1267 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1267 Ser Arg Tyr Lys Lys Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1268 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1268 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Lys Trp Val Lys Phe             20 <210> 1269 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1269 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Lys Val Lys Phe             20 <210> 1270 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1270 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Lys Lys Phe             20 <210> 1271 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1271 Ser Arg Tyr Lys Leu Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1272 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1272 Ser Arg Tyr Lys Trp Phe Cys Leu Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1273 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1273 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Leu Val Lys Phe             20 <210> 1274 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1274 Ser Arg Tyr Lys Ser Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1275 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1275 Ser Arg Tyr Lys Trp Ser Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1276 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1276 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Ser Val Lys Phe             20 <210> 1277 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1277 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Ser Lys Phe             20 <210> 1278 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1278 Ser Arg Tyr Pro Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1279 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1279 Ser Arg Tyr Lys Pro Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1280 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1280 Ser Arg Tyr Lys Trp Pro Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1281 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1281 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Pro Trp Val Lys Phe             20 <210> 1282 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1282 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Pro Val Lys Phe             20 <210> 1283 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1283 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Pro Lys Phe             20 <210> 1284 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 1284 Ser Arg Tyr Lys Trp Phe Cys Glu Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1285 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1285 Ser Arg Tyr Lys Trp Phe Cys His Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1286 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1286 Ser Arg Tyr Lys Trp Phe Cys Ile Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1287 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1287 Ser Arg Tyr Lys Trp Phe Cys Val Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1288 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1288 Ser Arg Tyr Lys Trp Phe Cys Tyr Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1289 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (9) <223> D-Asp <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1289 Ser Arg Tyr Lys Trp Phe Cys Gly Asp Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1290 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> DISULFID &Lt; 222 > (11) <223> Cys residues linked via disufide bond <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 1290 Xaa Ser Gly Ala Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met 1 5 10 15 Lys Gly Thr Met Ser Cys Val Trp Val Lys Phe Arg Tyr Asp Thr Ser             20 25 30 <210> 1291 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> DISULFID <222> (8) (19) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 1291 Xaa Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr 1 5 10 15 Met Ser Cys Val Trp Val Lys Phe             20 <210> 1292 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 1292 Ser Arg Tyr Lys Trp Phe Cys Gly Met Arg Asp Met Lys Gly Thr Met 1 5 10 15 Ser Cys Val Trp Val Lys Phe             20 <210> 1293 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 1293 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Ser Ser Met His Phe Trp Arg Trp Ser Thr Ser             20 25 30 <210> 1294 <400> 1294 000 <210> 1295 <400> 1295 000 <210> 1296 <400> 1296 000 <210> 1297 <400> 1297 000 <210> 1298 <400> 1298 000 <210> 1299 <400> 1299 000 <210> 1300 <400> 1300 000 <210> 1301 <400> 1301 000 <210> 1302 <400> 1302 000 <210> 1303 <400> 1303 000 <210> 1304 <400> 1304 000 <210> 1305 <400> 1305 000 <210> 1306 <400> 1306 000 <210> 1307 <400> 1307 000 <210> 1308 <400> 1308 000 <210> 1309 <400> 1309 000 <210> 1310 <400> 1310 000 <210> 1311 <400> 1311 000 <210> 1312 <400> 1312 000 <210> 1313 <400> 1313 000 <210> 1314 <400> 1314 000 <210> 1315 <400> 1315 000 <210> 1316 <400> 1316 000 <210> 1317 <400> 1317 000 <210> 1318 <400> 1318 000 <210> 1319 <400> 1319 000 <210> 1320 <400> 1320 000 <210> 1321 <400> 1321 000 <210> 1322 <400> 1322 000 <210> 1323 <400> 1323 000 <210> 1324 <400> 1324 000 <210> 1325 <400> 1325 000 <210> 1326 <400> 1326 000 <210> 1327 <400> 1327 000 <210> 1328 <400> 1328 000 <210> 1329 <400> 1329 000 <210> 1330 <400> 1330 000 <210> 1331 <400> 1331 000 <210> 1332 <400> 1332 000 <210> 1333 <400> 1333 000 <210> 1334 <400> 1334 000 <210> 1335 <400> 1335 000 <210> 1336 <400> 1336 000 <210> 1337 <400> 1337 000 <210> 1338 <400> 1338 000 <210> 1339 <400> 1339 000 <210> 1340 <400> 1340 000 <210> 1341 <400> 1341 000 <210> 1342 <400> 1342 000 <210> 1343 <400> 1343 000 <210> 1344 <400> 1344 000 <210> 1345 <400> 1345 000 <210> 1346 <400> 1346 000 <210> 1347 <400> 1347 000 <210> 1348 <400> 1348 000 <210> 1349 <400> 1349 000 <210> 1350 <400> 1350 000 <210> 1351 <400> 1351 000 <210> 1352 <400> 1352 000 <210> 1353 <400> 1353 000 <210> 1354 <400> 1354 000 <210> 1355 <400> 1355 000 <210> 1356 <400> 1356 000 <210> 1357 <400> 1357 000 <210> 1358 <400> 1358 000 <210> 1359 <400> 1359 000 <210> 1360 <400> 1360 000 <210> 1361 <400> 1361 000 <210> 1362 <400> 1362 000 <210> 1363 <400> 1363 000 <210> 1364 <400> 1364 000 <210> 1365 <400> 1365 000 <210> 1366 <400> 1366 000 <210> 1367 <400> 1367 000 <210> 1368 <400> 1368 000 <210> 1369 <400> 1369 000 <210> 1370 <400> 1370 000 <210> 1371 <400> 1371 000 <210> 1372 <400> 1372 000 <210> 1373 <400> 1373 000 <210> 1374 <400> 1374 000 <210> 1375 <400> 1375 000 <210> 1376 <400> 1376 000 <210> 1377 <400> 1377 000 <210> 1378 <400> 1378 000 <210> 1379 <400> 1379 000 <210> 1380 <400> 1380 000 <210> 1381 <400> 1381 000 <210> 1382 <400> 1382 000 <210> 1383 <400> 1383 000 <210> 1384 <400> 1384 000 <210> 1385 <400> 1385 000 <210> 1386 <400> 1386 000 <210> 1387 <400> 1387 000 <210> 1388 <400> 1388 000 <210> 1389 <400> 1389 000 <210> 1390 <400> 1390 000 <210> 1391 <400> 1391 000 <210> 1392 <400> 1392 000 <210> 1393 <400> 1393 000 <210> 1394 <400> 1394 000 <210> 1395 <400> 1395 000 <210> 1396 <400> 1396 000 <210> 1397 <400> 1397 000 <210> 1398 <400> 1398 000 <210> 1399 <400> 1399 000 <210> 1400 <400> 1400 000 <210> 1401 <400> 1401 000 <210> 1402 <400> 1402 000 <210> 1403 <400> 1403 000 <210> 1404 <400> 1404 000 <210> 1405 <400> 1405 000 <210> 1406 <400> 1406 000 <210> 1407 <400> 1407 000 <210> 1408 <400> 1408 000 <210> 1409 <400> 1409 000 <210> 1410 <400> 1410 000 <210> 1411 <400> 1411 000 <210> 1412 <400> 1412 000 <210> 1413 <400> 1413 000 <210> 1414 <400> 1414 000 <210> 1415 <400> 1415 000 <210> 1416 <400> 1416 000 <210> 1417 <400> 1417 000 <210> 1418 <400> 1418 000 <210> 1419 <400> 1419 000 <210> 1420 <400> 1420 000 <210> 1421 <400> 1421 000 <210> 1422 <400> 1422 000 <210> 1423 <400> 1423 000 <210> 1424 <400> 1424 000 <210> 1425 <400> 1425 000 <210> 1426 <400> 1426 000 <210> 1427 <400> 1427 000 <210> 1428 <400> 1428 000 <210> 1429 <400> 1429 000 <210> 1430 <400> 1430 000 <210> 1431 <400> 1431 000 <210> 1432 <400> 1432 000 <210> 1433 <400> 1433 000 <210> 1434 <400> 1434 000 <210> 1435 <400> 1435 000 <210> 1436 <400> 1436 000 <210> 1437 <400> 1437 000 <210> 1438 <400> 1438 000 <210> 1439 <400> 1439 000 <210> 1440 <400> 1440 000 <210> 1441 <400> 1441 000 <210> 1442 <400> 1442 000 <210> 1443 <400> 1443 000 <210> 1444 <400> 1444 000 <210> 1445 <400> 1445 000 <210> 1446 <400> 1446 000 <210> 1447 <400> 1447 000 <210> 1448 <400> 1448 000 <210> 1449 <400> 1449 000 <210> 1450 <400> 1450 000 <210> 1451 <400> 1451 000 <210> 1452 <400> 1452 000 <210> 1453 <400> 1453 000 <210> 1454 <400> 1454 000 <210> 1455 <400> 1455 000 <210> 1456 <400> 1456 000 <210> 1457 <400> 1457 000 <210> 1458 <400> 1458 000 <210> 1459 <400> 1459 000 <210> 1460 <400> 1460 000 <210> 1461 <400> 1461 000 <210> 1462 <400> 1462 000 <210> 1463 <400> 1463 000 <210> 1464 <400> 1464 000 <210> 1465 <400> 1465 000 <210> 1466 <400> 1466 000 <210> 1467 <400> 1467 000 <210> 1468 <400> 1468 000 <210> 1469 <400> 1469 000 <210> 1470 <400> 1470 000 <210> 1471 <400> 1471 000 <210> 1472 <400> 1472 000 <210> 1473 <400> 1473 000 <210> 1474 <400> 1474 000 <210> 1475 <400> 1475 000 <210> 1476 <400> 1476 000 <210> 1477 <400> 1477 000 <210> 1478 <400> 1478 000 <210> 1479 <400> 1479 000 <210> 1480 <400> 1480 000 <210> 1481 <400> 1481 000 <210> 1482 <400> 1482 000 <210> 1483 <400> 1483 000 <210> 1484 <400> 1484 000 <210> 1485 <400> 1485 000 <210> 1486 <400> 1486 000 <210> 1487 <400> 1487 000 <210> 1488 <400> 1488 000 <210> 1489 <400> 1489 000 <210> 1490 <400> 1490 000 <210> 1491 <400> 1491 000 <210> 1492 <400> 1492 000 <210> 1493 <400> 1493 000 <210> 1494 <400> 1494 000 <210> 1495 <400> 1495 000 <210> 1496 <400> 1496 000 <210> 1497 <400> 1497 000 <210> 1498 <400> 1498 000 <210> 1499 <400> 1499 000 <210> 1500 <400> 1500 000 <210> 1501 <400> 1501 000 <210> 1502 <400> 1502 000 <210> 1503 <400> 1503 000 <210> 1504 <400> 1504 000 <210> 1505 <400> 1505 000 <210> 1506 <400> 1506 000 <210> 1507 <400> 1507 000 <210> 1508 <400> 1508 000 <210> 1509 <400> 1509 000 <210> 1510 <400> 1510 000 <210> 1511 <400> 1511 000 <210> 1512 <400> 1512 000 <210> 1513 <400> 1513 000 <210> 1514 <400> 1514 000 <210> 1515 <400> 1515 000 <210> 1516 <400> 1516 000 <210> 1517 <400> 1517 000 <210> 1518 <400> 1518 000 <210> 1519 <400> 1519 000 <210> 1520 <400> 1520 000 <210> 1521 <400> 1521 000 <210> 1522 <400> 1522 000 <210> 1523 <400> 1523 000 <210> 1524 <400> 1524 000 <210> 1525 <400> 1525 000 <210> 1526 <400> 1526 000 <210> 1527 <400> 1527 000 <210> 1528 <400> 1528 000 <210> 1529 <400> 1529 000 <210> 1530 <400> 1530 000 <210> 1531 <400> 1531 000 <210> 1532 <400> 1532 000 <210> 1533 <400> 1533 000 <210> 1534 <400> 1534 000 <210> 1535 <400> 1535 000 <210> 1536 <400> 1536 000 <210> 1537 <400> 1537 000 <210> 1538 <400> 1538 000 <210> 1539 <400> 1539 000 <210> 1540 <400> 1540 000 <210> 1541 <400> 1541 000 <210> 1542 <400> 1542 000 <210> 1543 <400> 1543 000 <210> 1544 <400> 1544 000 <210> 1545 <400> 1545 000 <210> 1546 <400> 1546 000 <210> 1547 <400> 1547 000 <210> 1548 <400> 1548 000 <210> 1549 <400> 1549 000 <210> 1550 <400> 1550 000 <210> 1551 <400> 1551 000 <210> 1552 <400> 1552 000 <210> 1553 <400> 1553 000 <210> 1554 <400> 1554 000 <210> 1555 <400> 1555 000 <210> 1556 <400> 1556 000 <210> 1557 <400> 1557 000 <210> 1558 <400> 1558 000 <210> 1559 <400> 1559 000 <210> 1560 <400> 1560 000 <210> 1561 <400> 1561 000 <210> 1562 <400> 1562 000 <210> 1563 <400> 1563 000 <210> 1564 <400> 1564 000 <210> 1565 <400> 1565 000 <210> 1566 <400> 1566 000 <210> 1567 <400> 1567 000 <210> 1568 <400> 1568 000 <210> 1569 <400> 1569 000 <210> 1570 <400> 1570 000 <210> 1571 <400> 1571 000 <210> 1572 <400> 1572 000 <210> 1573 <400> 1573 000 <210> 1574 <400> 1574 000 <210> 1575 <400> 1575 000 <210> 1576 <400> 1576 000 <210> 1577 <400> 1577 000 <210> 1578 <400> 1578 000 <210> 1579 <400> 1579 000 <210> 1580 <400> 1580 000 <210> 1581 <400> 1581 000 <210> 1582 <400> 1582 000 <210> 1583 <400> 1583 000 <210> 1584 <400> 1584 000 <210> 1585 <400> 1585 000 <210> 1586 <400> 1586 000 <210> 1587 <400> 1587 000 <210> 1588 <400> 1588 000 <210> 1589 <400> 1589 000 <210> 1590 <400> 1590 000 <210> 1591 <400> 1591 000 <210> 1592 <400> 1592 000 <210> 1593 <400> 1593 000 <210> 1594 <400> 1594 000 <210> 1595 <400> 1595 000 <210> 1596 <400> 1596 000 <210> 1597 <400> 1597 000 <210> 1598 <400> 1598 000 <210> 1599 <400> 1599 000 <210> 1600 <400> 1600 000 <210> 1601 <400> 1601 000 <210> 1602 <400> 1602 000 <210> 1603 <400> 1603 000 <210> 1604 <400> 1604 000 <210> 1605 <400> 1605 000 <210> 1606 <400> 1606 000 <210> 1607 <400> 1607 000 <210> 1608 <400> 1608 000 <210> 1609 <400> 1609 000 <210> 1610 <400> 1610 000 <210> 1611 <400> 1611 000 <210> 1612 <400> 1612 000 <210> 1613 <400> 1613 000 <210> 1614 <400> 1614 000 <210> 1615 <400> 1615 000 <210> 1616 <400> 1616 000 <210> 1617 <400> 1617 000 <210> 1618 <400> 1618 000 <210> 1619 <400> 1619 000 <210> 1620 <400> 1620 000 <210> 1621 <400> 1621 000 <210> 1622 <400> 1622 000 <210> 1623 <400> 1623 000 <210> 1624 <400> 1624 000 <210> 1625 <400> 1625 000 <210> 1626 <400> 1626 000 <210> 1627 <400> 1627 000 <210> 1628 <400> 1628 000 <210> 1629 <400> 1629 000 <210> 1630 <400> 1630 000 <210> 1631 <400> 1631 000 <210> 1632 <400> 1632 000 <210> 1633 <400> 1633 000 <210> 1634 <400> 1634 000 <210> 1635 <400> 1635 000 <210> 1636 <400> 1636 000 <210> 1637 <400> 1637 000 <210> 1638 <400> 1638 000 <210> 1639 <400> 1639 000 <210> 1640 <400> 1640 000 <210> 1641 <400> 1641 000 <210> 1642 <400> 1642 000 <210> 1643 <400> 1643 000 <210> 1644 <400> 1644 000 <210> 1645 <400> 1645 000 <210> 1646 <400> 1646 000 <210> 1647 <400> 1647 000 <210> 1648 <400> 1648 000 <210> 1649 <400> 1649 000 <210> 1650 <400> 1650 000 <210> 1651 <400> 1651 000 <210> 1652 <400> 1652 000 <210> 1653 <400> 1653 000 <210> 1654 <400> 1654 000 <210> 1655 <400> 1655 000 <210> 1656 <400> 1656 000 <210> 1657 <400> 1657 000 <210> 1658 <400> 1658 000 <210> 1659 <400> 1659 000 <210> 1660 <400> 1660 000 <210> 1661 <400> 1661 000 <210> 1662 <400> 1662 000 <210> 1663 <400> 1663 000 <210> 1664 <400> 1664 000 <210> 1665 <400> 1665 000 <210> 1666 <400> 1666 000 <210> 1667 <400> 1667 000 <210> 1668 <400> 1668 000 <210> 1669 <400> 1669 000 <210> 1670 <400> 1670 000 <210> 1671 <400> 1671 000 <210> 1672 <400> 1672 000 <210> 1673 <400> 1673 000 <210> 1674 <400> 1674 000 <210> 1675 <400> 1675 000 <210> 1676 <400> 1676 000 <210> 1677 <400> 1677 000 <210> 1678 <400> 1678 000 <210> 1679 <400> 1679 000 <210> 1680 <400> 1680 000 <210> 1681 <400> 1681 000 <210> 1682 <400> 1682 000 <210> 1683 <400> 1683 000 <210> 1684 <400> 1684 000 <210> 1685 <400> 1685 000 <210> 1686 <400> 1686 000 <210> 1687 <400> 1687 000 <210> 1688 <400> 1688 000 <210> 1689 <400> 1689 000 <210> 1690 <400> 1690 000 <210> 1691 <400> 1691 000 <210> 1692 <400> 1692 000 <210> 1693 <400> 1693 000 <210> 1694 <400> 1694 000 <210> 1695 <400> 1695 000 <210> 1696 <400> 1696 000 <210> 1697 <400> 1697 000 <210> 1698 <400> 1698 000 <210> 1699 <400> 1699 000 <210> 1700 <400> 1700 000 <210> 1701 <400> 1701 000 <210> 1702 <400> 1702 000 <210> 1703 <400> 1703 000 <210> 1704 <400> 1704 000 <210> 1705 <400> 1705 000 <210> 1706 <400> 1706 000 <210> 1707 <400> 1707 000 <210> 1708 <400> 1708 000 <210> 1709 <400> 1709 000 <210> 1710 <400> 1710 000 <210> 1711 <400> 1711 000 <210> 1712 <400> 1712 000 <210> 1713 <400> 1713 000 <210> 1714 <400> 1714 000 <210> 1715 <400> 1715 000 <210> 1716 <400> 1716 000 <210> 1717 <400> 1717 000 <210> 1718 <400> 1718 000 <210> 1719 <400> 1719 000 <210> 1720 <400> 1720 000 <210> 1721 <400> 1721 000 <210> 1722 <400> 1722 000 <210> 1723 <400> 1723 000 <210> 1724 <400> 1724 000 <210> 1725 <400> 1725 000 <210> 1726 <400> 1726 000 <210> 1727 <400> 1727 000 <210> 1728 <400> 1728 000 <210> 1729 <400> 1729 000 <210> 1730 <400> 1730 000 <210> 1731 <400> 1731 000 <210> 1732 <400> 1732 000 <210> 1733 <400> 1733 000 <210> 1734 <400> 1734 000 <210> 1735 <400> 1735 000 <210> 1736 <400> 1736 000 <210> 1737 <400> 1737 000 <210> 1738 <400> 1738 000 <210> 1739 <400> 1739 000 <210> 1740 <400> 1740 000 <210> 1741 <400> 1741 000 <210> 1742 <400> 1742 000 <210> 1743 <400> 1743 000 <210> 1744 <400> 1744 000 <210> 1745 <400> 1745 000 <210> 1746 <400> 1746 000 <210> 1747 <400> 1747 000 <210> 1748 <400> 1748 000 <210> 1749 <400> 1749 000 <210> 1750 <400> 1750 000 <210> 1751 <400> 1751 000 <210> 1752 <400> 1752 000 <210> 1753 <400> 1753 000 <210> 1754 <400> 1754 000 <210> 1755 <400> 1755 000 <210> 1756 <400> 1756 000 <210> 1757 <400> 1757 000 <210> 1758 <400> 1758 000 <210> 1759 <400> 1759 000 <210> 1760 <400> 1760 000 <210> 1761 <400> 1761 000 <210> 1762 <400> 1762 000 <210> 1763 <400> 1763 000 <210> 1764 <400> 1764 000 <210> 1765 <400> 1765 000 <210> 1766 <400> 1766 000 <210> 1767 <400> 1767 000 <210> 1768 <400> 1768 000 <210> 1769 <400> 1769 000 <210> 1770 <400> 1770 000 <210> 1771 <400> 1771 000 <210> 1772 <400> 1772 000 <210> 1773 <400> 1773 000 <210> 1774 <400> 1774 000 <210> 1775 <400> 1775 000 <210> 1776 <400> 1776 000 <210> 1777 <400> 1777 000 <210> 1778 <400> 1778 000 <210> 1779 <400> 1779 000 <210> 1780 <400> 1780 000 <210> 1781 <400> 1781 000 <210> 1782 <400> 1782 000 <210> 1783 <400> 1783 000 <210> 1784 <400> 1784 000 <210> 1785 <400> 1785 000 <210> 1786 <400> 1786 000 <210> 1787 <400> 1787 000 <210> 1788 <400> 1788 000 <210> 1789 <400> 1789 000 <210> 1790 <400> 1790 000 <210> 1791 <400> 1791 000 <210> 1792 <400> 1792 000 <210> 1793 <400> 1793 000 <210> 1794 <400> 1794 000 <210> 1795 <400> 1795 000 <210> 1796 <400> 1796 000 <210> 1797 <400> 1797 000 <210> 1798 <400> 1798 000 <210> 1799 <400> 1799 000 <210> 1800 <400> 1800 000 <210> 1801 <400> 1801 000 <210> 1802 <400> 1802 000 <210> 1803 <400> 1803 000 <210> 1804 <400> 1804 000 <210> 1805 <400> 1805 000 <210> 1806 <400> 1806 000 <210> 1807 <400> 1807 000 <210> 1808 <400> 1808 000 <210> 1809 <400> 1809 000 <210> 1810 <400> 1810 000 <210> 1811 <400> 1811 000 <210> 1812 <400> 1812 000 <210> 1813 <400> 1813 000 <210> 1814 <400> 1814 000 <210> 1815 <400> 1815 000 <210> 1816 <400> 1816 000 <210> 1817 <400> 1817 000 <210> 1818 <400> 1818 000 <210> 1819 <400> 1819 000 <210> 1820 <400> 1820 000 <210> 1821 <400> 1821 000 <210> 1822 <400> 1822 000 <210> 1823 <400> 1823 000 <210> 1824 <400> 1824 000 <210> 1825 <400> 1825 000 <210> 1826 <400> 1826 000 <210> 1827 <400> 1827 000 <210> 1828 <400> 1828 000 <210> 1829 <400> 1829 000 <210> 1830 <400> 1830 000 <210> 1831 <400> 1831 000 <210> 1832 <400> 1832 000 <210> 1833 <400> 1833 000 <210> 1834 <400> 1834 000 <210> 1835 <400> 1835 000 <210> 1836 <400> 1836 000 <210> 1837 <400> 1837 000 <210> 1838 <400> 1838 000 <210> 1839 <400> 1839 000 <210> 1840 <400> 1840 000 <210> 1841 <400> 1841 000 <210> 1842 <400> 1842 000 <210> 1843 <400> 1843 000 <210> 1844 <400> 1844 000 <210> 1845 <400> 1845 000 <210> 1846 <400> 1846 000 <210> 1847 <400> 1847 000 <210> 1848 <400> 1848 000 <210> 1849 <400> 1849 000 <210> 1850 <400> 1850 000 <210> 1851 <400> 1851 000 <210> 1852 <400> 1852 000 <210> 1853 <400> 1853 000 <210> 1854 <400> 1854 000 <210> 1855 <400> 1855 000 <210> 1856 <400> 1856 000 <210> 1857 <400> 1857 000 <210> 1858 <400> 1858 000 <210> 1859 <400> 1859 000 <210> 1860 <400> 1860 000 <210> 1861 <400> 1861 000 <210> 1862 <400> 1862 000 <210> 1863 <400> 1863 000 <210> 1864 <400> 1864 000 <210> 1865 <400> 1865 000 <210> 1866 <400> 1866 000 <210> 1867 <400> 1867 000 <210> 1868 <400> 1868 000 <210> 1869 <400> 1869 000 <210> 1870 <400> 1870 000 <210> 1871 <400> 1871 000 <210> 1872 <400> 1872 000 <210> 1873 <400> 1873 000 <210> 1874 <400> 1874 000 <210> 1875 <400> 1875 000 <210> 1876 <400> 1876 000 <210> 1877 <400> 1877 000 <210> 1878 <400> 1878 000 <210> 1879 <400> 1879 000 <210> 1880 <400> 1880 000 <210> 1881 <400> 1881 000 <210> 1882 <400> 1882 000 <210> 1883 <400> 1883 000 <210> 1884 <400> 1884 000 <210> 1885 <400> 1885 000 <210> 1886 <400> 1886 000 <210> 1887 <400> 1887 000 <210> 1888 <400> 1888 000 <210> 1889 <400> 1889 000 <210> 1890 <400> 1890 000 <210> 1891 <400> 1891 000 <210> 1892 <400> 1892 000 <210> 1893 <400> 1893 000 <210> 1894 <400> 1894 000 <210> 1895 <400> 1895 000 <210> 1896 <400> 1896 000 <210> 1897 <400> 1897 000 <210> 1898 <400> 1898 000 <210> 1899 <400> 1899 000 <210> 1900 <400> 1900 000 <210> 1901 <400> 1901 000 <210> 1902 <400> 1902 000 <210> 1903 <400> 1903 000 <210> 1904 <400> 1904 000 <210> 1905 <400> 1905 000 <210> 1906 <400> 1906 000 <210> 1907 <400> 1907 000 <210> 1908 <400> 1908 000 <210> 1909 <400> 1909 000 <210> 1910 <400> 1910 000 <210> 1911 <400> 1911 000 <210> 1912 <400> 1912 000 <210> 1913 <400> 1913 000 <210> 1914 <400> 1914 000 <210> 1915 <400> 1915 000 <210> 1916 <400> 1916 000 <210> 1917 <400> 1917 000 <210> 1918 <400> 1918 000 <210> 1919 <400> 1919 000 <210> 1920 <400> 1920 000 <210> 1921 <400> 1921 000 <210> 1922 <400> 1922 000 <210> 1923 <400> 1923 000 <210> 1924 <400> 1924 000 <210> 1925 <400> 1925 000 <210> 1926 <400> 1926 000 <210> 1927 <400> 1927 000 <210> 1928 <400> 1928 000 <210> 1929 <400> 1929 000 <210> 1930 <400> 1930 000 <210> 1931 <400> 1931 000 <210> 1932 <400> 1932 000 <210> 1933 <400> 1933 000 <210> 1934 <400> 1934 000 <210> 1935 <400> 1935 000 <210> 1936 <400> 1936 000 <210> 1937 <400> 1937 000 <210> 1938 <400> 1938 000 <210> 1939 <400> 1939 000 <210> 1940 <400> 1940 000 <210> 1941 <400> 1941 000 <210> 1942 <400> 1942 000 <210> 1943 <400> 1943 000 <210> 1944 <400> 1944 000 <210> 1945 <400> 1945 000 <210> 1946 <400> 1946 000 <210> 1947 <400> 1947 000 <210> 1948 <400> 1948 000 <210> 1949 <400> 1949 000 <210> 1950 <400> 1950 000 <210> 1951 <400> 1951 000 <210> 1952 <400> 1952 000 <210> 1953 <400> 1953 000 <210> 1954 <400> 1954 000 <210> 1955 <400> 1955 000 <210> 1956 <400> 1956 000 <210> 1957 <400> 1957 000 <210> 1958 <400> 1958 000 <210> 1959 <400> 1959 000 <210> 1960 <400> 1960 000 <210> 1961 <400> 1961 000 <210> 1962 <400> 1962 000 <210> 1963 <400> 1963 000 <210> 1964 <400> 1964 000 <210> 1965 <400> 1965 000 <210> 1966 <400> 1966 000 <210> 1967 <400> 1967 000 <210> 1968 <400> 1968 000 <210> 1969 <400> 1969 000 <210> 1970 <400> 1970 000 <210> 1971 <400> 1971 000 <210> 1972 <400> 1972 000 <210> 1973 <400> 1973 000 <210> 1974 <400> 1974 000 <210> 1975 <400> 1975 000 <210> 1976 <400> 1976 000 <210> 1977 <400> 1977 000 <210> 1978 <400> 1978 000 <210> 1979 <400> 1979 000 <210> 1980 <400> 1980 000 <210> 1981 <400> 1981 000 <210> 1982 <400> 1982 000 <210> 1983 <400> 1983 000 <210> 1984 <400> 1984 000 <210> 1985 <400> 1985 000 <210> 1986 <400> 1986 000 <210> 1987 <400> 1987 000 <210> 1988 <400> 1988 000 <210> 1989 <400> 1989 000 <210> 1990 <400> 1990 000 <210> 1991 <400> 1991 000 <210> 1992 <400> 1992 000 <210> 1993 <400> 1993 000 <210> 1994 <400> 1994 000 <210> 1995 <400> 1995 000 <210> 1996 <400> 1996 000 <210> 1997 <400> 1997 000 <210> 1998 <400> 1998 000 <210> 1999 <400> 1999 000 <210> 2000 <400> 2000 000 <210> 2001 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2001 Ser Gly Tyr Ala Ser Phe Ala Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2002 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2002 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2003 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (35) <223> C-terminal amidation <400> 2003 Lys Lys Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val 1 5 10 15 Ser Lys Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr             20 25 30 Ser Lys Lys         35 <210> 2004 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2004 Ala Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2005 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2005 Ser Ala Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2006 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2006 Ser Gly Tyr Ala Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2007 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2007 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Ala Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2008 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2008 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ala Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2009 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2009 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ala Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2010 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2010 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Ala Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2011 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2011 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Ala Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2012 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2012 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Ala Thr Ser             20 25 30 <210> 2013 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2013 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Ala Ser             20 25 30 <210> 2014 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2014 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ala             20 25 30 <210> 2015 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2015 Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ala Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2016 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 2016 Lys Lys Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser Lys Lys             20 25 30 <210> 2017 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 2017 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met Ala Leu Ala Arg Leu Tyr Tyr             20 25 <210> 2018 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2018 Ser Gly Tyr Ala Ser Phe Pro Ala Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2019 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2019 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Ala His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2020 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2020 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Ala Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2021 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2021 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Ala Tyr Tyr Lys Thr Ser             20 25 30 <210> 2022 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2022 Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Met Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2023 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2023 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2024 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2024 Ala Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2025 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2025 Gly Tyr Ala Ala Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2026 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2026 Gly Tyr Ala Ser Phe Pro Trp Ala Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2027 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2027 Gly Tyr Ala Ser Phe Pro Trp Phe Val Ala Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2028 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2028 Cys Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2029 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2029 Gly Cys Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2030 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2030 Gly Tyr Cys Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2031 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2031 Gly Tyr Ala Cys Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2032 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2032 Gly Tyr Ala Ser Cys Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2033 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2033 Gly Tyr Ala Ser Phe Pro Cys Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2034 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2034 Gly Tyr Ala Ser Phe Pro Trp Cys Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2035 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2035 Gly Tyr Ala Ser Phe Pro Trp Phe Cys Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2036 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2036 Gly Tyr Ala Ser Phe Pro Trp Phe Val Cys Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2037 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2037 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Cys His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2038 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2038 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Cys Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2039 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2039 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Cys Trp Glu Met Ala             20 <210> 2040 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2040 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Cys Glu Met Ala             20 <210> 2041 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2041 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Cys Met Ala             20 <210> 2042 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2042 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Cys Ala             20 <210> 2043 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2043 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Cys             20 <210> 2044 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2044 Asp Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2045 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2045 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Phe Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2046 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2046 Gly Tyr Gly Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2047 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2047 Gly Tyr Ala Gly Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2048 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2048 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Gly Trp Glu Met Ala             20 <210> 2049 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2049 Gly Tyr His Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2050 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2050 Gly Tyr Ala His Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2051 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2051 Gly Tyr Ala Ser His Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2052 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2052 Gly Tyr Ala Ser Phe Pro Trp His Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2053 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2053 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp His Met Ala             20 <210> 2054 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2054 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met His             20 <210> 2055 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2055 Gly Tyr Ile Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2056 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2056 Gly Tyr Ala Ile Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2057 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2057 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Ile His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2058 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2058 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Ile Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2059 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2059 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ile Trp Glu Met Ala             20 <210> 2060 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2060 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Ile Glu Met Ala             20 <210> 2061 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2061 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ile             20 <210> 2062 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2062 Lys Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2063 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2063 Gly Lys Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2064 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2064 Gly Tyr Lys Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2065 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2065 Gly Tyr Ala Lys Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2066 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2066 Gly Tyr Ala Ser Lys Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2067 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2067 Gly Tyr Ala Ser Phe Pro Trp Lys Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2068 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2068 Gly Tyr Ala Ser Phe Pro Trp Phe Val Lys Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2069 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2069 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Lys His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2070 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2070 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Lys His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2071 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2071 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Lys Trp Glu Met Ala             20 <210> 2072 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2072 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Lys Met Ala             20 <210> 2073 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2073 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Lys             20 <210> 2074 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2074 Leu Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2075 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2075 Gly Tyr Leu Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2076 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2076 Gly Tyr Ala Leu Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2077 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2077 Gly Tyr Ala Ser Phe Pro Trp Phe Val Leu Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2078 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2078 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Leu Trp Glu Met Ala             20 <210> 2079 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2079 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Leu             20 <210> 2080 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2080 Met Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2081 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2081 Gly Tyr Met Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2082 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2082 Gly Tyr Ala Met Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2083 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2083 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Met His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2084 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2084 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Met             20 <210> 2085 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2085 Asn Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2086 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2086 Gly Tyr Ala Asn Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2087 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2087 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Asn Trp Glu Met Ala             20 <210> 2088 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2088 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Asn             20 <210> 2089 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2089 Pro Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2090 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2090 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Gln Trp Glu Met Ala             20 <210> 2091 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2091 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Gln             20 <210> 2092 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2092 Arg Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2093 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2093 Gly Arg Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2094 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2094 Gly Tyr Arg Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2095 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2095 Gly Tyr Ala Arg Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2096 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2096 Gly Tyr Ala Ser Arg Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2097 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2097 Gly Tyr Ala Ser Phe Pro Arg Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2098 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2098 Gly Tyr Ala Ser Phe Pro Trp Arg Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2099 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2099 Gly Tyr Ala Ser Phe Pro Trp Phe Arg Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2100 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2100 Gly Tyr Ala Ser Phe Pro Trp Phe Val Arg Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2101 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2101 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Arg His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2102 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2102 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Arg His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2103 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2103 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Arg Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2104 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2104 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Arg Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2105 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2105 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Arg Trp Glu Met Ala             20 <210> 2106 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2106 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Arg Glu Met Ala             20 <210> 2107 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2107 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Arg Met Ala             20 <210> 2108 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2108 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Arg             20 <210> 2109 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2109 Ser Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2110 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2110 Gly Tyr Ser Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2111 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2111 Gly Tyr Ala Ser Phe Pro Trp Phe Val Ser Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2112 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2112 Thr Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2113 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2113 Gly Tyr Thr Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2114 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2114 Gly Tyr Ala Thr Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2115 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2115 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Thr Trp Glu Met Ala             20 <210> 2116 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2116 Gly Tyr Ala Ser Phe Pro Trp Val Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2117 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2117 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Val His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2118 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2118 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Val Trp Glu Met Ala             20 <210> 2119 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2119 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Val             20 <210> 2120 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2120 Gly Trp Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2121 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2121 Gly Tyr Trp Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2122 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2122 Gly Tyr Ala Ser Trp Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2123 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2123 Gly Tyr Ala Ser Phe Pro Trp Trp Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2124 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2124 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Trp His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2125 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 2125 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Trp             20 <210> 2126 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2126 Gly Tyr Ala Ser Phe Pro Trp Tyr Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2127 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 2127 Met Lys Ser Arg Ser Leu Gly Leu Ala Tyr Phe Ala Lys His Ser Ser 1 5 10 15 Leu Glu Val Leu Gln Thr Arg Lys Val Ala Ala Pro Tyr Tyr             20 25 30 <210> 2128 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 2128 Lys Lys Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val 1 5 10 15 Ser Lys Arg Ser Lys Glu Met Ala Leu Ala Arg Lys Lys             20 25 <210> 2129 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 2129 Lys Lys Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser Lys Glu 1 5 10 15 Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser Lys Lys             20 25 <210> 2130 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 2130 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met Ala Leu Ala Arg Leu Tyr             20 <210> 2131 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2131 Ser Gly Ala Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2132 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2132 Ser Gly Tyr Ala Ser Ala Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2133 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2133 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Ala Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2134 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2134 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu Ala Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2135 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2135 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Ala Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2136 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2136 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Ala 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2137 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2137 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Ala Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2138 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2138 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Ala Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2139 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2139 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Ala Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2140 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2140 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Ala Tyr Lys Thr Ser             20 25 30 <210> 2141 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 2141 Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Ala Lys Thr Ser             20 25 30 <210> 2142 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 2142 Gly Ser Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val 1 5 10 15 Ser Lys Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr             20 25 30 Ser      <210> 2143 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2143 Gly Tyr Trp Ser Phe Pro His Ala Val Trp His His Val Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2144 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2144 Gly Tyr Ala Ser Phe Trp Gln Ala Val Gln Leu His Val Trp Lys Arg 1 5 10 15 Ser Lys Glu Ile Ala             20 <210> 2145 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2145 Gly Tyr Ala Ser Phe Pro Leu Ile Val Trp Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2146 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2146 Gly Tyr Ala Ser Phe Trp Gln Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Ile Ala             20 <210> 2147 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2147 Gly Tyr Ala Ser Phe Pro Ala Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2148 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2148 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Ala His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2149 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2149 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Ala His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2150 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2150 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Ala Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2151 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2151 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Ala Met Ala             20 <210> 2152 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2152 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Ala Ala             20 <210> 2153 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2153 Gly Tyr Ala Ser Phe Cys Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2154 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2154 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Cys Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2155 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2155 Gly Asp Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2156 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2156 Gly Tyr Asp Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2157 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2157 Gly Tyr Ala Asp Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2158 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2158 Gly Tyr Ala Ser Asp Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2159 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2159 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Asp Met Ala             20 <210> 2160 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2160 Gly Tyr Glu Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2161 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2161 Gly Tyr Ala Glu Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2162 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2162 Phe Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2163 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2163 Gly Phe Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2164 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2164 Gly Tyr Phe Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2165 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2165 Gly Tyr Ala Phe Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2166 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2166 Gly Tyr Ala Ser Phe Pro Phe Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2167 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2167 Gly Tyr Ala Ser Phe Pro Trp Phe Phe Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2168 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2168 Gly Tyr Ala Ser Phe Pro Trp Phe Val Phe Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2169 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2169 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Phe His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2170 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2170 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Phe 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2171 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2171 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Phe Trp Glu Met Ala             20 <210> 2172 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2172 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Phe Glu Met Ala             20 <210> 2173 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2173 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Phe Met Ala             20 <210> 2174 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2174 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Phe Ala             20 <210> 2175 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2175 Gly Tyr Ala Ser Gly Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2176 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2176 Gly Tyr Ala Ser Phe Pro Gly Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2177 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2177 Gly Tyr Ala Ser Phe Pro Trp Gly Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2178 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2178 Gly Tyr Ala Ser Phe Pro Trp Phe Gly Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2179 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2179 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gly Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2180 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2180 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Gly His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2181 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2181 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Gly His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2182 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2182 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Gly Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2183 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2183 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Gly Met Ala             20 <210> 2184 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2184 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Gly Ala             20 <210> 2185 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2185 Gly His Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2186 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2186 Gly Tyr Ala Ser Phe Pro His Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2187 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2187 Gly Tyr Ala Ser Phe Pro Trp Phe His Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2188 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2188 Gly Tyr Ala Ser Phe Pro Trp Phe Val His Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2189 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2189 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His His His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2190 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2190 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu His Ala             20 <210> 2191 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2191 Ile Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2192 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2192 Gly Tyr Ala Ser Ile Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2193 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2193 Gly Tyr Ala Ser Phe Pro Ile Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2194 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2194 Gly Tyr Ala Ser Phe Pro Trp Phe Ile Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2195 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2195 Gly Tyr Ala Ser Phe Pro Trp Phe Val Ile Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2196 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2196 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Ile Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2197 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2197 Gly Tyr Ala Ser Phe Lys Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2198 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2198 Gly Tyr Ala Ser Phe Pro Lys Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2199 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2199 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Lys Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2200 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2200 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2201 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2201 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Lys Ala             20 <210> 2202 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2202 Gly Tyr Ala Ser Leu Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2203 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2203 Gly Tyr Ala Ser Phe Pro Leu Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2204 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2204 Gly Tyr Ala Ser Phe Pro Trp Leu Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2205 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2205 Gly Tyr Ala Ser Phe Pro Trp Phe Leu Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2206 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2206 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Leu Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2207 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2207 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Leu His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2208 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2208 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Leu Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2209 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2209 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Leu Glu Met Ala             20 <210> 2210 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2210 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Leu Met Ala             20 <210> 2211 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2211 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Leu Ala             20 <210> 2212 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2212 Gly Met Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2213 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2213 Gly Tyr Ala Ser Met Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2214 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2214 Gly Tyr Ala Ser Phe Pro Trp Met Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2215 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2215 Gly Tyr Ala Ser Phe Pro Trp Phe Met Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2216 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2216 Gly Tyr Ala Ser Phe Pro Trp Phe Val Met Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2217 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2217 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Met His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2218 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2218 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Met Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2219 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2219 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Met Glu Met Ala             20 <210> 2220 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2220 Gly Asn Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2221 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2221 Gly Tyr Asn Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2222 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2222 Gly Tyr Ala Ser Asn Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2223 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2223 Gly Tyr Ala Ser Phe Pro Asn Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2224 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2224 Gly Tyr Ala Ser Phe Pro Trp Asn Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2225 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2225 Gly Tyr Ala Ser Phe Pro Trp Phe Val Asn Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2226 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2226 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Asn His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2227 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2227 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Asn Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2228 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) C-terminal N-methyl <400> 2228 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Asn Met Ala             20 <210> 2229 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2229 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Asn Ala             20 <210> 2230 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2230 Gly Pro Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2231 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2231 Gly Tyr Pro Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2232 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2232 Gly Tyr Ala Ser Pro Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2233 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2233 Gly Tyr Ala Ser Phe Pro Trp Pro Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2234 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2234 Gly Tyr Ala Ser Phe Pro Trp Phe Val Pro Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2235 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2235 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Pro Met Ala             20 <210> 2236 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2236 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Pro             20 <210> 2237 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2237 Gln Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2238 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2238 Gly Tyr Gln Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2239 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2239 Gly Tyr Ala Gln Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2240 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2240 Gly Tyr Ala Ser Gln Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2241 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2241 Gly Tyr Ala Ser Phe Pro Trp Gln Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2242 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2242 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Gln His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2243 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2243 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Gln Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2244 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2244 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Gln Glu Met Ala             20 <210> 2245 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2245 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Gln Met Ala             20 <210> 2246 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2246 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Gln Ala             20 <210> 2247 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2247 Gly Tyr Ala Ser Phe Arg Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2248 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2248 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Arg Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2249 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2249 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Arg Ala             20 <210> 2250 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2250 Gly Ser Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2251 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2251 Gly Tyr Ala Ser Ser Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2252 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2252 Gly Tyr Ala Ser Phe Pro Ser Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2253 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2253 Gly Tyr Ala Ser Phe Pro Trp Ser Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2254 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2254 Gly Tyr Ala Ser Phe Pro Trp Phe Ser Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2255 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2255 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Ser His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2256 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2256 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Ser His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2257 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2257 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2258 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2258 Gly Thr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2259 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2259 Gly Tyr Ala Ser Thr Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2260 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2260 Gly Tyr Ala Ser Phe Pro Thr Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2261 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2261 Gly Tyr Ala Ser Phe Pro Trp Thr Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2262 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2262 Gly Tyr Ala Ser Phe Pro Trp Phe Thr Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2263 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2263 Gly Tyr Ala Ser Phe Pro Trp Phe Val Thr Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2264 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2264 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Thr His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2265 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2265 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Thr Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2266 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2266 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Thr             20 <210> 2267 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2267 Gly Tyr Ala Val Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2268 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2268 Gly Tyr Ala Ser Val Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2269 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2269 Gly Tyr Ala Ser Phe Pro Trp Phe Val Val Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2270 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2270 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Val Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2271 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2271 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Val Glu Met Ala             20 <210> 2272 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2272 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Val Met Ala             20 <210> 2273 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2273 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Val Ala             20 <210> 2274 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2274 Trp Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2275 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2275 Gly Tyr Ala Trp Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2276 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2276 Gly Tyr Ala Ser Phe Pro Trp Phe Trp Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2277 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2277 Gly Tyr Ala Ser Phe Pro Trp Phe Val Trp Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2278 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2278 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Trp His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2279 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2279 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Trp Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2280 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2280 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Trp Trp Glu Met Ala             20 <210> 2281 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2281 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Trp Met Ala             20 <210> 2282 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2282 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Trp Ala             20 <210> 2283 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2283 Gly Tyr Tyr Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2284 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 2284 Gly Tyr Ala Tyr Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2285 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) N-terminal acytlation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2285 Gly Tyr Ala Ser Tyr Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2286 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2286 Gly Tyr Ala Ser Phe Pro Tyr Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2287 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2287 Gly Tyr Ala Ser Phe Pro Trp Phe Tyr Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2288 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2288 Gly Tyr Ala Ser Phe Pro Trp Phe Val Tyr Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2289 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2289 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Tyr His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2290 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2290 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Tyr His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2291 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2291 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Tyr Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2292 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2292 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Tyr Trp Glu Met Ala             20 <210> 2293 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2293 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Tyr Glu Met Ala             20 <210> 2294 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2294 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Tyr Met Ala             20 <210> 2295 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2295 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Tyr Ala             20 <210> 2296 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2296 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Tyr             20 <210> 2297 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2297 Lys Met Gln Leu Arg Val Tyr Ala Ser Thr Ala His Ser Arg Tyr Leu 1 5 10 15 Leu Gly Ser Ser Leu Phe Pro Lys Tyr Ala Glu Val Lys Ala             20 25 30 <210> 2298 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2298 Lys Lys Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val 1 5 10 15 Ser Lys Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Lys             20 25 30 <210> 2299 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2299 Lys Lys Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val 1 5 10 15 Ser Lys Arg Ser Lys Glu Met Ala Lys Lys             20 25 <210> 2300 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2300 Lys Lys Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val 1 5 10 15 Ser Lys Arg Ser Lys Lys Lys             20 <210> 2301 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 2301 Lys Lys Val Gln Leu His Val Ser Lys Arg Ser Lys Glu Met Ala Leu 1 5 10 15 Ala Arg Leu Tyr Tyr Lys Thr Ser Lys Lys             20 25 <210> 2302 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 2302 Lys Lys His Val Ser Lys Arg Ser Lys Glu Met Ala Leu Ala Arg Leu 1 5 10 15 Tyr Tyr Lys Thr Ser Lys Lys             20 <210> 2303 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 2303 Lys Lys Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser 1 5 10 15 Lys Arg Ser Lys Glu Met Lys Lys             20 <210> 2304 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 2304 Lys Lys Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys 1 5 10 15 Arg Ser Lys Glu Met Ala Lys Lys             20 <210> 2305 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 2305 Lys Lys Val Gln Leu His Val Ser Lys Arg Ser Lys Glu Met Ala Leu 1 5 10 15 Ala Arg Leu Tyr Tyr Lys Lys Lys             20 <210> 2306 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 2306 Lys Lys Gln Leu His Val Ser Lys Arg Ser Lys Glu Met Ala Leu Ala 1 5 10 15 Arg Leu Tyr Tyr Lys Thr Lys Lys             20 <210> 2307 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 2307 Lys Lys Leu His Val Ser Lys Arg Ser Lys Glu Met Ala Leu Ala Arg 1 5 10 15 Leu Tyr Tyr Lys Thr Ser Lys Lys             20 <210> 2308 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 2308 Lys Lys Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val 1 5 10 15 Ser Lys Arg Ser Lys Glu Lys Lys             20 <210> 2309 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 2309 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met Ala              <210> 2310 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (18). (18) <223> C-terminal amidation <400> 2310 Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser Lys Glu 1 5 10 15 Met Ala          <210> 2311 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> C-terminal amidation <400> 2311 Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Lys Glu Met 1 5 10 15 Ala      <210> 2312 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (18). (18) <223> C-terminal amidation <400> 2312 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met          <210> 2313 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (17) <223> C-terminal amidation <400> 2313 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu      <210> 2314 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 2314 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met Ala Leu             20 <210> 2315 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2315 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met Ala Leu Ala             20 <210> 2316 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 2316 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met Ala Leu Ala Arg             20 <210> 2317 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 2317 Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Ser 1 5 10 15 Glu Met Ala Leu Ala Arg Leu             20 <210> 2318 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 2318 Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Ser Arg Ser 1 5 10 15 Lys Glu Met Ala             20 <210> 2319 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2319 Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2320 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2320 Gly Tyr Ala Ser Phe Ala Leu Ser Val Gln Leu His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2321 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2321 Gly Tyr Ala Ser Phe Ala Leu Ala Val Gln Leu His Val Ala Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2322 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2322 Gly Tyr Ala Ser Phe Ala Leu Ala Val Gln Leu His Val Met Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2323 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 2323 Phe Pro Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Lys Glu Met 1 5 10 15 Ala Leu Ala              <210> 2324 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (14) <223> C-terminal amidation <400> 2324 Gln Leu His Val Ser Lys Arg Ser Lys Glu Met Ala Leu Ala 1 5 10 <210> 2325 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (7) (7) <223> C-terminal amidation <400> 2325 Ser Gly Tyr Ala Ser Phe Pro 1 5 <210> 2326 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 2326 Leu Ala Val Gln Leu His Val Ser Lys Arg Ser Lys Glu Met Ala Leu 1 5 10 15 Ala Arg Leu              <210> 2327 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2327 Val Tyr Ala Ser Phe Phe Leu Thr Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2328 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2328 Gly Tyr Trp Ser Phe Pro Gln Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2329 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2329 Gly Tyr Ala Ser Phe Ile Leu Ala Val Gln Leu His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2330 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2330 Gly Tyr Trp Ser Phe Tyr Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2331 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2331 Ser Tyr Ala Ser Phe Phe Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Glu Glu Met Ala             20 <210> 2332 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2332 Gly Tyr Ala Ser Phe Ile Leu Ala Val Gln Leu His Ile Ile Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2333 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2333 Gly Met Ala Ser Phe Phe Leu Ala Arg Asp Leu His Trp Ser Lys Val 1 5 10 15 Phe Lys Glu Met Ala             20 <210> 2334 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2334 Glu Tyr Ala Gln Phe Trp Leu Ala Val Gln Leu His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2335 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2335 Gly Tyr Ala Ser Phe Pro Leu Ile Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2336 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2336 Gly Tyr Ala Ser Phe Pro Ile His Val Gln His His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2337 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2337 Gly Tyr Ala Ser Phe Ala Leu Met Val Gln Leu His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2338 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2338 Gly Tyr Ala Ser Phe His Gln Ala Val Gln Arg His Val Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2339 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2339 Gly Tyr Ala Ser Phe Ala Leu Met Val Gln His His Val Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2340 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2340 Gly Tyr Ala Ser Phe Ser Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2341 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2341 Gly Tyr His Ser Phe Lys Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Ile Ala             20 <210> 2342 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2342 Gly Tyr Ala Ser Tyr Val Leu Ala Val Gln His His Val Val Ser Trp Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2343 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2343 His Tyr His Ser Leu Pro Lys Gln Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2344 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2344 Gly Tyr Ala Ser Phe Ser Leu Ala Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Tyr Glu Met Ala             20 <210> 2345 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2345 Gly Tyr Ala Ser Phe Glu Leu Leu Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2346 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2346 Ser Tyr Ser Ser Phe Lys Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2347 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2347 Gly Tyr Ala Trp Phe Pro Leu Asn Val Trp Leu His Val His Lys Arg 1 5 10 15 Ser His Glu Met Ala             20 <210> 2348 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2348 Gly Tyr Ala Ser Phe Trp Leu Ser Val Gln Thr His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2349 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2349 Gly Tyr Ala Ser Phe Pro Leu Met Val Gln Leu His Val Ile Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2350 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2350 Gly Tyr Trp Ser Phe Asn Leu Val Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2351 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2351 Gly Tyr Ala Ser Phe His Leu Ala Val Gln Leu His Val Trp Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2352 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2352 Gly Tyr Ala Ser Phe Trp Leu Val Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2353 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2353 Gly Tyr Trp Ser Phe Pro Leu Ala Val Gln Leu His Val Trp Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2354 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2354 Gly Tyr Ala Ser Phe Pro Trp Tyr Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2355 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2355 Gly Tyr Thr Ser Phe Gln Leu Ala Val Gln Leu His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2356 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2356 Arg Tyr Ala Ser Phe Pro Leu Ala Val Tyr Leu His Val Thr Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2357 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2357 Gly Tyr Trp Ser Phe Pro Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Leu Lys Glu Met Ala             20 <210> 2358 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2358 Gly His Ala Ser Phe Gln Thr Ala Val Gln Gln His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2359 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (11) <223> C-terminal amidation <400> 2359 Phe His Val Ser Lys Arg Ser Lys Glu Met Ala 1 5 10 <210> 2360 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2360 Gly Tyr Ala Ser Phe Trp His Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2361 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2361 Gly Ile Ala Ser Phe Ile Leu Ala Val Gln Leu His Val Tyr Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2362 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2362 Gly Tyr Thr Ser Phe Met Gln Ala Val Gln His His Val Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Ile Ala             20 <210> 2363 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2363 His Tyr His Ser Phe Tyr Leu Ala Val Gln Leu His Val Trp Glu Arg 1 5 10 15 Ser Tyr Glu Met Ala             20 <210> 2364 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2364 Gly Tyr Ala Ser Phe Trp His Ala Val Gln His His Val Thr Lys Arg 1 5 10 15 Ser Arg Glu Met Ala             20 <210> 2365 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2365 Gly Tyr Ala Ser Phe Thr Leu Thr Val Gln Leu His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2366 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2366 Gly Tyr Ala Ser Phe Ile Leu Thr Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2367 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2367 Gly Tyr Ala Ser Phe Trp Leu Ala Val Gln Ile His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2368 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2368 Gly Tyr Ala Ser Phe Ile Leu Ala Val Gln His His Val Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2369 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2369 Ser Tyr Ala Ser Phe Pro Pro Ala Val Met Leu His Val Trp Lys Arg 1 5 10 15 Ser Tyr Glu Met Ala             20 <210> 2370 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2370 Gly Tyr Ala Ser Phe Asn Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2371 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2371 Gly Tyr Trp Ser Phe Asn Leu Ala Val Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2372 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2372 Gly Tyr Ala Ser Phe Phe Leu Ala Val Gln Leu His Val Ser Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2373 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2373 Gly Tyr Ala Ser Phe Trp Leu Ala Val Gln Met His Val Val Trp Lys Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2374 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2374 Gly Tyr Ala Ser Phe Ser Leu Ala Ile Gln Leu His Val Ser Ser Arg 1 5 10 15 Ser Lys Glu Met Ala             20 <210> 2375 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2375 Gly Ala Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2376 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2376 Gly Tyr Ala Ser Ala Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2377 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2377 Gly Tyr Ala Ser Phe Ala Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2378 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2378 Gly Tyr Ala Ser Phe Pro Trp Phe Ala Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2379 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2379 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Ala Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2380 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2380 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Ala Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2381 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2381 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Ala 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2382 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2382 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Ala Glu Met Ala             20 <210> 2383 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2383 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Cys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2384 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2384 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Cys 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2385 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2385 Gly Tyr Ala Ser Phe Asp Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2386 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2386 Gly Tyr Ala Ser Phe Pro Asp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2387 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2387 Gly Tyr Ala Ser Phe Pro Trp Asp Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2388 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2388 Gly Tyr Ala Ser Phe Pro Trp Phe Asp Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2389 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2389 Gly Tyr Ala Ser Phe Pro Trp Phe Val Asp Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2390 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2390 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Asp His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2391 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2391 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Asp Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2392 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2392 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Asp His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2393 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2393 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Asp Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2394 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2394 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Asp Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2395 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2395 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Asp 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2396 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2396 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Asp Trp Glu Met Ala             20 <210> 2397 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2397 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Asp Glu Met Ala             20 <210> 2398 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2398 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Asp Ala             20 <210> 2399 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2399 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Asp             20 <210> 2400 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2400 Gly Glu Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2401 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is 2-Amino-isobutyric acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2401 Gly Tyr Ala Ser Glu Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2402 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2402 Gly Tyr Ala Ser Phe Glu Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2403 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2403 Gly Tyr Ala Ser Phe Pro Glu Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2404 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2404 Gly Tyr Ala Ser Phe Pro Trp Glu Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2405 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2405 Gly Tyr Ala Ser Phe Pro Trp Phe Glu Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2406 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2406 Gly Tyr Ala Ser Phe Pro Trp Phe Val Glu Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2407 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2407 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Glu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2408 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2408 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Glu Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2409 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2409 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Glu His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2410 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2410 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Glu Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2411 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2411 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Glu Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2412 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2412 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Glu 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2413 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2413 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Glu Trp Glu Met Ala             20 <210> 2414 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2414 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Glu Glu Met Ala             20 <210> 2415 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2415 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Glu Ala             20 <210> 2416 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2416 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Glu             20 <210> 2417 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2417 Gly Tyr Ala Ser Phe Phe Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2418 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2418 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Phe Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2419 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2419 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Phe Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2420 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2420 Gly Tyr Ala Ser Phe Gly Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2421 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2421 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Gly Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2422 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2422 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Gly Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2423 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2423 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Gly 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2424 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2424 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Gly Glu Met Ala             20 <210> 2425 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2425 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His His Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2426 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2426 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys His 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2427 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2427 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser His Glu Met Ala             20 <210> 2428 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2428 Gly Tyr Ala Ser Phe Ile Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2429 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2429 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Ile Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2430 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2430 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Ile 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2431 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2431 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Lys 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2432 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2432 Gly Tyr Ala Ser Phe Leu Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2433 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2433 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Leu Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2434 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2434 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Leu 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2435 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2435 Gly Tyr Ala Ser Phe Met Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2436 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2436 Gly Tyr Ala Ser Phe Pro Met Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2437 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2437 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Met Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2438 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2438 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Met Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2439 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2439 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Met 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2440 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2440 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Met Met Ala             20 <210> 2441 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2441 Gly Tyr Ala Ser Phe Asn Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2442 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2442 Gly Tyr Ala Ser Phe Pro Trp Phe Asn Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2443 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2443 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Asn Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2444 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2444 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Asn His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2445 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2445 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Asn Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2446 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2446 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Asn 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2447 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2447 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Asn Glu Met Ala             20 <210> 2448 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2448 Gly Tyr Ala Ser Phe Pro Pro Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2449 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2449 Gly Tyr Ala Ser Phe Pro Trp Phe Pro Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2450 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2450 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Pro His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2451 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2451 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Pro Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2452 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2452 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Pro His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2453 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2453 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val Pro Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2454 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2454 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Pro Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2455 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2455 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Pro 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2456 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2456 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Pro Trp Glu Met Ala             20 <210> 2457 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2457 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Pro Glu Met Ala             20 <210> 2458 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2458 Gly Gln Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2459 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2459 Gly Tyr Ala Ser Phe Gln Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2460 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2460 Gly Tyr Ala Ser Phe Pro Gln Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2461 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2461 Gly Tyr Ala Ser Phe Pro Trp Phe Gln Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2462 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 2462 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Gln Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2463 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2463 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Gln His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2464 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2464 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Gln Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2465 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2465 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Gln 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2466 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2466 Gly Tyr Ala Ser Phe Ser Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2467 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2467 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Ser Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2468 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2468 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Ser Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2469 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2469 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Ser 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2470 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2470 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Ser Glu Met Ala             20 <210> 2471 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2471 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Ser Met Ala             20 <210> 2472 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2472 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Ser Ala             20 <210> 2473 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2473 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ser             20 <210> 2474 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2474 Gly Tyr Ala Ser Phe Thr Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2475 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2475 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Thr Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2476 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2476 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Thr His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2477 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2477 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Thr Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2478 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2478 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Thr 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2479 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2479 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Thr Glu Met Ala             20 <210> 2480 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2480 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Thr Met Ala             20 <210> 2481 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2481 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Thr Ala             20 <210> 2482 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2482 Val Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2483 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2483 Gly Val Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2484 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2484 Gly Tyr Val Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2485 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2485 Gly Tyr Ala Ser Phe Val Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2486 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <220> <221> MOD_RES &Lt; 222 > (21) <223> N-terminal acetylation <400> 2486 Gly Tyr Ala Ser Phe Pro Val Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2487 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2487 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Val Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2488 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2488 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Val Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2489 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2489 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Val 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2490 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2490 Gly Tyr Ala Ser Phe Trp Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2491 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2491 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Trp Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2492 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2492 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Trp Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2493 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2493 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Trp 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2494 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2494 Gly Tyr Ala Ser Phe Tyr Trp Phe Val Gln Leu His Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2495 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2495 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu Tyr Val His Lys Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2496 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2496 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Tyr Arg 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2497 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 2497 Gly Tyr Ala Ser Phe Pro Trp Phe Val Gln Leu His Val His Lys Tyr 1 5 10 15 Ser Trp Glu Met Ala             20 <210> 2498 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 2498 Xaa Ser Gly Tyr Ala Ser Phe Pro Leu Ala Val Gln Leu His Val Ser 1 5 10 15 Lys Arg Ser Lys Glu Met Ala Leu Ala Arg Leu Tyr Tyr Lys Thr Ser             20 25 30 <210> 2499 <400> 2499 000 <210> 2500 <400> 2500 000 <210> 2501 <400> 2501 000 <210> 2502 &Lt; 400 > 2502 000 <210> 2503 <400> 2503 000 <210> 2504 <400> 2504 000 <210> 2505 <400> 2505 000 <210> 2506 <400> 2506 000 <210> 2507 <400> 2507 000 <210> 2508 <400> 2508 000 <210> 2509 <400> 2509 000 <210> 2510 <400> 2510 000 <210> 2511 <400> 2511 000 <210> 2512 <400> 2512 000 <210> 2513 <400> 2513 000 <210> 2514 <400> 2514 000 <210> 2515 <400> 2515 000 <210> 2516 <400> 2516 000 <210> 2517 <400> 2517 000 <210> 2518 <400> 2518 000 <210> 2519 <400> 2519 000 <210> 2520 <400> 2520 000 <210> 2521 <400> 2521 000 <210> 2522 <400> 2522 000 <210> 2523 <400> 2523 000 <210> 2524 <400> 2524 000 <210> 2525 <400> 2525 000 <210> 2526 <400> 2526 000 <210> 2527 <400> 2527 000 <210> 2528 <400> 2528 000 <210> 2529 <400> 2529 000 <210> 2530 <400> 2530 000 <210> 2531 <400> 2531 000 <210> 2532 <400> 2532 000 <210> 2533 <400> 2533 000 <210> 2534 <400> 2534 000 <210> 2535 <400> 2535 000 <210> 2536 <400> 2536 000 <210> 2537 <400> 2537 000 <210> 2538 <400> 2538 000 <210> 2539 <400> 2539 000 <210> 2540 <400> 2540 000 <210> 2541 <400> 2541 000 <210> 2542 <400> 2542 000 <210> 2543 <400> 2543 000 <210> 2544 <400> 2544 000 <210> 2545 <400> 2545 000 <210> 2546 <400> 2546 000 <210> 2547 <400> 2547 000 <210> 2548 <400> 2548 000 <210> 2549 <400> 2549 000 <210> 2550 <400> 2550 000 <210> 2551 <400> 2551 000 <210> 2552 <400> 2552 000 <210> 2553 <400> 2553 000 <210> 2554 <400> 2554 000 <210> 2555 <400> 2555 000 <210> 2556 <400> 2556 000 <210> 2557 <400> 2557 000 <210> 2558 <400> 2558 000 <210> 2559 <400> 2559 000 <210> 2560 <400> 2560 000 <210> 2561 <400> 2561 000 <210> 2562 <400> 2562 000 <210> 2563 <400> 2563 000 <210> 2564 <400> 2564 000 <210> 2565 <400> 2565 000 <210> 2566 <400> 2566 000 <210> 2567 <400> 2567 000 <210> 2568 <400> 2568 000 <210> 2569 <400> 2569 000 <210> 2570 <400> 2570 000 <210> 2571 <400> 2571 000 <210> 2572 <400> 2572 000 <210> 2573 <400> 2573 000 <210> 2574 <400> 2574 000 <210> 2575 <400> 2575 000 <210> 2576 <400> 2576 000 <210> 2577 <400> 2577 000 <210> 2578 <400> 2578 000 <210> 2579 <400> 2579 000 <210> 2580 <400> 2580 000 <210> 2581 <400> 2581 000 <210> 2582 <400> 2582 000 <210> 2583 <400> 2583 000 <210> 2584 <400> 2584 000 <210> 2585 <400> 2585 000 <210> 2586 <400> 2586 000 <210> 2587 <400> 2587 000 <210> 2588 <400> 2588 000 <210> 2589 <400> 2589 000 <210> 2590 <400> 2590 000 <210> 2591 <400> 2591 000 <210> 2592 <400> 2592 000 <210> 2593 <400> 2593 000 <210> 2594 <400> 2594 000 <210> 2595 <400> 2595 000 <210> 2596 <400> 2596 000 <210> 2597 <400> 2597 000 <210> 2598 <400> 2598 000 <210> 2599 <400> 2599 000 <210> 2600 <400> 2600 000 <210> 2601 <400> 2601 000 <210> 2602 <400> 2602 000 <210> 2603 <400> 2603 000 <210> 2604 <400> 2604 000 <210> 2605 <400> 2605 000 <210> 2606 <400> 2606 000 <210> 2607 <400> 2607 000 <210> 2608 <400> 2608 000 <210> 2609 <400> 2609 000 <210> 2610 <400> 2610 000 <210> 2611 <400> 2611 000 <210> 2612 <400> 2612 000 <210> 2613 <400> 2613 000 <210> 2614 <400> 2614 000 <210> 2615 <400> 2615 000 <210> 2616 <400> 2616 000 <210> 2617 <400> 2617 000 <210> 2618 <400> 2618 000 <210> 2619 <400> 2619 000 <210> 2620 <400> 2620 000 <210> 2621 <400> 2621 000 <210> 2622 <400> 2622 000 <210> 2623 <400> 2623 000 <210> 2624 <400> 2624 000 <210> 2625 <400> 2625 000 <210> 2626 <400> 2626 000 <210> 2627 <400> 2627 000 <210> 2628 <400> 2628 000 <210> 2629 <400> 2629 000 <210> 2630 <400> 2630 000 <210> 2631 <400> 2631 000 <210> 2632 <400> 2632 000 <210> 2633 <400> 2633 000 <210> 2634 <400> 2634 000 <210> 2635 <400> 2635 000 <210> 2636 <400> 2636 000 <210> 2637 <400> 2637 000 <210> 2638 <400> 2638 000 <210> 2639 <400> 2639 000 <210> 2640 <400> 2640 000 <210> 2641 <400> 2641 000 <210> 2642 <400> 2642 000 <210> 2643 <400> 2643 000 <210> 2644 <400> 2644 000 <210> 2645 <400> 2645 000 <210> 2646 <400> 2646 000 <210> 2647 <400> 2647 000 <210> 2648 <400> 2648 000 <210> 2649 <400> 2649 000 <210> 2650 <400> 2650 000 <210> 2651 <400> 2651 000 <210> 2652 <400> 2652 000 <210> 2653 <400> 2653 000 <210> 2654 <400> 2654 000 <210> 2655 <400> 2655 000 <210> 2656 <400> 2656 000 <210> 2657 <400> 2657 000 <210> 2658 <400> 2658 000 <210> 2659 <400> 2659 000 <210> 2660 <400> 2660 000 <210> 2661 <400> 2661 000 <210> 2662 <400> 2662 000 <210> 2663 <400> 2663 000 <210> 2664 <400> 2664 000 <210> 2665 <400> 2665 000 <210> 2666 <400> 2666 000 <210> 2667 <400> 2667 000 <210> 2668 <400> 2668 000 <210> 2669 <400> 2669 000 <210> 2670 <400> 2670 000 <210> 2671 <400> 2671 000 <210> 2672 <400> 2672 000 <210> 2673 <400> 2673 000 <210> 2674 <400> 2674 000 <210> 2675 <400> 2675 000 <210> 2676 <400> 2676 000 <210> 2677 <400> 2677 000 <210> 2678 <400> 2678 000 <210> 2679 <400> 2679 000 <210> 2680 <400> 2680 000 <210> 2681 <400> 2681 000 <210> 2682 <400> 2682 000 <210> 2683 <400> 2683 000 <210> 2684 <400> 2684 000 <210> 2685 <400> 2685 000 <210> 2686 <400> 2686 000 <210> 2687 <400> 2687 000 <210> 2688 <400> 2688 000 <210> 2689 <400> 2689 000 <210> 2690 <400> 2690 000 <210> 2691 <400> 2691 000 <210> 2692 <400> 2692 000 <210> 2693 <400> 2693 000 <210> 2694 <400> 2694 000 <210> 2695 <400> 2695 000 <210> 2696 <400> 2696 000 <210> 2697 <400> 2697 000 <210> 2698 <400> 2698 000 <210> 2699 <400> 2699 000 <210> 2700 <400> 2700 000 <210> 2701 &Lt; 400 > 2701 000 <210> 2702 <400> 2702 000 <210> 2703 <400> 2703 000 <210> 2704 <400> 2704 000 <210> 2705 <400> 2705 000 <210> 2706 <400> 2706 000 <210> 2707 <400> 2707 000 <210> 2708 <400> 2708 000 <210> 2709 <400> 2709 000 <210> 2710 <400> 2710 000 <210> 2711 <400> 2711 000 <210> 2712 <400> 2712 000 <210> 2713 <400> 2713 000 <210> 2714 <400> 2714 000 <210> 2715 <400> 2715 000 <210> 2716 <400> 2716 000 <210> 2717 <400> 2717 000 <210> 2718 <400> 2718 000 <210> 2719 <400> 2719 000 <210> 2720 <400> 2720 000 <210> 2721 <400> 2721 000 <210> 2722 <400> 2722 000 <210> 2723 <400> 2723 000 <210> 2724 <400> 2724 000 <210> 2725 <400> 2725 000 <210> 2726 <400> 2726 000 <210> 2727 <400> 2727 000 <210> 2728 <400> 2728 000 <210> 2729 <400> 2729 000 <210> 2730 <400> 2730 000 <210> 2731 <400> 2731 000 <210> 2732 <400> 2732 000 <210> 2733 <400> 2733 000 <210> 2734 <400> 2734 000 <210> 2735 <400> 2735 000 <210> 2736 <400> 2736 000 <210> 2737 <400> 2737 000 <210> 2738 <400> 2738 000 <210> 2739 <400> 2739 000 <210> 2740 <400> 2740 000 <210> 2741 <400> 2741 000 <210> 2742 <400> 2742 000 <210> 2743 <400> 2743 000 <210> 2744 <400> 2744 000 <210> 2745 <400> 2745 000 <210> 2746 <400> 2746 000 <210> 2747 <400> 2747 000 <210> 2748 <400> 2748 000 <210> 2749 <400> 2749 000 <210> 2750 <400> 2750 000 <210> 2751 <400> 2751 000 <210> 2752 <400> 2752 000 <210> 2753 <400> 2753 000 <210> 2754 <400> 2754 000 <210> 2755 <400> 2755 000 <210> 2756 <400> 2756 000 <210> 2757 <400> 2757 000 <210> 2758 <400> 2758 000 <210> 2759 <400> 2759 000 <210> 2760 <400> 2760 000 <210> 2761 <400> 2761 000 <210> 2762 <400> 2762 000 <210> 2763 <400> 2763 000 <210> 2764 <400> 2764 000 <210> 2765 <400> 2765 000 <210> 2766 <400> 2766 000 <210> 2767 <400> 2767 000 <210> 2768 <400> 2768 000 <210> 2769 <400> 2769 000 <210> 2770 <400> 2770 000 <210> 2771 <400> 2771 000 <210> 2772 <400> 2772 000 <210> 2773 <400> 2773 000 <210> 2774 <400> 2774 000 <210> 2775 <400> 2775 000 <210> 2776 <400> 2776 000 <210> 2777 <400> 2777 000 <210> 2778 <400> 2778 000 <210> 2779 <400> 2779 000 <210> 2780 <400> 2780 000 <210> 2781 <400> 2781 000 <210> 2782 <400> 2782 000 <210> 2783 <400> 2783 000 <210> 2784 <400> 2784 000 <210> 2785 <400> 2785 000 <210> 2786 <400> 2786 000 <210> 2787 <400> 2787 000 <210> 2788 <400> 2788 000 <210> 2789 <400> 2789 000 <210> 2790 <400> 2790 000 <210> 2791 <400> 2791 000 <210> 2792 <400> 2792 000 <210> 2793 <400> 2793 000 <210> 2794 <400> 2794 000 <210> 2795 <400> 2795 000 <210> 2796 <400> 2796 000 <210> 2797 <400> 2797 000 <210> 2798 <400> 2798 000 <210> 2799 <400> 2799 000 <210> 2800 <400> 2800 000 <210> 2801 <400> 2801 000 <210> 2802 <400> 2802 000 <210> 2803 <400> 2803 000 <210> 2804 <400> 2804 000 <210> 2805 <400> 2805 000 <210> 2806 <400> 2806 000 <210> 2807 <400> 2807 000 <210> 2808 <400> 2808 000 <210> 2809 <400> 2809 000 <210> 2810 <400> 2810 000 <210> 2811 <400> 2811 000 <210> 2812 <400> 2812 000 <210> 2813 <400> 2813 000 <210> 2814 <400> 2814 000 <210> 2815 <400> 2815 000 <210> 2816 <400> 2816 000 <210> 2817 <400> 2817 000 <210> 2818 <400> 2818 000 <210> 2819 <400> 2819 000 <210> 2820 <400> 2820 000 <210> 2821 <400> 2821 000 <210> 2822 <400> 2822 000 <210> 2823 <400> 2823 000 <210> 2824 <400> 2824 000 <210> 2825 <400> 2825 000 <210> 2826 <400> 2826 000 <210> 2827 <400> 2827 000 <210> 2828 <400> 2828 000 <210> 2829 <400> 2829 000 <210> 2830 <400> 2830 000 <210> 2831 <400> 2831 000 <210> 2832 <400> 2832 000 <210> 2833 <400> 2833 000 <210> 2834 <400> 2834 000 <210> 2835 <400> 2835 000 <210> 2836 <400> 2836 000 <210> 2837 <400> 2837 000 <210> 2838 <400> 2838 000 <210> 2839 <400> 2839 000 <210> 2840 <400> 2840 000 <210> 2841 <400> 2841 000 <210> 2842 <400> 2842 000 <210> 2843 <400> 2843 000 <210> 2844 <400> 2844 000 <210> 2845 <400> 2845 000 <210> 2846 <400> 2846 000 <210> 2847 <400> 2847 000 <210> 2848 <400> 2848 000 <210> 2849 <400> 2849 000 <210> 2850 <400> 2850 000 <210> 2851 <400> 2851 000 <210> 2852 <400> 2852 000 <210> 2853 <400> 2853 000 <210> 2854 <400> 2854 000 <210> 2855 <400> 2855 000 <210> 2856 <400> 2856 000 <210> 2857 <400> 2857 000 <210> 2858 <400> 2858 000 <210> 2859 <400> 2859 000 <210> 2860 <400> 2860 000 <210> 2861 <400> 2861 000 <210> 2862 <400> 2862 000 <210> 2863 <400> 2863 000 <210> 2864 <400> 2864 000 <210> 2865 <400> 2865 000 <210> 2866 <400> 2866 000 <210> 2867 <400> 2867 000 <210> 2868 <400> 2868 000 <210> 2869 <400> 2869 000 <210> 2870 <400> 2870 000 <210> 2871 <400> 2871 000 <210> 2872 <400> 2872 000 <210> 2873 <400> 2873 000 <210> 2874 <400> 2874 000 <210> 2875 <400> 2875 000 <210> 2876 <400> 2876 000 <210> 2877 <400> 2877 000 <210> 2878 <400> 2878 000 <210> 2879 <400> 2879 000 <210> 2880 <400> 2880 000 <210> 2881 <400> 2881 000 <210> 2882 <400> 2882 000 <210> 2883 <400> 2883 000 <210> 2884 <400> 2884 000 <210> 2885 <400> 2885 000 <210> 2886 <400> 2886 000 <210> 2887 <400> 2887 000 <210> 2888 <400> 2888 000 <210> 2889 <400> 2889 000 <210> 2890 <400> 2890 000 <210> 2891 <400> 2891 000 <210> 2892 <400> 2892 000 <210> 2893 <400> 2893 000 <210> 2894 <400> 2894 000 <210> 2895 <400> 2895 000 <210> 2896 <400> 2896 000 <210> 2897 <400> 2897 000 <210> 2898 <400> 2898 000 <210> 2899 <400> 2899 000 <210> 2900 <400> 2900 000 <210> 2901 <400> 2901 000 <210> 2902 <400> 2902 000 <210> 2903 <400> 2903 000 <210> 2904 <400> 2904 000 <210> 2905 <400> 2905 000 <210> 2906 <400> 2906 000 <210> 2907 <400> 2907 000 <210> 2908 <400> 2908 000 <210> 2909 <400> 2909 000 <210> 2910 <400> 2910 000 <210> 2911 <400> 2911 000 <210> 2912 <400> 2912 000 <210> 2913 <400> 2913 000 <210> 2914 <400> 2914 000 <210> 2915 <400> 2915 000 <210> 2916 <400> 2916 000 <210> 2917 <400> 2917 000 <210> 2918 <400> 2918 000 <210> 2919 <400> 2919 000 <210> 2920 <400> 2920 000 <210> 2921 <400> 2921 000 <210> 2922 <400> 2922 000 <210> 2923 <400> 2923 000 <210> 2924 <400> 2924 000 <210> 2925 <400> 2925 000 <210> 2926 <400> 2926 000 <210> 2927 <400> 2927 000 <210> 2928 <400> 2928 000 <210> 2929 <400> 2929 000 <210> 2930 <400> 2930 000 <210> 2931 <400> 2931 000 <210> 2932 <400> 2932 000 <210> 2933 <400> 2933 000 <210> 2934 <400> 2934 000 <210> 2935 <400> 2935 000 <210> 2936 <400> 2936 000 <210> 2937 <400> 2937 000 <210> 2938 <400> 2938 000 <210> 2939 <400> 2939 000 <210> 2940 <400> 2940 000 <210> 2941 <400> 2941 000 <210> 2942 <400> 2942 000 <210> 2943 <400> 2943 000 <210> 2944 <400> 2944 000 <210> 2945 <400> 2945 000 <210> 2946 <400> 2946 000 <210> 2947 <400> 2947 000 <210> 2948 <400> 2948 000 <210> 2949 <400> 2949 000 <210> 2950 <400> 2950 000 <210> 2951 <400> 2951 000 <210> 2952 <400> 2952 000 <210> 2953 <400> 2953 000 <210> 2954 <400> 2954 000 <210> 2955 <400> 2955 000 <210> 2956 <400> 2956 000 <210> 2957 <400> 2957 000 <210> 2958 <400> 2958 000 <210> 2959 <400> 2959 000 <210> 2960 <400> 2960 000 <210> 2961 <400> 2961 000 <210> 2962 <400> 2962 000 <210> 2963 <400> 2963 000 <210> 2964 <400> 2964 000 <210> 2965 <400> 2965 000 <210> 2966 <400> 2966 000 <210> 2967 <400> 2967 000 <210> 2968 <400> 2968 000 <210> 2969 <400> 2969 000 <210> 2970 <400> 2970 000 <210> 2971 <400> 2971 000 <210> 2972 <400> 2972 000 <210> 2973 <400> 2973 000 <210> 2974 <400> 2974 000 <210> 2975 <400> 2975 000 <210> 2976 <400> 2976 000 <210> 2977 <400> 2977 000 <210> 2978 <400> 2978 000 <210> 2979 <400> 2979 000 <210> 2980 <400> 2980 000 <210> 2981 <400> 2981 000 <210> 2982 <400> 2982 000 <210> 2983 <400> 2983 000 <210> 2984 <400> 2984 000 <210> 2985 <400> 2985 000 <210> 2986 <400> 2986 000 <210> 2987 <400> 2987 000 <210> 2988 <400> 2988 000 <210> 2989 <400> 2989 000 <210> 2990 <400> 2990 000 <210> 2991 <400> 2991 000 <210> 2992 <400> 2992 000 <210> 2993 <400> 2993 000 <210> 2994 <400> 2994 000 <210> 2995 <400> 2995 000 <210> 2996 <400> 2996 000 <210> 2997 <400> 2997 000 <210> 2998 <400> 2998 000 <210> 2999 <400> 2999 000 <210> 3000 <400> 3000 000 <210> 3001 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> DISULFID <222> (6) <223> Cys residues linked via disfide bond <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 3001 Xaa Ser Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His 1 5 10 15 Asn Lys Leu Ile Gly Tyr Glu Arg Arg Tyr Asn Cys Thr Ser             20 25 30 <210> 3002 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 3002 Xaa Ser Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His 1 5 10 15 Asn Lys Leu Ile Gly Tyr Glu Arg Arg Tyr Asn Cys Thr Ser             20 25 30 <210> 3003 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <220> <221> MOD_RES &Lt; 222 > (30) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (31) <223> Linked to Biotin <400> 3003 Ser Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn 1 5 10 15 Lys Leu Ile Gly Tyr Glu Arg Arg Tyr Asn Cys Thr Ser Xaa Lys             20 25 30 <210> 3004 <211> 34 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (34) <223> C-terminal amidation <400> 3004 Xaa Lys Lys Ser Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr 1 5 10 15 Met Trp Pro Asp Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr Ser             20 25 30 Lys Lys          <210> 3005 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (35) <223> Linked to Biotin <220> <221> MOD_RES &Lt; 222 > (35) <223> C-terminal amidation <400> 3005 Lys Lys Ser Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met 1 5 10 15 Trp Pro Asp Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr Ser Xaa             20 25 30 Lys Lys Lys         35 <210> 3006 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3006 Xaa Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr 1 5 10 15 Ile Gly Asn Met Gly Met Tyr Ala Ala Gln Leu Lys Phe Arg Thr Ser             20 25 30 <210> 3007 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (13) <223> C-terminal amidation <400> 3007 Xaa Leu Ser Leu Val Gly Ser Phe Ala Val Leu Cys Ala 1 5 10 <210> 3008 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 3008 Xaa Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn 1 5 10 15 Lys Leu Ile Gly Tyr             20 <210> 3009 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotin <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 3009 Xaa Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile 1 5 10 15 Gly Tyr Glu Arg Arg             20 <210> 3010 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotin <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 3010 Xaa Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His His Lys Leu 1 5 10 15 Ile Gly Tyr Glu Arg             20 <210> 3011 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotin <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 3011 Xaa Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly Tyr Glu 1 5 10 15 Arg Arg Tyr Asn Cys             20 <210> 3012 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 3012 Xaa Tyr Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala Ala Gln Leu 1 5 10 15 Lys Phe Arg              <210> 3013 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 3013 Xaa Tyr Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala Ala Gln Leu 1 5 10 15 Lys Phe Arg Thr Ser             20 <210> 3014 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 3014 Xaa Leu Tyr Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala Ala Gln 1 5 10 15 Leu Lys Phe Arg Thr             20 <210> 3015 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3015 Xaa Ser Gly Gln Phe Trp His Gly Leu Leu Leu Pro Lys Gly Ile Val 1 5 10 15 Leu Asn Trp Thr Leu Lys Pro Trp Trp Met Ile Gly Ala Phe Thr Ser             20 25 30 <210> 3016 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES &Lt; 222 > (32) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (33) <223> Linked to Biotin <220> <221> MOD_RES &Lt; 222 > (33) <223> C-terminal amidation <400> 3016 Ser Gly Gln Phe Trp His Gly Leu Leu Leu Pro Lys Gly Ile Val Leu 1 5 10 15 Asn Trp Thr Leu Lys Pro Trp Trp Met Ile Gly Ala Phe Thr Ser Xaa             20 25 30 Lys      <210> 3017 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3017 Xaa Ser Gly Arg Val Ser Tyr Tyr Trp Gly Val Lys Trp Ser Gln Gln 1 5 10 15 Met Pro Met Ser Trp Trp Pro Asp Thr Trp Tyr Thr Phe Asp Thr Ser             20 25 30 <210> 3018 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (33) <223> Linked to Biotin <220> <221> MOD_RES &Lt; 222 > (33) <223> C-terminal amidation <400> 3018 Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile 1 5 10 15 Gly Asn Met Gly Met Tyr Ala Gln Leu Lys Phe Arg Thr Ser Xaa             20 25 30 Lys      <210> 3019 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3019 Xaa Ser Gly Arg Phe Thr Thr Arg Leu Trp Tyr Phe Ser Trp Asp Arg 1 5 10 15 Leu Pro Trp Tyr Met Pro Phe Lys Gln Tyr Val Leu Ser Ser Thr Ser             20 25 30 <210> 3020 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3020 Xaa Ser Gly Ser Tyr Gln Trp Trp Ala Arg Pro Tyr Arg Met Trp Phe 1 5 10 15 Gly Leu Pro Tyr Trp Asn Gln Arg Val Ile Phe Pro Trp Asn Thr Ser             20 25 30 <210> 3021 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 3021 Xaa Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala Ala 1 5 10 15 Gln Leu Lys Phe Arg             20 <210> 3022 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (21) <223> C-terminal amidation <400> 3022 Xaa Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly 1 5 10 15 Tyr Glu Arg Arg Tyr             20 <210> 3023 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (17) <223> C-terminal amidation <400> 3023 Xaa Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly Tyr Glu 1 5 10 15 Arg      <210> 3024 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3024 Phe Gln Arg Lys Gly Asn Val Phe Val Asp Gly Tyr Phe Glu Arg Leu 1 5 10 15 Arg Ala Lys Leu             20 <210> 3025 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3025 Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile 1 5 10 15 Gly Asn Met Gly Met Tyr Ala Gln Leu Lys Phe Arg Thr Ser             20 25 30 <210> 3026 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 3026 Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly 1 5 10 15 Tyr Glu Arg Arg Tyr Asn Cys             20 <210> 3027 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 3027 Lys Lys Ser Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg 1 5 10 15 His Asn Lys Leu Ile Gly Tyr Glu Arg Arg Tyr Asn Lys Lys             20 25 30 <210> 3028 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3028 Lys Lys Ser Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met 1 5 10 15 Trp Pro Asp Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr Lys Lys             20 25 30 <210> 3029 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (33) <223> C-terminal amidation <400> 3029 Lys Lys Ser Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg 1 5 10 15 His Asn Lys Leu Ile Gly Tyr Glu Arg Arg Tyr Asn Cys Thr Ser Lys             20 25 30 Lys      <210> 3030 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3030 Lys Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly Tyr 1 5 10 15 Glu Arg Arg Tyr Asn Cys Lys Lys             20 <210> 3031 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (35) <223> C-terminal amidation <400> 3031 Lys Lys Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu 1 5 10 15 Thr Ile Gly Asn Met Gly Met Tyr Ala Gln Leu Lys Phe Arg Thr             20 25 30 Ser Lys Lys         35 <210> 3032 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 3032 Lys Lys Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys 1 5 10 15 Leu Ile Gly Tyr Glu Arg Arg Tyr Asn Cys Thr Ser Lys Lys             20 25 30 <210> 3033 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (27) <223> C-terminal amidation <400> 3033 Lys Lys Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly 1 5 10 15 Tyr Glu Arg Arg Tyr Asn Cys Thr Ser Lys Lys             20 25 <210> 3034 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 3034 Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met Gly Met 1 5 10 15 Tyr Ala Ala Gln Leu Lys Phe             20 <210> 3035 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 3035 Lys Lys Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp 1 5 10 15 Pro Asp Ile Lys Gly Glu Val Ile Val Leu Phe Gly Lys Lys             20 25 30 <210> 3036 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (33) <223> C-terminal amidation <400> 3036 Lys Lys Ser Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met 1 5 10 15 Trp Pro Asp Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr Ser Lys             20 25 30 Lys      <210> 3037 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3037 Lys Lys Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp 1 5 10 15 Pro Asp Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr Ser Lys Lys             20 25 30 <210> 3038 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Carboxyfluorescein <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 3038 Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met 1 5 10 15 Gly Met Tyr Ala Ala Gln Leu Lys Phe             20 25 <210> 3039 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3039 Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met Gly 1 5 10 15 Met Tyr Ala Ala Gln Leu Lys Phe             20 <210> 3040 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3040 Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met 1 5 10 15 Gly Met Tyr Ala Ala Gln Leu Lys             20 <210> 3041 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 3041 Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile 1 5 10 15 Gly Tyr Glu Arg Arg Tyr Asn Cys Thr Ser             20 25 <210> 3042 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 3042 Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly 1 5 10 15 Tyr Glu Arg Arg Tyr Asn Cys Thr Ser             20 25 <210> 3043 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3043 Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly Tyr 1 5 10 15 Glu Arg Arg Tyr Asn Cys Thr Ser             20 <210> 3044 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 3044 Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile 1 5 10 15 Gly Tyr Glu Arg Arg Tyr Asn Cys Thr             20 25 <210> 3045 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3045 Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile 1 5 10 15 Gly Tyr Glu Arg Arg Tyr Asn Cys             20 <210> 3046 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3046 Lys Lys Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp 1 5 10 15 Pro Asp Ile Lys Gly Glu Val Ile Val Leu Phe Lys Lys             20 25 <210> 3047 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3047 Ser Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn 1 5 10 15 Lys Leu Ile Gly Tyr Glu Arg Arg Tyr Asn Cys Thr Ser             20 25 <210> 3048 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal aceylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 3048 Lys Lys Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu 1 5 10 15 Thr Ile Gly Asn Met Lys Lys             20 <210> 3049 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3049 Thr Asn Tyr Thr Gly Ser Glu Lys Cys Ile Arg Phe Val Thr Arg Arg 1 5 10 15 Tyr Leu Gly Val Arg Ile Asn Cys Phe His Lys Gly Ser             20 25 <210> 3050 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3050 Thr Arg Asn Val Val Arg Arg Tyr Glu Cys Phe Gly Ser Thr Gly Cys 1 5 10 15 Ile Lys Tyr Phe Ile His Ser Arg Thr Gly Leu Asn Lys             20 25 <210> 3051 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (27) <223> C-terminal amidation <400> 3051 Lys Lys Ser Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg 1 5 10 15 His Asn Lys Leu Ile Gly Tyr Glu Arg Lys Lys             20 25 <210> 3052 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) C-terminal N-ethyl <400> 3052 Lys Lys Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His 1 5 10 15 Asn Lys Leu Ile Gly Tyr Lys Lys             20 <210> 3053 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3053 Lys Lys Cys Thr Lys Val Ile Val Phe Thr Phe Arg His His Lys Leu 1 5 10 15 Ile Gly Tyr Glu Arg Arg Lys Lys             20 <210> 3054 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 3054 Met Leu Gly Val Leu Met Arg Gly Ile Ser Ala Leu Thr Gly Asp Tyr 1 5 10 15 Thr Ala Arg Phe Glu Phe Tyr Leu Asn Lys Gln Thr Phe Asn             20 25 30 <210> 3055 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3055 Lys Lys Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys 1 5 10 15 Leu Ile Gly Tyr Glu Arg Lys Lys             20 <210> 3056 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (33) <223> C-terminal amidation <400> 3056 Lys Lys Val Gly Ser Val Thr Arg Trp Ser Met Tyr Gly Pro Ile Phe 1 5 10 15 Ile Lys Phe Thr Trp Thr Leu Glu Gln Pro Val Gly Trp Asp His Lys             20 25 30 Lys      <210> 3057 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 3057 Lys Lys Phe Trp Thr Met Trp Pro Asp Ile Lys Gly Glu Val Ile Val 1 5 10 15 Leu Phe Gly Thr Ser Lys Lys             20 <210> 3058 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3058 Lys Lys His Pro Arg Tyr Phe Trp Thr Met Trp Pro Asp Ile Lys Gly 1 5 10 15 Glu Val Ile Val Leu Phe Lys Lys             20 <210> 3059 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3059 Lys Lys Tyr Phe Trp Thr Met Trp Pro Asp Ile Lys Gly Glu Val Ile 1 5 10 15 Val Leu Phe Gly Thr Ser Lys Lys             20 <210> 3060 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3060 Lys Lys Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu 1 5 10 15 Thr Ile Gly Asn Met Gly Lys Lys             20 <210> 3061 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3061 Lys Lys Ser Gly Arg Gly Cys Thr Lys Val Ile Val Phe Thr Phe Arg 1 5 10 15 His Asn Lys Leu Ile Gly Lys Lys             20 <210> 3062 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3062 Lys Lys Thr Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile 1 5 10 15 Gly Tyr Glu Arg Arg Tyr Lys Lys             20 <210> 3063 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3063 Lys Lys Lys Val Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly 1 5 10 15 Tyr Glu Arg Arg Tyr Asn Lys Lys             20 <210> 3064 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3064 Lys Lys Ile Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly Tyr Glu 1 5 10 15 Arg Arg Tyr Asn Cys Thr Lys Lys             20 <210> 3065 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (33) <223> C-terminal amidation <400> 3065 Lys Lys Leu Thr Gly Asp Trp Thr Tyr Phe Trp Ser Lys Val Ile Trp 1 5 10 15 Gly Pro Gly Val Ile Glu Arg Gln Met Pro Val Ser Thr Phe His Lys             20 25 30 Lys      <210> 3066 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3066 Lys Lys Ser Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met 1 5 10 15 Trp Pro Asp Ile Lys Gly Glu Val Ile Val Leu Lys Lys             20 25 <210> 3067 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 3067 Lys Lys Ser Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met 1 5 10 15 Trp Pro Asp Ile Lys Gly Glu Val Lys Lys             20 25 <210> 3068 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 3068 Lys Lys Ser Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met 1 5 10 15 Trp Pro Asp Ile Lys Lys Lys             20 <210> 3069 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3069 Lys Lys Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp Pro Asp Ile 1 5 10 15 Lys Gly Glu Val Ile Val Leu Phe Gly Thr Ser Lys Lys             20 25 <210> 3070 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 3070 Lys Lys Pro Arg Tyr Phe Trp Thr Met Trp Pro Asp Ile Lys Gly Glu 1 5 10 15 Val Ile Val Leu Phe Gly Thr Ser Lys Lys             20 25 <210> 3071 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3071 Lys Lys Ser Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met 1 5 10 15 Trp Pro Asp Ile Lys Gly Lys Lys             20 <210> 3072 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3072 Lys Lys Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp Pro Asp 1 5 10 15 Ile Lys Gly             20 <210> 3073 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3073 Lys Lys Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu 1 5 10 15 Thr Ile Gly Asn Met Gly Met Tyr Ala Ala Gln Leu Lys Phe Lys Lys             20 25 30 <210> 3074 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3074 Lys Lys Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu 1 5 10 15 Thr Ile Gly Asn Met Gly Met Tyr Ala Ala Gln Lys Lys             20 25 <210> 3075 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 3075 Lys Lys Ser Gly Asn Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu 1 5 10 15 Thr Ile Gly Asn Met Gly Met Tyr Lys Lys             20 25 <210> 3076 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3076 Lys Lys Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile Gly 1 5 10 15 Asn Met Gly Met Tyr Ala Gln Leu Lys Phe Arg Thr Ser Lys Lys             20 25 30 <210> 3077 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3077 Lys Lys Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met Gly 1 5 10 15 Met Tyr Ala Gln Leu Lys Phe Arg Thr Ser Lys Lys             20 25 <210> 3078 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (26) <223> C-terminal amidation <400> 3078 Lys Lys Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala 1 5 10 15 Ala Gln Leu Lys Phe Arg Thr Ser Lys Lys             20 25 <210> 3079 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (23) <223> C-terminal amidation <400> 3079 Lys Lys Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala Ala Gln Leu 1 5 10 15 Lys Phe Arg Thr Ser Lys Lys             20 <210> 3080 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3080 Lys Lys Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala 1 5 10 15 Ala Gln Leu Lys Phe Arg Lys Lys             20 <210> 3081 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3081 Lys Lys Leu Tyr Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala Ala 1 5 10 15 Gln Leu Lys Phe Arg Thr Lys Lys             20 <210> 3082 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3082 Lys Lys Tyr Phe Leu Thr Ile Gly Asn Met Gly Met Tyr Ala Ala Gln 1 5 10 15 Leu Lys Phe Arg Thr Ser Lys Lys             20 <210> 3083 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (24) <223> C-terminal amidation <400> 3083 Lys Lys Val Phe Thr Phe Arg His Asn Lys Leu Ile Gly Tyr Glu Arg 1 5 10 15 Arg Tyr Asn Cys Thr Ser Lys Lys             20 <210> 3084 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 3084 Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile Gly Asn Met 1 5 10 15 Gly Met Tyr Ala Ala Gln             20 <210> 3085 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3085 Ser Gly Asp Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile 1 5 10 15 Gly Asn Met Arg Met Tyr Ala Val Gln Leu Lys Phe Arg Thr Ser             20 25 30 <210> 3086 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3086 Ser Gly Asp Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Thr 1 5 10 15 Gly Asn Met Arg Met Tyr Ala Val Gln Leu Lys Phe Arg Thr Ser             20 25 30 <210> 3087 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3087 Ser Gly Asp Thr Phe Val Asp Glu Arg Leu Leu Tyr Phe Leu Thr Ile 1 5 10 15 Gly Asp Met Arg Met Tyr Ala Val Gln Leu Lys Phe Arg Thr Ser             20 25 30 <210> 3088 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3088 Lys Lys Gly Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp 1 5 10 15 Pro Asp Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr Lys Lys             20 25 30 <210> 3089 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (30) <223> C-terminal amidation <400> 3089 Lys Lys Val Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp Pro 1 5 10 15 Asp Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr Lys Lys             20 25 30 <210> 3090 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (29). (29) <223> C-terminal amidation <400> 3090 Lys Lys Trp Gln Thr His Pro Arg Tyr Phe Trp Thr Met Trp Pro Asp 1 5 10 15 Ile Lys Gly Glu Val Ile Val Leu Phe Gly Thr Lys Lys             20 25 <210> 3091 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3091 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Cys Ser Met His Phe Trp Arg Trp Ser Thr Ser             20 25 30 <210> 3092 <211> 32 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal Biotinyl <220> <221> MOD_RES <222> (1) Xaa is (13-Amino-4,7,10-trioxa-tridecyl) -succinamic acid <220> <221> MOD_RES &Lt; 222 > (32) <223> C-terminal amidation <400> 3092 Xaa Ser Gly Gly Arg Lys His Leu His Phe Leu Arg Ser Asn Gly Lys 1 5 10 15 Pro Ser Arg Ala Leu Cys Ser Met His Phe Trp Arg Trp Ser Thr Ser             20 25 30 <210> 3093 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3093 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Ser Ser Met His Phe Trp Arg Trp Ser Thr Ser             20 25 30 <210> 3094 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3094 Lys Gly Ser Ser Arg Gly His Asn Ala Leu Lys Thr His Ser Trp 1 5 10 15 Met Ser Pro Phe Arg Arg Arg Gly Ser Trp Ser Leu His Phe Lys             20 25 30 <210> 3095 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3095 Lys Ser Arg Ser Gly Phe Trp His Ala Trp Ser His Arg Thr Arg Pro 1 5 10 15 Met Lys Ser Arg Leu His Leu Gly Lys Phe Ser Asn Ser Ser Gly             20 25 30 <210> 3096 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (28) <223> C-terminal amidation <400> 3096 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Ser Ser Met His Phe Trp Arg Trp             20 25 <210> 3097 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (25) <223> N-terminal amidation <400> 3097 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Ser Ser Met His Phe             20 25 <210> 3098 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 3098 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Ser Ser             20 <210> 3099 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 3099 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala              <210> 3100 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (28) <223> C-terminal amidation <400> 3100 Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro Ser Arg Ala 1 5 10 15 Leu Ser Ser Met His Phe Trp Arg Trp Ser Thr Ser             20 25 <210> 3101 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 3101 Lys His Phe Leu Arg Ser Asn Gly Lys Pro Ser Arg Ala Leu Ser Ser 1 5 10 15 Met His Phe Trp Arg Trp Ser Thr Ser             20 25 <210> 3102 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 3102 Leu Arg Ser Ser Gn Lys Pro Ser Ser Ala Leu Ser Ser Met His Phe 1 5 10 15 Trp Arg Trp Ser Thr Ser             20 <210> 3103 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 3103 Asn Gly Lys Pro Ser Arg Ala Leu Ser Ser Met His Phe Trp Arg Trp 1 5 10 15 Ser Thr Ser              <210> 3104 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3104 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu             20 <210> 3105 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3105 Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro Ser Arg Ala 1 5 10 15 Leu Ser Ser Met             20 <210> 3106 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3106 Lys His Phe Leu Arg Ser Asn Gly Lys Pro Ser Arg Ala Leu Ser Ser 1 5 10 15 Met His Phe Trp             20 <210> 3107 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3107 Leu Arg Ser Ser Gn Lys Pro Ser Ser Ala Leu Ser Ser Met His Phe 1 5 10 15 Trp Arg Trp Ser             20 <210> 3108 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 3108 Ser Asn Gly Lys Pro Ser Arg Ala Leu Ser Ser Met His Phe Trp Arg 1 5 10 15 Trp Ser Thr Ser             20 <210> 3109 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is selected from the group consisting of Leu, Pro, Lys, Ser,        Trp, Val, Asn, and Gln <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is selected from the group consisting of Leu, Arg, Asn, Phe,        and Ile <220> <221> MOD_RES &Lt; 222 > (3) &Lt; 223 > Xaa is selected from the group consisting of Tyr, Val, Pro, and        Cys <220> <221> MOD_RES <222> (4) (4) <223> Xaa is selected from the group consisting of Phe, Leu, Gly <220> <221> MOD_RES &Lt; 222 > (5) &Lt; 223 > Xaa is selected from the group consisting of Leu, Trp, Val, Ala,        Met, Thr, and Ser <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is selected from the group consisting of Thr, Phe, Val, Arg,        Ala, Asp, Leu, Glu, Ser, and Tyr <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is selected from the group consisting of Ile, Met, Gly, Gln,        Asp, and Arg <220> <221> MOD_RES &Lt; 222 > (8) Xaa is selected from the group consisting of Gly, Trp, Tyr, Leu,        Met, and His <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is selected from the group consisting of Asn, Pro, Phe, His,        Lys, and Tyr <220> <221> MOD_RES &Lt; 222 > (10) &Lt; 223 > Xaa is selected from the group consisting of Met, Asp, Glu, Val,        Gly, and Lys <220> <221> MOD_RES &Lt; 222 > (11) &Lt; 223 > Xaa is selected from the group consisting of Gly, Ile, Arg, Ser,        Thr, and Leu <220> <221> MOD_RES (12). (12) &Lt; 223 > Xaa is selected from the group consisting of Met, Lys, Leu, and        Ile <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is selected from the group consisting of Tyr, Gly, Arg, and        Ser <220> <221> MOD_RES &Lt; 222 > (14) &Lt; 223 > Xaa is selected from the group consisting of Ala, Glu, Ser, Cys,        and Tyr <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is selected from the group consisting of Ala, Val, Lys, and        Glu <400> 3109 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 <210> 3110 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is selected from a group consisting of Val, Trp, Tyr, and Phe <220> <221> MOD_RES <222> (2) (2) <223> Xaa is selected from a group consisting of Asp, Gln, and Ser <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected from a group consisting of Glu, Thr, Asn, and Ser <220> <221> MOD_RES <222> (4) (4) <223> Xaa is selected from a group consisting of Arg, His, Lys, and Ala <400> 3110 Xaa Xaa Xaa Xaa One <210> 3111 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is selected from a group consisting of Phe and Val <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is selected from a group consisting of Val, Trp, Tyr, and Phe <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected from a group consisting of Asp, Gln, and Ser <220> <221> MOD_RES <222> (4) (4) <223> Xaa is selected from a group consisting of Glu, Thr, Asn, and Ser <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is selected from a group consisting of Arg, His, Lys, and Ala <400> 3111 Xaa Xaa Xaa Xaa Xaa 1 5 <210> 3112 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is selected from a group consisting of Thr and Gly <220> <221> MOD_RES <222> (2) (2) <223> Xaa is selected from a group consisting of Phe and Val <220> <221> MOD_RES &Lt; 222 > (3) &Lt; 223 > Xaa is selected from a group consisting of Val, Trp, Tyr, and Phe <220> <221> MOD_RES <222> (4) (4) <223> Xaa is selected from a group consisting of Asp, Gln, and Ser <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is selected from a group consisting of Glu, Thr, Asn, and Ser <220> <221> MOD_RES <222> (6) <223> Xaa is selected from a group consisting of Arg, His, Lys, and Ala <400> 3112 Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 3113 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) Xaa is selected from a group consisting of Gln, Ile, Glu, Trp,        Arg, Leu, and Asn <220> <221> MOD_RES <222> (2) (2) <223> Xaa is selected from a group consisting of Leu, Val, Met, and Arg <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected from a group consisting of Lys, Leu, Ala, and Tyr <400> 3113 Xaa Xaa Xaa Phe One <210> 3114 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) Xaa is selected from a group consisting of Gln, Ile, Glu, Trp,        Arg, Leu, and Asn <220> <221> MOD_RES <222> (2) (2) <223> Xaa is selected from a group consisting of Leu, Val, Met, and Arg <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected from a group consisting of Lys, Leu, Ala, and Tyr <400> 3114 Xaa Xaa Xaa Pro Gly 1 5 <210> 3115 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) Xaa is selected from a group consisting of Gln, Ile, Glu, Trp,        Arg, Leu, and Asn <220> <221> MOD_RES <222> (2) (2) <223> Xaa is selected from a group consisting of Leu, Val, Met, and Arg <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected from a group consisting of Lys, Leu, Ala, and Tyr <400> 3115 Xaa Xaa Xaa Pro Gly Thr 1 5 <210> 3116 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Bhf,        Lys, Leu, Met, Asn, Nmf, Gln, Arg,        Thr, Val, Trp and Tyr <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Gly, Lys,        and Gln <220> <221> MOD_RES &Lt; 222 > (3) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala, Aib,        Lys, Leu, Met, Asn, Pro, Gly, His, Ile,        Gln, Arg, Ser, Thr, Val, Trp and Tyr <220> <221> MOD_RES <222> (4) (4) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala, Aib,        Bhk, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, D-Lys, Leu, Met,        Asn, Nmk, Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is an amino acid selected from the group consisting of D-Ala,        Ala, Aib, Bal, Cys, Asp, D-Asp, Glu, Phe, Gly, His, Lys, D-        Leu, Met, Asn, Nmg, D-Pro, Gln, Arg, Ser, Thr, Val, Trp and Tyr <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala, Aib,        Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln,        Arg, Ser, Thr, Val, Trp and Tyr <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala, Phe,        Gly, Ile, Lys, Leu, Nmv, Pro, Gln, Ser, Val, Trp and Tyr <220> <221> MOD_RES &Lt; 222 > (8) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Phe, His,        Lys, Trp and Tyr <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala, Aib,        D-Phe, Ile, Lys, Ser, Thr, and Val <220> <221> MOD_RES &Lt; 222 > (10) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala, Aib,        Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn,        Gln, Arg, Ser, Thr, Val, Trp and Tyr <220> <221> MOD_RES &Lt; 222 > (11) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Aib, Cys,        Lys, Gly, and Nmg <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala, Aib,        Cys, Glu, Phe, Gly, His, Lys, Leu, Met, Gln, Arg, Trp, and Tyr <220> <221> MOD_RES &Lt; 222 > (14) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala, Aib,        Bhe, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro,        Gln, Arg, Ser, Thr, Val, Trp, and Tyr <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is an amino acid selected from the group consisting of        (omega-methyl) -Arg, Asp, Glu, Lys and Arg <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is an amino acid selected from the group consisting of        (omega-methyl) -Arg, Ala, Aib, Bhr, Cys, Cha, Cit, Asp, Dab, Dap,        Glu, Eag, Eew, Phe, Gly, His, Har, Hci, Hle, Ile, Lys, Leu, Met,        Asn, Nle, Nva, Opa, Orn, Gln, Arg, Ser, Thr, Val, Trp and Tyr <220> <221> MOD_RES <222> (18). (18) <223> Xaa is an amino acid selected from the group consisting of Ala, Bal,        Lys, Leu, Met, Asn, Gln, Arg, Phe, Gly, His, Ile,        Ser, Thr, Val, Trp and Tyr <220> <221> MOD_RES <222> (19). (19) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Bhk, Lys,        Arg, and Val <220> <221> MOD_RES &Lt; 222 > (20) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Aib,        Gly, His, Ile, Lys, Leu, Nml, Gln, Arg, Ser, Thr,        Val, Trp and Tyr or is absent <400> 3116 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa Leu 1 5 10 15 Xaa Xaa Xaa Xaa             20 <210> 3117 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (4) (4) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (6) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (7) (7) <223> Xaa is an amino acid selected from the group consisting of Ile        and Val <220> <221> MOD_RES &Lt; 222 > (8) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (10) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Cys        and Phe <220> <221> MOD_RES &Lt; 222 > (14) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (18). (18) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (20) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Lys        and Leu <400> 3117 Xaa Gln Xaa Xaa Xaa Xaa Xaa Xaa Val Xaa Gly Tyr Xaa Xaa Arg Leu 1 5 10 15 Xaa Xaa Lys Xaa             20 <210> 3118 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Pro, Arg, Ser, Thr, Val        and Trp or is absent <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        As, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Arg, Ser, Thr,        Val and Trp or is absent <220> <221> misc_feature &Lt; 222 > (3) <223> Xaa can be any naturally occurring amino acid <220> <221> MOD_RES <222> (4) (4) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, Glu, Phe, Gly, Ile, Lys, Leu, Arg, Ser, Thr, Val and Trp <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Phe,        His, Ile, Lys, Leu, Arg, Val and Trp <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Cys,        Hcy, Dap and Lys, preferably selected from the group consisting of        of Cys and Hcy <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (8) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Gly, Arg, Ser and Thr <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Ile, Lys, Leu, Met, D-Met, Nle, D-Pro, Arg, and Val <220> <221> MOD_RES &Lt; 222 > (10) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Gly, Ile, Lys, Leu, Pro, Arg, Ser, Thr and Val <220> <221> MOD_RES &Lt; 222 > (11) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Asp,        Glu, Gly, Ser and Thr <220> <221> MOD_RES (12). (12) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, D-Asp, Glu, D-Glu, Phe, D-Phe, Gly, Ile, Lys, D-Lys,        D-Arg, D-Arg, Ser, Leu, D-Leu, Met, D-Met, Nle, D-        D-Ser, Thr, D-Thr, Val, D-Val, Trp and D-Trp <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, D-Asp, Glu, D-Glu, Phe, Gly, Ile, Lys, Leu,        Thr, Val and Trp <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, Glu, Phe, Gly, Ile, Lys, Leu, Met, Nle, Arg, Ser, Thr, Val        and Trp <220> <221> MOD_RES &Lt; 222 > (16) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, Glu, Phe, Ile, Lys, Leu, Met, Nle, Arg, Ser, Thr, Val, Trp        and Tyr <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, Glu, Phe, Gly, Ile, Lys, Leu, Arg, Ser, Thr, Val, Trp and        Tyr <220> <221> MOD_RES <222> (18). (18) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Cys and        Asp <220> <221> MOD_RES <222> (19). (19) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Phe, Ile, Leu, Ser, Thr, Val, and Trp <220> <221> MOD_RES &Lt; 222 > (20) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Phe and        Trp <220> <221> MOD_RES &Lt; 222 > (21) <223> Xaa is an amino acid selected from a group consisting of Ile,        Leu, and Val <220> <221> MOD_RES &Lt; 222 > (22) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, Glu, Phe, Gly, Ile, Lys, Leu, Pro, Arg, Ser, Thr, Val, and        Trp <220> <221> MOD_RES &Lt; 222 > (23) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Ala,        Asp, Glu, Phe, Gly, Ile, Lys, Leu, Arg, Ser, Thr, Val, Trp and        Tyr or is absent <400> 3118 Xaa Xaa Xaa Xaa Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa             20 <210> 3119 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is selected from any amino acid or is absent <220> <221> MOD_RES <222> (2) (2) <223> Xaa is selected from any amino acid or is absent <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected a group of amino acids consisting of Phe and Tyr <220> <221> MOD_RES <222> (6) <223> Xaa is selected a group of amino acids consisting of Phe and His <220> <221> DISULFID <222> (7). (18) <223> Cys residues linked via disulfide bond <220> <221> MOD_RES &Lt; 222 > (8) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (9) <223> Xaa is selected from a group of amino acids consisting of Met and Val <220> <221> MOD_RES &Lt; 222 > (10) <223> Xaa is selected from any amino acid <220> <221> MOD_RES (12). (12) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (13) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (15) <223> Xaa is selected a group of amino acids consisting of Ile and Thr <220> <221> MOD_RES &Lt; 222 > (16) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is selected a group of amino acids consisting of Ser and Thr <220> <221> MOD_RES <222> (19). (19) <223> Xaa is selected as a group of amino acids consisting of Ala and Val <220> <221> MOD_RES &Lt; 222 > (22) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (23) <223> Xaa is selected from any amino acid or is absent <400> 3119 Xaa Xaa Xaa Lys Trp Xaa Cys Xaa Xaa Xaa Asp Xaa Xaa Gly Xaa Xaa 1 5 10 15 Xaa Cys Xaa Trp Val Xaa Xaa             20 <210> 3120 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser,        Thr, Trp, Glu, His and Tyr or is absent <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, Met, Asn, Pro, Arg, Ser, Thr, Trp, Tyr,        Gly, Ile, and Leu or is absent <220> <221> MOD_RES &Lt; 222 > (3) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, Met, Asn, Pro, Arg, Ser, Phe, Gly, His,        Thr, Trp, and Tyr <220> <221> MOD_RES <222> (4) (4) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, Leu, Met, Asn, Gln, Arg, Phe, Gly, His, Ile,        Ser, Thr, Val, Trp, Tyr and Pro <220> <221> MOD_RES &Lt; 222 > (5) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Cys,        Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr,        Val, Trp, and Tyr <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Trp, Cys, Lys, Pro, Arg, and His <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Gln,        Ala, Cys, Phe, Gly, His, Ile, Lys, Leu, Asn, Arg, Thr, Trp and        Tyr <220> <221> MOD_RES &Lt; 222 > (8) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr,        Val, Trp, Tyr and Ile <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Cys, Phe, Gly, His, Ile, Leu, Met, Arg, Ser, Thr, Val, Trp, Tyr        and Lys <220> <221> MOD_RES &Lt; 222 > (10) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Cys, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln,        Thr, Val, Trp, and Tyr <220> <221> MOD_RES &Lt; 222 > (11) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Gly, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp,        Cys, Phe, and His <220> <221> MOD_RES (12). (12) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Cys, His, Ile, Lys, Leu, and Arg <220> <221> MOD_RES &Lt; 222 > (13) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Cys, Phe, Gly, His, Lys, Leu, Met, Arg, Ser, Val, Trp, Tyr, and        Ile <220> <221> MOD_RES &Lt; 222 > (14) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Cys, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val,        Trp, Tyr, and Lys <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, and Arg <220> <221> MOD_RES &Lt; 222 > (16) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Phe, Lys, and Arg <220> <221> MOD_RES &Lt; 222 > (17) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Leu, Asn, Gln, Arg, Ser, Thr, Val, Trp,        Tyr, His, and Met <220> <221> MOD_RES <222> (18). (18) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Cys, Phe, Ile, Lys, Leu, Met, Gln, Arg, Val, Trp, and Tyr <220> <221> MOD_RES <222> (19). (19) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, Leu, Asn, Pro, Gln, Arg, Val, Cys, Asp, Glu, Phe, Gly, His,        Trp, Tyr, and Ile <220> <221> MOD_RES &Lt; 222 > (20) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, Leu, Met, Asn, Gln, Arg, Val, Trp, Tyr,        Ile, and Pro <220> <221> MOD_RES &Lt; 222 > (21) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Lys, Leu, Met, Pro, Arg, Thr, Val, Trp, Tyr, Phe,        and Gly <400> 3120 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa             20 <210> 3121 <211> 21 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is selected from any amino acid or is absent <220> <221> MOD_RES <222> (2) (2) <223> Xaa is selected from any amino acid or is absent <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (4) (4) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (6) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (7) (7) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (8) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (9) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (10) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (11) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (13) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (14) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is an amino acid selected from a group consisting of Lys and        Arg <220> <221> MOD_RES &Lt; 222 > (17) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (18). (18) <223> Xaa is selected from any amino acid <220> <221> MOD_RES <222> (19). (19) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (20) <223> Xaa is selected from any amino acid <220> <221> MOD_RES &Lt; 222 > (21) <223> Xaa is selected from any amino acid <400> 3121 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Arg 1 5 10 15 Xaa Xaa Xaa Xaa Xaa             20 <210> 3122 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Glu, and Pro or is absent <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Phe,        Leu, Tyr, and Met <220> <221> MOD_RES <222> (4) (4) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Met,        Gln, Arg, Ser, Thr, and Cys <220> <221> MOD_RES &Lt; 222 > (5) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Aib,        Lys, Pro, Arg, Glu, Ile, Tyr, Met, and Trp <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is an amino acid selected from the group consisting of D-Ala,        Asp, D-Asp, Gly, His, Lys, D-Lys, Asn,        Ala, Glu, Cys, and Met <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Cys, Asp, Gly, His, Lys, Asn, Gln, Arg, Ser, and Met <220> <221> MOD_RES &Lt; 222 > (8) <223> Xaa is an amino acid selected from the group consisting of Ile        and Val <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Phe,        His, and Tyr <220> <221> MOD_RES &Lt; 222 > (11) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Asp, Glu, Lys, Met, Asn, Gln, Arg, Phe, His Pro, Ser, Val Trp <220> <221> MOD_RES &Lt; 222 > (14) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Cys        and Phe <220> <221> MOD_RES &Lt; 222 > (15) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Cys, Asp, Glu, Lys, Leu, Met Asn, Gln, Arg, Thr, Val and Aib <220> <221> MOD_RES <222> (18). (18) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Aib, Cys, Cha, Dab, Dap, Eag, Eew, His, Har, Hci, Hle, Lys,        Nva, Opa, Orn, Arg, Ile, Leu, Ser, and Met <220> <221> MOD_RES <222> (19). (19) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Ala,        Leu, Asn, Met, and Arg <220> <221> MOD_RES &Lt; 222 > (20) &Lt; 223 > Xaa is an amino acid selected from the group consisting of Lys        and Leu <400> 3122 Xaa Xaa Gln Xaa Xaa Xaa Xaa Xaa Xaa Val Xaa Gly Tyr Xaa Xaa Arg 1 5 10 15 Leu Xaa Lys Xaa             20 <210> 3123 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is Leu or Lys <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is Gln or Lys <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is Val or Lys <220> <221> MOD_RES <222> (4) (4) <223> Xaa is Ala or Lys <400> 3123 Xaa Xaa Xaa Xaa One <210> 3124 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) &Lt; 223 > Xaa is Arg or Lys <220> <221> MOD_RES <222> (2) (2) <223> Xaa is Leu or Lys <220> <221> MOD_RES &Lt; 222 > (3) &Lt; 223 > Xaa is Gln or Lys <220> <221> MOD_RES <222> (4) (4) <223> Xaa is Val or Lys <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is Ala or Lys <400> 3124 Xaa Xaa Xaa Xaa Xaa 1 5 <210> 3125 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is Gly or Lys <220> <221> MOD_RES <222> (2) (2) &Lt; 223 > Xaa is Arg or Lys <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is Leu or Lys <220> <221> MOD_RES <222> (4) (4) &Lt; 223 > Xaa is Gln or Lys <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is Val or Lys <220> <221> MOD_RES <222> (6) <223> Xaa is Ala or Lys <400> 3125 Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 3126 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is Val or Lys <220> <221> MOD_RES <222> (2) (2) <223> Xaa is Gly or Lys <220> <221> MOD_RES &Lt; 222 > (3) &Lt; 223 > Xaa is Arg or Lys <220> <221> MOD_RES <222> (4) (4) <223> Xaa is Leu or Lys <220> <221> MOD_RES &Lt; 222 > (5) &Lt; 223 > Xaa is Gln or Lys <220> <221> MOD_RES <222> (6) <223> Xaa is Val or Lys <220> <221> MOD_RES <222> (7) (7) <223> Xaa is Ala or Lys <400> 3126 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 3127 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is Gly or Lys <220> <221> MOD_RES <222> (2) (2) <223> Xaa is Val or Lys <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is Gly or Lys <220> <221> MOD_RES <222> (4) (4) &Lt; 223 > Xaa is Arg or Lys <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is Leu or Lys <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is Gln or Lys <220> <221> MOD_RES <222> (7) (7) <223> Xaa is Val or Lys <220> <221> MOD_RES &Lt; 222 > (8) <223> Xaa is Ala or Lys <400> 3127 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 3128 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is Ser or Lys <220> <221> MOD_RES <222> (2) (2) <223> Xaa is Gly or Lys <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is Val or Lys <220> <221> MOD_RES <222> (4) (4) <223> Xaa is Gly or Lys <220> <221> MOD_RES &Lt; 222 > (5) &Lt; 223 > Xaa is Arg or Lys <220> <221> MOD_RES <222> (6) <223> Xaa is Leu or Lys <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is Gln or Lys <220> <221> MOD_RES &Lt; 222 > (8) <223> Xaa is Val or Lys <220> <221> MOD_RES &Lt; 222 > (9) <223> Xaa is Ala or Lys <400> 3128 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 <210> 3129 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (2) (2) <223> Xaa is Ser or Lys <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is Gly or Lys <220> <221> MOD_RES <222> (4) (4) <223> Xaa is Val or Lys <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is Gly or Lys <220> <221> MOD_RES <222> (6) &Lt; 223 > Xaa is Arg or Lys <220> <221> MOD_RES <222> (7) (7) <223> Xaa is Leu or Lys <220> <221> MOD_RES &Lt; 222 > (8) &Lt; 223 > Xaa is Gln or Lys <220> <221> MOD_RES &Lt; 222 > (9) <223> Xaa is Val or Lys <220> <221> MOD_RES &Lt; 222 > (10) <223> Xaa is Ala or Lys <400> 3129 Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 3130 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES &Lt; 222 > (3) <223> Xaa is Ser or Lys <220> <221> MOD_RES <222> (4) (4) <223> Xaa is Gly or Lys <220> <221> MOD_RES &Lt; 222 > (5) <223> Xaa is Val or Lys <220> <221> MOD_RES <222> (6) <223> Xaa is Gly or Lys <220> <221> MOD_RES <222> (7) (7) &Lt; 223 > Xaa is Arg or Lys <220> <221> MOD_RES &Lt; 222 > (8) <223> Xaa is Leu or Lys <220> <221> MOD_RES &Lt; 222 > (9) &Lt; 223 > Xaa is Gln or Lys <220> <221> MOD_RES &Lt; 222 > (10) <223> Xaa is Val or Lys <220> <221> MOD_RES &Lt; 222 > (11) <223> Xaa is Ala or Lys <400> 3130 Lys Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 <210> 3131 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> Xaa is Tyr or Lys <220> <221> MOD_RES <222> (2) (2) <223> Xaa is Ser or Lys <400> 3131 Xaa Xaa Lys Lys One <210> 3132 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3132 Lys Gly Ser Ser Arg Gly His Asn Ala Leu Lys Thr His Ser Trp 1 5 10 15 Met Ser Pro Phe Arg Arg Arg Gly Ser Trp Ser Leu His Phe Lys             20 25 30 <210> 3133 <211> 31 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (31) <223> C-terminal amidation <400> 3133 Lys Ser Arg Ser Gly Phe Trp His Ala Trp Ser His Arg Thr Arg Pro 1 5 10 15 Met Lys Ser Arg Leu His Leu Gly Lys Phe Ser Asn Ser Ser Gly             20 25 30 <210> 3134 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (28) <223> C-terminal amidation <400> 3134 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Ser Ser Met His Phe Trp Arg Trp             20 25 <210> 3135 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 3135 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Ser Ser Met His Phe             20 25 <210> 3136 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 3136 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu Ser Ser             20 <210> 3137 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 3137 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala              <210> 3138 <211> 28 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <400> 3138 Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro Ser Arg Ala 1 5 10 15 Leu Ser Ser Met His Phe Trp Arg Trp Ser Thr Ser             20 25 <210> 3139 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (25) <223> C-terminal amidation <400> 3139 Lys His Phe Leu Arg Ser Asn Gly Lys Pro Ser Arg Ala Leu Ser Ser 1 5 10 15 Met His Phe Trp Arg Trp Ser Thr Ser             20 25 <210> 3140 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (22) <223> C-terminal amidation <400> 3140 Leu Arg Ser Ser Gn Lys Pro Ser Ser Ala Leu Ser Ser Met His Phe 1 5 10 15 Trp Arg Trp Ser Thr Ser             20 <210> 3141 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES <222> (19). (19) <223> C-terminal amidation <400> 3141 Asn Gly Lys Pro Ser Arg Ala Leu Ser Ser Met His Phe Trp Arg Trp 1 5 10 15 Ser Thr Ser              <210> 3142 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3142 Ser Gly Gly Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro 1 5 10 15 Ser Arg Ala Leu             20 <210> 3143 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3143 Arg Lys His Lys His Phe Leu Arg Ser Asn Gly Lys Pro Ser Arg Ala 1 5 10 15 Leu Ser Ser Met             20 <210> 3144 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3144 Lys His Phe Leu Arg Ser Asn Gly Lys Pro Ser Arg Ala Leu Ser Ser 1 5 10 15 Met His Phe Trp             20 <210> 3145 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic peptide <220> <221> MOD_RES <222> (1) <223> N-terminal acetylation <220> <221> MOD_RES &Lt; 222 > (20) <223> C-terminal amidation <400> 3145 Ser Asn Gly Lys Pro Ser Arg Ala Leu Ser Ser Met His Phe Trp Arg 1 5 10 15 Trp Ser Thr Ser             20

Claims (133)

A peptide that binds to TFPI, consisting of an amino acid sequence at least 90% identical to the amino acid sequence:
Ac-FQSKpNVHVDGYFERL-Aib-AKL- NH 2 ( SEQ ID NO: 178). The peptide of claim 1, wherein the peptide has the structure:
(I) (SEQ ID NO: 3116): X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013-X1014-X1015-X1016-
X1001 is an amino acid selected from the group consisting of F, L, Y and M;
X1002 is Q;
X1003 is an amino acid selected from the group consisting of M, Q, R, S, T and C;
X1004 is an amino acid selected from the group consisting of Aib, K, P, R, E, G, I, Y, M and W;
X1005 is an amino acid selected from the group consisting of a, Aib, D, d, G, H, K, k, N, Nmg, p, Q, R, A, E, C and M;
X1006 is an amino acid selected from the group consisting of A, C, D, G, H, K, N, Q, R, S and M;
X1007 is an amino acid selected from the group consisting of I and V;
X1008 is an amino acid selected from the group consisting of F, H, and Y;
X1009 is V;
X1010 is an amino acid selected from the group consisting of A, D, E, K, M, N, Q, R, F, H, P, S, V, W and Y;
X1011 is G;
X1012 is Y;
X1013 is an amino acid selected from the group consisting of C and F;
X1014 is an amino acid selected from the group consisting of A, C, D, E, K, L, M, N, Q, R, T, V and Aib;
X1015 is R;
X1016 is L;
X1017 is selected from the group consisting of A, Aib, C, Cha, Dab, Dap, Eag, Eew, H, Har, Hci, Hle, K, Nle, Nva, Opa, Orn, R, I, Amino acids;
X1018 is an amino acid selected from the group consisting of A, L, N, M and R;
X1019 is K;
X1020 is an amino acid selected from the group consisting of K and L. delete 3. The peptide of claim 1 or 2,
X1019-X1001-X1002-X1003-X1004-X1005-X1006-X1007-X1008-X1009-X1010-X1011-X1012-X1013-X1014-X1015-X1016-X1017-X1018-X1019 (II)
Wherein X1000 is an N-terminal amino acid selected from the group consisting of A, E, and P directly linked to X1001, X1001 to X1019 are as defined in claim 2, and X1020 is absent. 3. The peptide of claim 1 or 2, wherein the peptide has an IC ₅₀ of less than 1000 nM. delete delete 3. The composition of claim 2, wherein at least one N-terminal amino acid (s) is further linked directly to X1001, wherein the N-terminal amino acid (s)
X1000,
X999-X1000,
X998-X999-X1000,
X997-X998-X999-X1000 (SEQ ID NO: 3123),
X996-X997-X998-X999-X1000 (SEQ ID NO: 3124),
X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3125),
X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3126),
X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3127)
X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3128)
X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3129), and
X990-X991-X992-X993-X994-X995-X996-X997-X998-X999-X1000 (SEQ ID NO: 3130)
Wherein X1000 is A or K; X999 is V or K; X998 is Q or K; X997 is L or K; X996 is R or K; X995 is G or K; X994 is V or K; X993 is G or K; X992 is S or K; X991 is K; X990 is a K-peptide. The method of claim 2, wherein one or more C-terminal amino acid (s) are further linked directly to X1020, wherein the C-terminal amino acid (s) are selected from the group consisting of X1021, X1021- X1022, X1021- X1022- X1023, and X1021- X1022- X1023-X1024 (SEQ ID NO: 3131), wherein X1021 is T or K, X1022 is S or K, X1023 is K, and X1024 is K. 3. A peptide according to claim 1 or 2, wherein the peptide contains at least two cysteine residues, wherein at least two of the cysteine residues are separated by at least three amino acid residues of formula I, To form a disulfide bond. delete delete delete 3. The peptide according to claim 1 or 2, which inhibits TFPI activity. 3. The peptide according to claim 1 or 2, wherein the peptide is conjugated to a water-soluble polymer. 3. The peptide of claim 1 or 2, wherein the peptide is conjugated to a polyethylene glycol (PEG) moiety. 3. A peptide according to claim 1 or 2, wherein said peptide is fused to one or more second peptides according to claims 1 or 2, linked by a multimerization domain, or attached via chemical linkage. 3. The peptide according to claim 1 or 2, for use in a method for the treatment of a subject. 19. The peptide of claim 18, wherein the method is for the treatment of a blood coagulation disorder, wherein the blood coagulation disorder comprises a bleeding disorder caused by a lack of blood coagulation factor activity and a lack of platelet activity. 10. A pharmaceutical composition comprising a peptide as defined in claim 1 or 2 and a pharmaceutically acceptable carrier,
Hypothermia; Hemophilia A; Hemophilia B; Hemophilia C; Aplastic anemia; Idiopathic or immune thrombocytopenia including idiopathic thrombocytopenic purpura associated with breast cancer; HIV-associated thrombocytopenia; HIV-associated thrombotic thrombocytopenic purpura; Metastatic tumors causing thrombocytopenia; Neonatal lupus syndrome systemic lupus including spleen enlargement; Fanconi syndrome; Vitamin B12 deficiency; Folate deficiency; May-Hegglin anomaly; Wiscott-Aldrich syndrome; Chronic liver disease; Myelodysplastic syndrome associated with thrombocytopenia; Paroxysmal nocturnal hemoglobinuria; Acute primary thrombocytopenia after C7E3 Fab (abciximab) therapy; Allogeneic immune thrombocytopenia including maternal allogeneic immune thrombocytopenia; Thrombocytopenia associated with anti-phospholipid antibodies and thrombosis; Autoimmune thrombocytopenia; Drug-induced immune thrombocytopenia including carboplatin-induced thrombocytopenia and heparin-induced thrombocytopenia; Fetal thrombocytopenia; Gestational thrombocytopenia; Hughes syndrome; Lupus positive thrombocytopenia; Blood loss including accidental blood or massive blood loss; Myeloproliferative disorders; Thrombocytopenia in patients with malignant tumors; Thrombotic thrombocytopenic purpuric fever including thrombotic microangiopathy which appears as thrombotic thrombocytopenic purpuric / hemolytic uremic syndrome in cancer patients; Purpura (PTP) after transfusion; Autoimmune hemolytic anemia; Factory diverticulum not visible to the naked eye; True erythrocyte anemia; Autoimmune thrombocytopenia; Pandemic nephropathy; Rifampicin-associated acute renal failure; Paris-Trousseau thrombocytopenia; Neonatal allogeneic immune thrombocytopenia; Paroxysmal nocturnal hemoglobinuria; Hematological changes in stomach cancer; Hemolytic uremic syndrome including urinary toxic conditions in children; Hematological findings associated with viral infection including hepatitis A virus; CMV-associated thrombocytopenia; Von Willebrand's disease; Adrenal bloody platelet dysfunction; Glanzman platelet hypofunction; Bernard-Soulier disease; Trauma-induced bleeding conditions; Deficiency of FXI; Deficiency of FXII; Deficiency of prekali crane; Deficiency of high molecular weight kininogen (HMWK); Vitamin K deficiency; Fibrinogenemia; Low fibrinogenemia; Abnormal fibrinogen; Alpha 2-antiplasmin deficiency; Or excessive bleeding. delete 3. A peptide according to claim 1 or 2 for use in the diagnosis of a subject suffering from a blood coagulation disorder or at risk of suffering from a blood coagulation disorder, said peptide being conjugated to a detectable moiety, Wherein the detection indicates that the subject is at risk of developing a blood clotting disorder or a blood clotting disorder and wherein the blood clotting disorder comprises a bleeding disorder caused by a lack of blood clotting factor activity and a lack of platelet activity, . a) contacting a sample containing TFPI with said peptide under appropriate conditions to form a complex between TFPI and the peptide as defined in claim 1 or 2;
b) removing the complex from the sample;
Optionally c) dissociating the complex to release TFPI
&Lt; / RTI &gt; 24. The method of claim 23, wherein the peptide is immobilized on a solid support. 24. The method of claim 23, wherein said peptide is immobilized on a chromatographic station, and step (c) comprises eluting TFPI bound to said immobilized peptide. delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete delete

Images